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ABSTRACT 
In the last years, different carrier systems - liposomes, niosomes, sphingosomes, 
microemulsions, multiple emulsions, nanoparticles, etc. - are being used for pharmaceutical 
application, cosmetics, agricultural and food products, with the aim of modifying the release 
profile of the incorporated substances. 
With regard to pharmaceutical application, new drug delivery systems have been developed 
in order to improve the therapeutic index of drugs, to optimize their therapeutic efficacy and to 
limit their side effects. The selection of a particular drug delivery system should be determined 
according to several considerations regarding, for instance, the in vivo therapeutic behaviour and 
interactions with the biological surroundings, the administration route, the use of excipients of 
accepted status, the possibility of industrial scale production and the costs. 
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) are new drug 
delivery systems composed of a lipid matrix that is solid both at room and body temperature. 
SLN and NLC represent alternative colloidal carrier systems, combining many advantages of 
other carriers reported above. For instance, unlike lipid emulsions, which have a fluid core, the 
solid core of SLN and NLC reduces the mobility of incorporated drug molecules, thus preventing 
their leakage from the carrier. Nevertheless, in comparison to the solid matrix of polymeric 
nanoparticles, the drug release from SLN and NLC is usually faster. 
One possible application of SLN and NLC aqueous dispersions is the topical administration, 
where these systems can be used for controlled drug release and stabilization against chemical 
degradation. Thus, these systems have been already used for incorporation of several drug 
substances for the treatment of skin and mucosal diseases. 
Fungal infections are one of the main dermatological disorders. In general, their treatment is 
based on the use of imidazole-containing conventional formulations. However, the risk of skin 
and mucosal irritation and, especially, the lack of a prolonged release profile are disadvantages 
related to the use of conventional topical formulations. 
The aim of the present thesis was the development and characterization of clotrimazole-
-containing SLN and NLC aqueous dispersions, as well as clotrimazole-loaded SLN and NLC 
containing hydrogels, for topical administration. 
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Clotrimazole is an imidazole drug with an effective broad spectrum against many fungi, and 
it was chosen as a model drug due to its high lipophilic character. 
After a screening study using 15 different lipids, Dynasan®\\6 was chosen as the lipid 
matrix for SLN and NLC preparation by the hot high pressure homogenization technique, using 
Tyloxapol® as emulsifying agent. 
Two different SLN aqueous dispersions [containing 10% and 20% (m/m) of lipid matrix] and 
one NLC aqueous dispersion [containing 20% (m/m) of lipid matrix] containing 5% of 
clotrimazole (m/m, with regard to the lipid matrix) were developed and characterized. 
In order to characterize all developed formulations, the particle size, zeta potential and lipid 
crystallinity were determined using different approaches, such as photon correlation 
spectroscopy (PCS), light diffraction (LD), polarized light microscopy, differential scanning 
calorimetry (DSC) and x-ray diffraction. In addition, encapsulation efficiency and loading 
capacity of SLN and NLC, as well as clotrimazole release profiles, were also determined. 
Results obtained by LD showed the colloidal size of prepared SLN and NLC. PCS analysis 
confirmed the presence of a mean particle size in nanometer range (between 180 and 215 nm), 
low polydispersity indices (between 0.175 and 0.225) and negative electric charge. Polarized 
light microscopy studies allowed excluding the existence of clotrimazole crystals insoluble in 
Dynasan®\16. The presence of crystalline lipid in SLN and NLC was confirmed by DSC and x-
ray diffraction. Obtained encapsulation efficiencies were higher than 64% and drug loading 
capacities were higher than 2.5%. In addition, all three developed formulations revealed the 
ability of controlling the drug release profile of clotrimazole. 
The stability study of formulations was carried out during a period of three months at 4°C, 
20°C and 40°C. All developed SLN and NLC aqueous dispersions showed good physically and 
chemically stability. The presence of clotrimazole does not interfere either with particle size or 
with chemical stability of formulations. Encapsulation efficiencies remained higher than 50% 
and drug loading capacities higher than 2% for SLN and NLC formulations, after 21 days of 
storage at room temperature (20°C). 
SLN and NLC aqueous dispersions have been incorporated into four different hydrogels, 
prepared with different gel forming agents: xanthan gum, hydroxyethylcellulose, CarbopoI®934 
and chitosan. 
After incorporation in semi-solid formulations, nanoparticles maintained their colloidal 
dimensions (between 170 and 330 nm) and their negative charge. SLN and NLC of chitosan 
hydrogels showed the highest mean particle size (330 nm) and presented a positive electric 
charge. 
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During the three months of storage period at room temperature (20°C) SLN and NLC 
incorporated in the different hydrogels maintained their colloidal size. By DSC studies, it was 
observed that clotrimazole does not interfere with the gel forming agents during the same period 
of time. 
With regard to rheological properties of semi-solid preparations, it was observed that the 
increase of lipidic content was responsible for the increase of elastic properties of formulations 
(increase of G ' in comparison toG"). 
Oclusive properties of SLN and NLC aqueous dispersions confirmed the importance of these 
carriers for increasing the occlusive and hydrating effects of semi-solid preparations for topical 
administration. 
According to the obtained results in the present work, SLN and NLC appear to be useful 
carriers for topical delivery of clotrimazole and, therefore, will constitute a promising approach 
for controlling the release of this drug in the treatment of antifungal skin and mucosal disorders. 
In addition, some of semi-solid developed formulations - especially hydrogels prepared with 
xanthan gum and Carbopol®934 - showed appropriate properties for being good therapeutic 
systems for topical administration of clotrimazole. 
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RESUMO 
Nos últimos anos têm sido desenvolvidos diferentes vectores de substâncias activas -
lipossomas, niossomas, esfingossomas, microemulsões, emulsões múltiplas, nanopartículas, etc. 
- para utilização nas áreas farmacêutica e cosmética e também na agricultura e em produtos 
alimentares, com a finalidade de controlar o perfil de libertação das substâncias incorporadas. 
No que se refere à área farmacêutica, estes novos sistemas visam essencialmente 
proporcionar um aumento do índice terapêutico e da eficácia terapêutica das substâncias 
incorporadas e reduzir os seus efeitos secundários. A selecção do vector mais adequado é 
determinada por um conjunto de factores, designadamente o seu comportamento in vivo e as 
interacções estabelecidas com o meio biológico, a via de administração pretendida, a utilização 
de excipientes aceites pelas autoridades, a possibilidade de produção do produto em escala 
industrial e os custos envolvidos. 
As nanopartículas lipídicas sólidas (Solid Lipid Nanopartides, SLN) e os vectores lipídicos 
nanoestruturados (Nanostructured Lipid Carriers, NLC) constituem sistemas muito recentes, 
formados por uma matriz lipídica que se apresenta no estado sólido, quer à temperatura 
ambiente, quer à temperatura corporal. As SLN e os NLC constituem alternativas vantajosas em 
relação aos restantes vectores, uma vez que conjugam algumas vantagens inerentes a cada um 
deles. Por exemplo, contrariamente às emulsões lipídicas, que comportam um núcleo interno 
líquido, o núcleo sólido das SLN e dos NLC reduz a mobilidade das substâncias incorporadas, 
evitando a sua difusão rápida para o exterior. No entanto, comparativamente às nanopartículas 
poliméricas, a libertação das substâncias activas a partir das SLN e dos NLC é, em regra, mais 
rápida. 
Uma das possíveis aplicações das dispersões aquosas de SLN e de NLC consiste na 
administração tópica, em que estes sistemas são usados para controlar o perfil de libertação das 
substâncias activas incorporadas e para as proteger contra a degradação química. Assim, estes 
sistemas têm vindo a sido utilizados para vectorizar diversas substâncias activas, com vista ao 
tratamento tópico de patologias quer da pele quer das mucosas. 
As infecções fúngicas constituem uma das principais dermatoses. Em geral, o seu tratamento 
é efectuado com base em formas farmacêuticas convencionais, contendo, designadamente, 
derivados imidazólicos. No entanto, o risco potencial de irritação da pele e das mucosas e, 
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especialmente, a impossibilidade de obtenção de uma libertação prolongada das substâncias 
activas constituem dificuldades inerentes às formas farmacêuticas convencionais. 
O objectivo da presente tese consistiu no desenvolvimento e na caracterização de dispersões 
aquosas de SLN e de NLC contendo clotrimazol e também de hidrogeles contendo clotrimazol 
incorporado em SLN e em NLC, para administração cutânea. 
O clotrimazol é um derivado imidazólico com um espectro alargado de acção contra 
numerosos fungos, tendo sido seleccionado como substância activa modelo para a realização do 
presente trabalho devido à sua lipofilia. 
Após uma série de estudos preliminares, envolvendo 15 lípidos quimicamente distintos, o 
Dynasan® 116 foi seleccionado para a preparação das SLN e dos NLC por homogeneização a alta 
pressão, realizada a quente, utilizando-se o Tyloxapof como agente tensioactivo. 
Foram desenvolvidas e caracterizadas duas dispersões aquosas de SLN [contendo 10% e 20% 
(m/m) de matriz lipídica] e uma dispersão aquosa de NLC [contendo 20% (m/m) de matriz 
lipídica], contendo 5% de clotrimazol (m/m, em relação à matriz lipídica). 
A caracterização das formulações desenvolvidas consistiu na avaliação das dimensões das 
partículas, do seu potencial zeta e da cristalinidade, utilizando diferentes técnicas, como a 
espectroscopia de correlação fotónica (PCS), a difracção laser (LD), a microscopia de luz 
polarizada, a calorimetria diferencial de varrimento (DSC) e a difracção de raios X. Além disso, 
procedeu-se à determinação da eficácia de encapsulação e da capacidade de carga das SLN e dos 
NLC preparados e também ao estudo dos respectivos perfis de libertação do clotrimazol. 
Os resultados obtidos por LD evidenciaram as dimensões coloidais das SLN e dos NLC 
preparados. A análise por PCS confirmou a obtenção de partículas com diâmetros médios 
nanométricos (entre 180 e 215 nm), baixos índices de polidispersão (entre 0,175 e 0,225) e carga 
eléctrica negativa. Os estudos de microscopia de luz polarizada permitiram excluir a existência 
de cristais de clotrimazol insolúveis no Dynasan® 116. A presença de lipído cristalino nas SLN e 
nos NLC foi confirmada por DSC e por difracção de raios X. A eficácia de encapsulação 
apresentou-se superior a 64% e a capacidade de carga superior a 2,5% para todas as formulações. 
Além disso, as três formulações desenvolvidas evidenciaram capacidade para controlar o perfil 
de libertação do clotrimazol. 
O estudo da estabilidade das formulações desenvolvidas decorreu durante um período de três 
meses, às temperaturas de 4°C, 20°C e 40°C. Todas as dispersões aquosas de SLN e de NLC 
evidenciaram boa estabilidade, quer do ponto de vista físico, quer do ponto de vista químico. 
Verificou-se ainda que a presença de clotrimazol não interfere nas dimensões das partículas nem 
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na estabilidade química das formulações. Ao fim de 21 dias de armazenamento à temperatura 
ambiente (20°C), a eficácia de encapsulação manteve-se superior a 50% e a capacidade de carga 
superior a 2%, quer para as SLN, quer para os NLC. 
As dispersões aquosas de SLN e NLC desenvolvidas foram, em seguida, incorporadas em 
quatro tipos de hidrogeles, preparados com diferentes agentes gelificantes: goma xantana, 
hidroxietilcelulose, Carbopo^934 e quitosano. 
Imediatamente após a incorporação das dispersões aquosas de SLN e de NLC contendo 
clotrimazol nas formulações semi-sólidas, verificou-se que as nanopartículas mantinham as suas 
dimensões coloidais (entre 170 e 330 nm) e apresentavam-se carregadas negativamente. As SLN 
e os NLC incorporados nos hidrogeles preparados com quitosano apresentaram o diâmetro médio 
mais elevado (330 nm) e carga eléctrica positiva. 
Durante o período de três meses, em que decorreu o estudo da estabilidade dos diferentes 
hidrogeles conservados à temperatura ambiente (20°C), verificou-se que as SLN e os NLC 
mantinham dimensões coloidais. Os estudos de DSC realizados durante este mesmo período 
demonstraram que o clotrimazol não estabelece interacções com os agentes gelificantes. 
Em relação às propriedades reológicas das preparações semi-sólidas desenvolvidas, 
verificou-se que o aumento do conteúdo lipídico era acompanhado por um aumento das 
propriedades elásticas das preparações (aumento de G' comparativamente a G"). 
As propriedades oclusivas das dispersões aquosas de SLN e de NLC confirmaram a sua 
capacidade para aumentar os efeitos oclusivo e hidratante das formulações semi-sólidas para 
aplicação tópica. 
De acordo com os resultados obtidos no presente trabalho, as SLN e os NLC demonstraram 
constituir vectores adequados para a cedência do clotrimazol a nível tópico, podendo 
proporcionar uma estratégia promissora para a obtenção de uma libertação controlada desta 
substância activa no tratamento tópico de infecções fúngicas da pele ou das mucosas. Além 
disso, algumas das formulações desenvolvidas - em especial as correspondentes aos hidrogeles 
preparados com goma xantana e com Carbopor934 - evidenciaram propriedades adequadas 
para constituírem sistemas terapêuticos apropriados para a aplicação tópica do clotrimazol. 
XX Zusammenfassung 
ZUSAMMENFASSUNG 
Wàhrend der letzten Jahre wurden verschiedene innovative Wirkstofftràgersysteme wie 
Liposomen, Niosomen, Sphingosomen, Mikroemulsionen, multiple Emulsionen und polymer 
Nanopartikel entwickelt, um eine kontrollierte oder verzõgerte Wirkstofffreisetzung zu 
verbessern. Dièse Système sollen es ermõglichen, den inkorporierten Arzneistoff nach der 
Applikation freizusetzen. 
Die Wahl eines bestimmten Wirkstofftragersystems sollte entsprechend einigen betreffend 
Betrachtungen, zum Beispiel, ihrer in vivo therapeutischen Leistung, dem Leitung Weg und ihren 
Abhãngigkeiten mit den biologischen Umlagerungen, dem Gebrauch der Bindemittel des 
geltenden Status und der Mõglichkeit der Produktion der industriellen Skala und ihrer Kosten 
festgestellt werden. 
Die Entwicklung hochpotenter Wirkstoffe und deren Einfiihrung in die Thérapie lósten in 
den letzten Jahren intensive Forschungen auf dem Gebiet der pharmazeutische Technologie aus. 
Eine Einarbeitung dieser Stoffe in die klassischen Arzneiformen kann Uberdosierungen und 
toxische Nebenwirkungen zur Folge haben. Problème ergeben sich ebenfalls aus der 
Anreicherung von Wirktoffen in Organen und Geweben entsprechend ihres 
Verteilungsverhaltens. Aus dieser Problematik resultieren neue innovative Strategien bei der 
Optimierung von Arzneizubereitungen. 
Feste Lipid-Nanopartikel (Solid lipid nanoparticles, SLN) und nanostrukturierte Lipidcarrier 
{Nanostructured Lipid Carriers, NLC) stellen alternative Tragersysteme zu Liposomen und 
Emulsionen zur topischen Anwendung dar. Sie bestehen aus festen Lipiden bzw. aus 
Mischungen von festen und flussigen Lipiden oder lipidahnlichen Substanzen wobei vorwiegend 
physiologisch gut vertrâgliche Lipide verwendet werden. Im Vergleich zu nanopartikulãren 
Carriersystemen aus Polymeren zeigen SLN und NLC eine relativ geringe Zytotoxizitát. 
Gegenuber den Liposomendispersionen, die bezuglich als problematisch zu betracheten sind, 
haben SLN und NLC Dispersionen bei geeigneter Zusammensetzung den Vorteil der hohen 
physikalischen Stabilitãt auch nach einer Lagerung von uber drei Jahren. Durch Inkorporation in 
die Lipidmatrix kónnen chemisch instabile Wirkstoffe vor Zersetzung geschutzt werden. Eine 
Variation der Wirkstofffreisetzung ist durch Inkorporation der SLN oder NLC in verschiedene 
halbfeste Grundlagen moglich. Neben einer verzógerten Freisetzung im Vergleich zu 
Nanoemulsionen besteht die Mõglichkeit einer beschleunigten Freisetzung. 
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Im Rahmen der vorliegenden Arbeit bescháftigte ich mich mit der Entwicklung und 
Charakterisierung von SLN und NLC flussigen Dispersionen. Um die Eignung von SLN und 
NLC zur verzõrgerten Arzneistoffreisetzung zu untersuchen, wurde Clotrimazol als lipophiler 
Modellarzneistoff eingesetzt. Clotrimazol ist ein Chlor-substituiertes Triphenylmethylimidazol 
mit einem Breitspektrum in einem sehr hohen Prozentsatz bei verschiedenen Pilzerkrankungen 
wirksam. Als Lipidmatrix zur Herstellung von SLN und NLC wurde von 15 verschiedene Lipide 
Dynasan®\ 16 ausgewãhlt. Zur Herstellung der clotrimazolhaltigen und Placebo SLN und NLC 
wurde das Verfahren der Heiphomogenisation eingesetzet. Tyloxapof* wurde als Emulgator 
ausgewãhlt. 
Zur Messung der PartikelgrõPe von SLN und NLC kõnnen unterschiedliche Verfahren zum 
Einsatz kommen, wie Photonenkorretationsspektroskopie und Laserdiffraktometrie. Die 
Partikelladdung gibt AufschuP uber die Stabilitát einer Dispersion gegeniiber Lagerung, 
ElektrolyteinfluP oder Scherkraft. Daher wurde Zetapotential der hergestellten SLN und NLC 
und der weiterverarbeiteten halbfesten Zubereitungen mittels Laser-Doppler-Anemometrie 
bestimmt. Zur Charakterisierung des Wirkstoffeinschlusses in SLN und NLC wurden ergãnzend 
dynamische Differenz-Wãrmestrom-Kalorimetrie, Rõntgendiffraktometrie und Mikroskopie mit 
polarisiertem Licht durchgefiihrt. 
Nach Vorbereitung clotrimazol-geladener SLN und NLC, wurden von eines E.E. stark als 
64% und von der Wirkstoff, die stark als 2,5% lãdt, fur allé Proben erreicht. AuBerdem kònnte 
ein E.E. stark als 50% fur allé nachgeforschten Formulierungen nach 21 Tagen Ablage bei 
Raumtemperatur beobachtet werden, ein kontrolliertes Freisetzungsprofil fur clotrimazol wurde 
mit diesen Formulierungen erzielt. Auch hier konnte festgestellt werden, dass bei den SLN und 
NLC Dispersionen die Freisetzungsprofile fast identisch waren. Beide konnten die Freisetzung 
verlangsamen. 
Nach eingehender Entwicklung und Charakterisierung der flûssigen Dispersionen wurden 
diese zu halbfesten Endprodukten weiterverarbeitet. Eine einfache topische Arzneiform stellen 
Hydrogele dar. Diese enthalten notwendigerweise einen Gelbildner, in der Regel ein Polymer. 
Vier verschiedene Hydrogele (Xanthan Gum, Hydroxyethylcellulose, Carbopoí®934 und 
Chitosan) wurden produziert. Aufgrund der bekannten Instabilitát der SLN und NLC 
Dispersionen in Gegenwart von Elektrolyten oder nach mechanischem Energieeintrag, musste 
zunãchst die nanopartikuláre Struktur der SLN in diesen Gelen sichergestellt werden. Es zeigte 
sich, dass SLN und NLC in Gelen keine Aggregatbildung aufweisen. Auch zeigten die SLN und 
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NLC in Hydrogele keine nennenswerten polymorphen Transformationen innerhalb von 
Lagerungszeiten bis zu 3 Monaten. Die untersuchten SLN und NLC erwiesen sich somit in den 
Hydrogelegrundlagen als physikalisch stabil. In der weiteren Entwicklung wurden die okkiusive 
Eigenschaften von SLN und NLC untersucht. 
Zusammenfassend ist es in dieser Arbeit gelungen, Clotrimazol SLN und NLC fur eine 
topische Applikation zu entwickeln. Die Ergebnisse zeigen weiterhin, dass SLN und NLC als 
Trágersysteme fur eine verzórgerte Arzneistofffreisetzung geeignet sind. Andererseits ermoglicht 
dièse Dynamik der Système, dass gezielt Freisetzungseigenschaften iiber bestimmte Trigger 
beeinfluBt werden kõnnen. Dièse Système zeigten sich aufgrund ihrer physikalischen Stability 
und ihrer rheologischen Eigenschaften als gut geeignet fur das Verspriihen mittels eines 
Pumpzerstaubers. 
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AIM AND ORGANIZATION OF THE THESIS 
The aim of the present thesis was the investigation of the promising potential of lipid 
nanoparticles, such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), as 
new carrier systems for clotrimazole for the treatment of fungal infections of the skin and 
mucosa. 
Concerning the organization of the present dissertation, it has been divided in 6 different 
chapters. 
In Chapter I a characterization of SLN and NLC as new drug delivery systems, as well as 
their importance for site-specific drug delivery, is provided. In this chapter the most important 
lipids and emulsifying agents used for the preparation of these systems are presented, as well as 
some examples of compounds that have been incorporated in these carriers. 
Chapter II comprises a theoretic outfit of the main theme of this dissertation. The 
physiological characteristics of the topical route are described in terms of structure, properties 
and functions of the skin and mucosa, and the main aspects concerning drug absorption through 
this route are also presented. In this chapter the most important innovative systems available for 
topical drug delivery are reviewed. It is emphasized the use and the development of SLN and 
NLC and their advantages over other drug carrier systems. An introduction to lipid 
polymorphism is presented, in order to understand the main thermodynamic modification that the 
lipid material can suffer during particle preparation and storage time. 
Chapter III describes all the materials used during this present study. This chapter is devoted 
to the physicochemical characteristics of the different lipids and emulsifying agents used for 
SLN and NLC preparation, as well as the characterization of clotrimazole, purified water, gel 
forming agents and other materials used in the research study. 
In Chapter IV the adopted preparation methods of SLN and NLC aqueous dispersions and 
hydrogels, as well as the analytical procedures used to characterize the developed formulations, 
are described in detail. 
In Chapter V all the results obtained are reunited and discussed. This chapter was 
chronologically organized in order to describe the development and the characterization of the 
formulations containing SLN and NLC as drug carriers of clotrimazole for topical 
administration. 
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Finally, Chapter VI is devoted to the main conclusions of these investigations and opens the 
future fields and perspectives for further investigations using SLN and NLC as drug delivery 
systems. 
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INTRODUCTION 
The concept of site-specific drug delivery is an old one [1]. Nevertheless, only recently full 
consideration has been given to the way in which this might be achieved in practice. Clearly, a 
drug's therapeutic index, as measured by its pharmacological response and safety, relies on the 
access and specific interaction of the drug with its candidate receptor, whilst minimizing its 
interactions with non-target tissues. 
Site-specific drug delivery may be achieved by using carrier systems, where reliance is 
placed on exploiting both the innate pathway of the carriers, and the protection that they can 
afford to drugs during transit through the body. The use of a carrier opens up the range of 
opportunities for adjusting both drug access to its site of action and its pharmaceutical response. 
The strategy for site-specific drug delivery should be based on consideration of the disease 
and drug access, retention and timing in its interaction with the target [2]. Thus, in the treatment 
of a disease with a carrier system one needs to have a clear understanding of the inherent 
anatomical and physiological characteristics Of the site-specific drug delivery, the location of the 
target, the pharmacology of the drug and the target site response. Furthermore, the potential side-
effects and the clinical utility of the therapeutic system need to be well defined. 
Promising examples of drug delivery systems are the solid lipid nanoparticles (SLN). These 
systems have been introduced in 1991 as a new generation of carrier systems, combining the 
advantages of existing carriers such as liposomes, niosomes, sphingosomes, microemulsions, 
multiple emulsions and polymeric nanoparticles, while avoiding some of their specific 
disadvantages [3-7]. 
Similar to emulsions and liposomes, SLN consist of physiologically well tolerated excipients, 
like acylglycerols and phospholipids, allowing the transport of lipophilic substances molecularly 
dispersed in the lipid matrix [5-7]. Due to the solid character of the SLN matrix, physical 
instabilities which have been observed when incorporating liposomes into creams can be 
minimized or completely avoided. 
Similar to polymeric nanoparticles, SLN can protect incorporated drug substances against 
chemical degradation and the drug can be released in a time-controlled manner [8-11]. However, 
for the production of SLN biodegradable raw materials such as acylglycerols, hard fats and 
waxes are used. 
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In contrast to polymeric nanoparticles, SLN can be produced at low costs and under sterile 
conditions [12,13]. Note that due to the low transition temperature of synthetic polymers, these 
later tend to be temperature sensitive, which means that they tend to stick at elevated 
temperatures and cannot be heated, sterilized or autoclaved. In contrast, SLN can be autoclaved 
or sterile filtered depending on the composition of the formulation [14-16]. SLN also have the 
advantage of industrial production by hot high pressure homogenization (HPH) [17,18]. They 
can be lyophilized [15,19-22], spray-dried [19,21] and sterilized [5,19], reflecting the high 
stability of these systems. In addition, sterically stabilized SLN can be prepared using 
polyethylene glycol (PEG) lipid conjugates as stealth agents [23-25]. 
More recently, a novel type of lipid nanoparticles called the nanostructured lipid carriers 
(NLC) was developed [26-29]. NLC are prepared from lipid blends, mixing solid and liquid 
lipids, while SLN are only made from solid lipids. Therefore, the former shows a new 
morphology, which affords an improvement of the loading capacity and the physical and 
chemical long-term stability in comparison to SLN. 
The toxicity is the governing factor deciding if a product has the possibility to be introduced 
to the pharmaceutical market. Ideally, the product should contain only excipients which are 
already accepted in formulations by the regulatory authorities. This is possible when using SLN 
and NLC for ophthalmic, oral or peroral administration, as well as for cosmetics and 
pharmaceuticals intended for topical route. The materials used are excipients already present in 
cosmetical and pharmaceutical products accepted by the regulatory authorities, the full range of 
GRAS1 substances and substances of recognized GRAS status are available. The list of these 
substances includes also compounds with surface activity or surfactants suibable for particle 
stabilization. The most frequently used lipids and emulsifying agents for the preparation of SLN 
and NLC are listed in Table I and II, respectively. 
Many lipophilic and hydrophilic compounds (including some peptides) have been 
incorporated into SLN and NLC using different approaches [6,7,30,31]. Several examples of 
drugs and other substances incorporated into SLN and/or NLC are given in Table III. 
1 Generally regarded as safe. 
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Table I: Examples of the most frequently used lipids for the preparation of SLN and NLC. 
Lipids References 
Triacylglycerols 
Tricaprin" [32,33] 
Trilaurina [9,20,34-49] 
Trirnyristin [ 13,35,36,42,44,46-48,50-61 ] 
Tripalmitin [35,36,42,44,46-48,54,56,61 -82] 
Tristearin [ 13,34-36,44,54,56,62,67,83-87] 
Hydrogenated coco-acylglycerols [31,44,48,49,85,86,88] 
Mono, di and triacylglycerols mixtures 
Witepsot*VI35 [54,62,63,68] 
Witepso(*H35 [43,53,54,88] 
WitepsoPftAl [44,89] 
Witepso^ESS [31,50,53] 
Glyceryl monostearate (Imwitor*9O0) [13,26,28,48,56,59,70,90,91] 
Glyceryl behenate (Comprito^U ATO) [9,11 -13,20,21,28,41 -43,48,50-52,54,56,57,59,70,75,83,84,92-110] 
Glyceryl palmitostearate (Precirol®ATO 5) [48,50,57,84] 
Acidan®N 12 [15] 
Diacylglycerol monocitrate monostearate [15,30] 
Waxes 
Cetyl palmitate [9,12,13,18,21,42,43,47,51,59,67,70,75,84-86,95,99,102,111-119] 
Beeswax [48,56,70] 
Hard fats 
Capric acid [120] 
Palmitic acid [120] 
Stearic acid [13,15,23-25,30,48,71,89,90,121-140] 
Behenic acid [15,30] 
Other lipids 
Cholesterol [41,50,93] 
Miglyofm [28,48,56,75,76,81,103,104,106,107,114-117] 
Parafin [13,56,75,108] 
a These lipids create supercooled melts. 
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Table II: Examples of the most frequently used emulsifying agents for the preparation of SLN and NLC. 
Emulsifiers References 
Soybean lecithin {Lipoid 5, Lipoi<P$\<Xï) [9,13,20,34-36,41-46,48,50,52,53,55,57,58,62,63,66,68,69,73,77, 
78,83,84,129,134,141] 
Egg lecithin {LipoicFESO) [26,33,50,60,66,67,115] 
Phosphatidylcholine (Epikuron®) [15,23-25,65,71,72,88,90,91,123,124,126,127,130,131,135-140, 
142] 
Poloxamer 188 19,11 -13,20,21,31,41,42,48-51,54,56-60,62,63,65,68,69,77,78,84, 
88,92,94-100,102,106,115,129,132,134] 
Poloxamer 182 [31] 
Poloxamer 184 [52] 
Poloxamer 235 [52] 
Poloxamer 335 [52] 
Poloxamer 407 [42,52,58-61,66,67,84,87,92,99] 
Poloxamine 908 [42,58,66,84,92,99] 
Tyloxapof® [35,36,44,47-49,53,64-66,73,76,79-82,141] 
Polysorbate 20 (Tween®20) [77,121,125,127] 
Polysorbate 60 (Tween®60) [125] 
Polysorbate 80 (7WÉ>«®80) [31,33,48,52,56,58-60,67,70,84,91,101,105,108-110,117,142] 
Sorbitan esthers [59,105,108] 
Sodium cocoamphoacetate [28,86,106] 
Sodium cholate [31,42,50,51,58-61,67,84,91] 
Sodium glycocholate [22-24,35,36,44-46,53,55,62,63,65,66,73,141,142] 
Taurocholic acid sodium salt [23-25,71,72,130,131,135-140,142] 
Taurodeoxycholic acid sodium salt [15,89,91,120-128] 
Butanol [71,90,121,124-128] 
Butiric acid [72,123,128] 
Monooctylphosphoric acid sodium [125] 
Cholesterol hemissuccinate [71,72] 
Polyoxyethylene alquil ethers [132] 
Cetylpyridinium chloride [46,58,60,108] 
Sodium dodecyl sulphate [59,60] 
Sodium dioctyl sulfosuccinate [58,128] 
Polyglycerol methylglucodistearate (Tego C«re®450) [18,47,59,85,86,114,116,117] 
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Table III: Examples of drugs and other substances incorporated into SLN and/or NLC. 
Incorporated drug or substance References 
Aciclovir [111,143,144] 
Albumin [24,84] 
Amphotericin B [145,146] 
3'-Azido-3'-deoxythymidine palmitate [38,39] 
Azidothymidine palmitate [40] 
Betamethasone valerate [53] 
Benzocain [147] 
Calixarenes [148-151] 
Camptothecin [129,134] 
Chloramphenicol [147] 
Cholesteryl acetate [65,142,152] 
Cholesteryl butyrate [153] 
Clotrimazole [79-82] 
Cortisone [53] 
Cyclodextrins [154,155] 
Cyclosporin A [29,133,135,156-161] 
Deoxycorticosterone acetate [121] 
Dexamethasone [162] 
Diazepam [15,53,115] 
3'-5,-dioctanoyl-5-fluoro-2'-deoxyuridine [87] 
DNA [84,108] 
Doxorubicin [71,122,136,137] 
Etomidate [9,41,43] 
Fenotiazin [30] 
Gadolinium (III) complexes [128] 
"mTc-HMPAOa [101,110] 
Hydrocortisone [90] 
Idarubicin [122] 
Insect repellents [48,163-165] 
Iotrolan [84] 
[D-Trp-6]LHRH b [123] 
Lysozyme [31] 
Menadione [36,53] 
* DL-hexamethylpropileneamine oxime 
b Luteinizing hormone-releasing hormone 
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Table III: Examples of drugs and other substances incorporated into SLN and/or NLC. 
(Continuation) 
Incorporated drug or substance References 
Nifedipine [30] 
Nile red [166] 
Nimesulide [167] 
Ovalbumin [168] 
Oxazepam [53] 
Oxytetracycline [34] 
Paclitaxel [71,72,132,169] 
Perfumes [48,170,171] 
Pilocarpine [124] 
Piribedil [109] 
Polycyclic aromatic hydrocarbons [127] 
Prednicarbate [57] 
Prednisolone [11,41,50,53,93,100,172] 
Progesterone [90] 
Retinoids [33,53,56,70,75,103,104,106,107,173-175] 
Rhodamine B [23] 
Somatostatin acetate [74] 
Spin-labelled compounds [68,69,77,78,176-178] 
Sunscreens [48,76,114,117,179-181] 
Tetracaine [9,41,43] 
Timolol [89,120] 
Thymopentin [126] 
Tobramycin [138-140] 
Tocopherol [47,48,85,116,182,183] 
Tributyrin [184] 
Ubidecarenone [18,53,63,73,85,141,185] 
Vitamin K [186] 
As reported before, SLN and NLC have been used for a variety of pharmaceutical 
applications, such as oral, peroral, parenteral, ophthalmic and also topical administration 
[10,48,57,85]. Recently, these systems have also been introduced as a novel topical carrier for 
cosmetics [56,185,187]. 
Due to the small size of these particles (nanometer range), they are not perceptible when 
applied to the skin. Since SLN and NLC aqueous dispersions are stable at high temperatures, 
they can be easily incorporated into hydrogels or creams, i.e. the water phase of a gel or cream 
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can be partly substituted by the aqueous dispersion during the production process, and can act as 
carriers for active ingredients which proved to be chemically unstable in aqueous formulations 
such as creams or lotions [185]. SLN and NLC can act as a drug reservoir providing controlled 
drug release and might also act as penetration enhancers, increasing the drug concentration in the 
upper skin layer [56,57]. Similar to liposomes they also can form a protective film [185,187]. 
Due to their small size a penetration into gaps between stratum corneum cells might be feasible. 
These properties can be used for the delivery of antifungal agents into skin and mucosa for 
the treatment of fungal infections, such as yeast infections. Candida albicans is a yeast that, in 
addition to its many systemic manifestations, can cause cutaneous mycoses, often on body sites 
where excessive moisture accumulates [188], Candida infections frequently occur in skin folds 
of obese individuals, under pendulous breasts, in armpits, in the crotch, and on nails and hands 
that spend a lot of time immersed in water or covered with nonporous gloves. The yeast 
multiplies in the cutaneous layers and causes local skin lesions. Persons with impaired 
immunologic or cellular defences may develop lesions that cover the entire body surface and the 
mucous membranes [189]. 
The azoles are a group of synthetic compounds used as antifungal agents because they 
interfere with the cell membrane growth of fungi by inhibiting the synthesis of ergosterol [188]. 
One group of azoles, - the imidazoles - , are effective broad spectrum antifungal drugs with few 
or no serious side effects. Clotrimazole and miconazole, for example, are found in topical 
ointments such as those used for vaginal yeast infections [190]. These antifungal agents are also 
effective against dermatophytes, when applied topically. Ketoconazole has been used 
successfully for treating systemic infections caused by several pathogenic moulds, yeast 
infections and dermatophytes [188]. 
It is well known that poor solubility of a drug in the carrier matrix results in a low affinity of 
the molecule for the carrier and is accompanied by a poor in vivo bioavailability. In order to 
develop SLN and NLC formulations for the treatment of fungal infections, clotrimazole was 
chosen as a model drug because of its lipophilic character and large spectrum against several 
pathogenic fungi. This drug was first entrapped into SLN and NLC using the hot high pressure 
homogenization technique and the obtained aqueous dispersions were incorporated in hydrogels. 
The developed formulations were characterized concerning the particle size and polydispersity 
index, particle crystallinity, entrapment efficiency, drug loading capacity and drug release 
profile. Rheological and occlusive properties of the obtained topical formulations were also 
investigated. 
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CHAPTER II 
COLLOIDAL DRUG CARRIERS FOR TOPICAL ROUTE 
2.1. Structure, properties and functions of the skin 
The skin is the largest organ in the body, occupying almost 2 m2 (21,5ft ) of surface area 
[191]. It varies in thickness on different parts of the body, from less than 0.5 mm on the eyelids 
to more than 5 mm on the middle of the upper back. A typical thickness is 1 to 2 mm. 
According to some authors [192], the structure of the skin can be divided in three main parts, 
as it is represented in Figure 2.1. The epidermis is the outermost layer of epithelial tissue, the 
dermis is a thicker layer of connective tissue beneath the epidermis and the hypodermis is a layer 
of loose, fibrous connective tissue beneath the dermis [48,193,194]. 
Hair shaft 
Duct of sweat gland 
Vessel 
Sebaceous (oil) gland 
Arrector pili muscle 
Free nerve ending 
Sudoriferous (sr.eat) gland 
Figure 2.1: Schematic representation of the skin structure, showing its many components in an ideal 
arrangement. (Adapted from Wissing [48]). 
The epidermis (from the Greek epi meaning over and derma meaning skin) is a stratified 
squamous epithelium and has an average thickness of 30 um to 4 mm [192]. The epidermis 
contains no blood vessels, but most of it is so thin that even minor cuts can reach the dermis and 
draw blood. In the thick epidermis of the palms of the hand and soles of the feet, there are five 
HYPODERMIS 
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typical layers {strata). Starting with the outermost layer, they are stratum corneum, stratum 
lucidum, stratum granulosum, stratum spinosum and stratum basale. The stratum spinosum and 
stratum basale together are known as the stratum germinativum because they generate new cells. 
In parts of the body other than the palms and soles, only the stratum corneum and stratum 
germinativum are regularly present. 
The stratum corneum is a flat, relatively thick layer of dead cells arranged in parallel rows 
[192]. It is a keratinized layer, consisting of soft keratin compared to the one existing in 
fingernails and toenails, which helps keeping the skin elasticity. This soft keratin also protects 
living cells underneath from being exposed to the air and drying out. The cells in the stratum 
corneum are constantly being renewed [195]. They are replaced by new cells that are formed by 
cell division and pushed up from the germinative layers below. It has been estimated that the 
equivalent of the full epidermal mass turns over through cell proliferation with a frequency of 1 
or 2 months. Environmental and disease factors accelerate the turnover, but not without leaving 
an imprint on the skin's membrane attributes [196]. 
The stratum lucidum consists of flat, translucent layer of dead cells that contain a protein 
called eleidin, which is probably a transitional substance between the soft keratin of the stratum 
corneum and the precursor of soft keratin, keratohyaline, of the layer below [192]. The stratum 
lucidum appears only in the palms of the hands and soles of the feet, acting as a protective shield 
against the ultraviolet (UV) rays of the sun and preventing sunburns. 
The stratum granulosum lies just below the stratum lucidum [192]. It is usually two to four 
cells thick. These cells also contain granules of keratohyaline and, therefore, the process of 
keratinization, which is associated with the dying cells, begins in this layer. 
The stratum spinosum is composed of several layers of polyhedral cells that have delicate 
spines protruding from their surface [192]. The interlocking spine-like projections help support 
this binding layer. Active protein synthesis takes place in the cells of the stratum spinosum, 
indicating that cell division and growth are occurring. Some new cells are formed here and are 
pushed to the surface to replace the keratinized cells of the stratum corneum. 
The stratum basale rests on the basement membrane next to the dermis [192]. It consists of a 
single layer of columnar or cuboidal cells. Like the stratum spinosum, it undergoes cell division 
to produce new cells to replace those being shed in the exposed superficial layer. 
Most of the skin is composed of dermis (average thickness of 0.04 to 1.6 mm), which is 
called "true skin", because it is a strong, flexible connective tissue meshwork of collagenous 
reticular and elastic fibres [192]. Collagenous fibres, which are formed from protein collagen, are 
very thick and give the skin much of its toughness. Although reticular fibres are thinner, they 
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provide a supporting network, while elastic fibres give the skin flexibility. The cells of the 
dermis are mostly fibroblasts, fat cells and macrophages. These later cells are responsible for 
digesting foreign substances. Blood vessels, lymphatic vessels, nerve vessels, nerve endings, hair 
follicles and glands are also present. The dermis is composed of two layers that are not clearly 
separated. The thin papillary layer is directly beneath the epidermis and the deeper, thicker layer 
is called reticular layer. 
Beneath the dermis lies the hypodermis (from the Greek hipo meaning under) or 
subcutaneous layer [192]. It is composed of loose, fibrous connective tissue, is generally much 
thicker than the dermis and is richly supplied with lymphatic and blood vessels and nerves. Also 
within the hypodermis are the coiled ducts of sudoriferous seat gland and the bases of hair 
follicles. While the boundary between the epidermis and dermis is distinct, the one which is 
between the dermis and the hypodermis is not. 
Where the skin is freely movable, hypodermis tissue fibres are scarce. Where it is attached to 
underlying bone or muscle, the hypodermis contains tightly woven fibres. In some areas of the 
hypodermis where extra padding is desirable, as in the breast or the heels, thick sheets of fat cells 
are present. 
An obvious function of the skin is to cover and protect the inner organs [191]. However, this 
is only one of its many functions. Other functions include protection against harmful 
microorganisms and foreign material from entering the body, defending the organism against 
disease [192]. It is also responsible for temperature regulation and for excretion of small amounts 
of waste materials. The skin helps screen out harmful excessive UV rays from the sun, but it also 
lets in some necessary UV rays for its synthesis property. This organ is an important sensory 
receptor that responds to heat, cold, touch, pressure and pain. 
2.2. Drug absorption through the skin 
The aim of topical drug delivery is to produce a desired therapeutic action at specific sites on 
the skin and mucosa [197]. While certain topical substances such as emollients, antimicrobials 
and deodorants act primarily on the surface of the skin, the target area for most topical disorders 
lies in the viable epidermis or upper dermis. This requires diffusive penetration into the skin 
and/or mucosa or percutaneous absorption. 
Diffusion is a process involving the random movement of molecules among the past one 
another as often and as fast as the void space between molecules allows [198]. Physiological 
membranes may be regarded as molecular and/or macromolecular diffusion regimes that are 
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fixed and compositionally distinct from phases they separate. Passive diffusion takes place when 
a solute's thermodynamic activity is unequal on each side of the membrane, i.e. when a 
concentration gradient is present. The random movements of molecules lead to drug penetration 
into and through the membrane, always from regions where the molecules are concentrated (at 
high activity) to where they are sparsely concentrated. A gradient develops across the membrane, 
which reflects the existing difference of concentration (activity) through the membrane. The rate 
of transport across any chosen plane within the membrane of diffusion reflects the number of 
molecules moving forward and back across that plane in an instant of time. The factors 
determining the transport rate are the difference of concentration between the two sides of the 
membrane and the ease of positional relocation of the diffusing species. Diffusion of substances 
is spontaneous and irreversible and continues until the activity of the permanent is level 
throughout the membrane. Note that drug substances cannot be returned to their original place 
without doing any work. 
The natural and irreversible tendency toward diffusive randomness of substances among one 
another arises as the result of increased entropy [198]. At constant temperature and pressure and 
when there is no other work except pressure-volume work, the thermodynamic driving force can 
be put in terms of the decrease in Gibbs' free energy of the system. Under isothermal conditions 
the Gibbs' equation is given by: 
AG = AH-TAS 
which indicates that the free energy change of a system "AG" is equal to the increase or decrease 
in its enthalpy "AH" less the product of the absolute temperature "T" and the system's entropy 
change "AS". If the change in AG is negative under the conditions specified, the process under 
consideration will be spontaneous via diffusion [198]. 
For components that form an ideal solution when applied to the skin, there is no enthalpy 
change associated with the diffusive movement [198]. On the contrary, the entire decrease in free 
energy arises from increased entropy. However, some enthalpy figures into the free energy 
change in all real situations (Gibbs' equation). The diffusive process is invariably driven by 
increased system entropy. Although an individual molecule's movements are without preferred 
direction, a so-called random-walk process, their random movements eventually lead to the 
alluded to evenness of distribution. 
When a drug delivery system is applied topically, the drug diffuses out of the system onto the 
surface tissues according to their concentration gradient and can enter through the follicular 
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region, through the sweat ducts or through the unbroken stratum corneum between these 
appendages [198]. It seems that eccrine glands do not play any significant role in cutaneous 
permeability. Substances may enter the ducts, and even the glands, but there appears to be no 
penetration from these areas to the dermis. 
In contrast to deeper skin layers, the lipid layers of the stratum corneum contain no 
phospholipids [192]. They are substituted by ceramides, which only have small head groups and 
therefore allow only limited hydration of the skin. The formation of small water pores is 
therefore prevented and the organism is protected against evaporation of water. The ceramides of 
the skin differ from those in other tissues, e.g. in the brain by impair length of their lipid side 
chains. The lipid mono-layers are therefore interdigitated to complex multi-layers, which are 
partially covalently coupled to the dead horny cells. The high degree of saturation of the 
ceramides and other stratum corneum lipids like cholesterol, cholesterol esters, cholesterol 
sulfates and free fatty acids, result in a gel-like lipid superstructure with low fluidity, which 
supports the low permeability of the skin [197]. 
By the transepidermal route, penetration of substances is fairly rapid, although slower than 
intestinal tract absorption, and is almost always accompanied by some degree of pilosebaceous 
penetration as well [197]. For substances that are absorbed through both pathways, the 
transepidermal route is the principal portal of entry because of the total, relatively small, 
absorbing surface offered by the pilosebaceous units. The epidermis presents a surface area 100 
to 1000 times grater than the other routes of absorption, such as intestinal route. The appendages, 
sweat glands and hair follicles are scattered throughout the skin in varying numbers, but are 
comparatively sparse, i.e. their total cross-sectional area is probably between 0.1 and 1.0% of the 
skin area. 
The particular route that the drug may take, and the relative importance of one in contrast to 
the other, depends almost entirely on the physicochemical properties of the drug and the 
conditions, each of the contending routes of permeability may change and be overwhelmingly 
dominant. In particular, the transient diffusion that occurs shortly after the application of a 
substance to the surface of the skin is shown to be potentially far grater through the appendages 
than through the matrix of the stratum corneum [197]. After steady-state diffusion has been 
established, the dominant diffusion mode is probably no longer intra-appendageal, but occurs 
through the matrix of the stratum corneum. Flux through shunts is difficult to measure 
experimentally, except possibly through hair. The recognition of transient diffusion, occurring 
primarily via follicles and ducts and steady-state diffusion occurring primarily through the intact 
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stratum corneum, results in a considerably more self-consistent and ordered treatment of the 
process of percutaneous absorption. 
Once a substance passes through the stratum corneum, there is apparently no significant 
further hindrance to penetration of the remaining epidermal layers [197]. There is then a rapid 
entry into the circulation via the capillaries. The concentration gradient essentially ends in the 
dermal layer at the beginning of the circulation. The systemic circulation acts as a reservoir for 
the drug. Once in the general circulation, the drug is diluted and distributed rapidly with little 
systemic build-up. 
Diffusion through the horny layer is a passive process [197]. There is a little evidence to 
support specialized active transport systems for cells of the stratum corneum. The passive 
process is affected only by the substance being absorbed, by the medium in which the substance 
is dispersed, and by ambient conditions. On the other hand, percutaneous absorption is a more 
complicated process, of which epidermal diffusion is the first phase, and clearance from the 
dermis the second. This latter depends on effective blood flow, interstitial fluid movement, 
lymphatic, and perhaps other factors related to dermal constituents [197]. 
2.3. Innovative drug carrier systems for topical administration 
Different drug delivery systems have been suggested as promising vehicles for enhancing the 
activity of several compounds into the skin and mucosa. This chapter pays a special attention to 
the main drug delivery systems for topical administration such as liposomes, niosomes, 
sphingosomes, microemulsions, multiple emulsions, polymeric nanoparticles, SLN and NLC. 
2.3.1. Liposomes 
Liposomes are vesicular carriers comprising a hydrophilic core surrounded by one or more 
lipid bilayer membranes [199,200]. The membranes normally consist of a bilayer of amphiphilic 
lipids, like phospholipids (lecithins), cholesterol and glycolipids. The hydrophilic parts of lipids, 
i.e. the head groups, are oriented to the aqueous side, while the lipophilic parts, i.e. the tails, of 
the molecules of both lipid layers (mono-layers, leaflets) face each other and form the 
hydrophobic inner space of the membrane [200]. The bilayer thickness is about 5 nm [201]. 
Liposomes are one of the most extensively investigated drug delivery systems [199]. These 
carriers can be produced in sizes from below 50 nm up to several um. Lipophilic drugs can be 
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incorporated into the lipid bilayers while hydrophilic drugs are solubilized in the inner aqueous 
core or between the layers. 
The New York Academy of Science has defined small unilamellar vesicles (SUV), large 
unilamellar vesicles (LUV) and multilamelar vesicles (MLV) as the three basic types of 
liposomes differing in their size and number of lamellae [202]. This definition has been 
expanded in the meantime. 
The advantages of these systems are its high drug loading capacity, the low inherent toxicity 
and immunogenicity and its biodegradability [199]. Drug release, in vivo stability and 
biodistribution are determined by size, surface hydrophobicity and membrane fluidity. Chemical 
and physical stability problems can lead to liposome aggregation and drug degradation or 
expulsion during storage and limit the performance of liposome based drug carriers. 
Liposomes were first introduced to the cosmetic market by Dior in 1986 and they were 
considered a major innovative carrier system in the dermal area [27,182]. After some years later, 
liposomes appeared on the market in pharmaceutical products. Although, their high costs and up-
scaling problems still are a great obstacle for the broad introduction of these carriers to the 
market. 
It was shown in many studies that conventional liposomes as intact hydrophilic vesicles do 
not penetrate through the skin and therefore do not possess a transepidermal carrier function for 
active substances [203,204]. In spite of electron microscopical investigations could demonstrate 
vesicles in deeper stratum corneum after topical liposome application [205], it resulted probably 
from vesiculation by stratum corneum lipids. Identical phenomena could be shown after 
application of non-ionic liposomes [206]. Nevertheless, a certain penetration supporting effect of 
liposomal preparations is probable. For the distribution of liposomal formulations it could be 
shown that lipophilic drugs like Cortisol are held for a long time in high concentrations in the 
stratum corneum (drug localizing effect) without reaching the systemic circulation [207]. A 
possible explanation is the occlusive effect of drying lecithin lamellae resulting in an increasing 
water content which supports penetration of both hydrophilic and lipophilic drugs into the upper 
skin layers. Another explanation is a facilitated penetration by formation of low molecular 
complexes of drug and liposomal lipid. Furthermore, poorly soluble drugs can be incorporated 
into the inner area of the liposome bilayer. Upon topical application these carriers are able to 
form a drug depot and facilitate the release into the skin through a large surface. 
A new development are the so-called transfersomes [208], which make possible the 
penetration of larger quantities of even large and hydrophilic active substances. Their mode of 
action is still under discussion. The large amount of contained emulsifying agents and skin lipids 
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are probably responsible for fluidization of the liposomes during the penetration of these drug 
delivery systems. Also the osmotic gradient over the stratum corneum seems to be involved. 
Examples of registered preparations and trademarks for liposomes and lipid-based 
formulations already in the pharmaceutical market are AmBisome®, Abelcet , Alveofact , 
Amphoci/®, DaunoXome®, Pevaryf-Lipogel, HeparinPur®, HeparinPur®-forte, Doxit and 
Caelix . 
2.3.2. Niosomes 
Niosomes are vesicles formed via the self-assembly of synthetic non-ionic surfactants [209]. 
These spherical vesicles with lipid bilayers like liposomes are designated as Non-ionic Surfactant 
Vesicles (NSV) [210]. They consist of synthetic non-ionic lipids, such as polyglycerolalkylether, 
polyoxyethylenalkylether and polyoxyethylenalkylester [211], which have a high chemical 
stability due to the saturated hydrocarbon chains and intramolecular ether bonds. 
2.3.3. Sphingosomes 
Sphingosomes are vesicles with a structure similar to liposomes but their membranes consist 
of sphingolipids and/or dérivâtes, such as ceramides [212]. These structures present the 
advantage of being composed of physiologic lipids from the stratum corneum. 
2.3.4. Microemulsions 
Microemulsions represent a surfactant-containing multiple component system consisting of a 
lipophilic and a hydrophilic component, as well as at least one surfactant, mostly applied 
together with a co-surfactant. First positive results have been published regarding physiologically 
compatible mixtures of the components with an optimized release of selected drugs [213,214]. 
These systems are close to spontaneous formed nanoparticles in terms of preparation, as well 
as to micellar systems in terms of properties. Due to ratio of oil and water, they cannot be 
considered micellar solutions [215]. Macroscopically, they appear as clear, one phase isotropic 
systems. The dispersed phase consists of very small particles (5-140 nm [216]) and its properties 
resemble those of a bulk phase rather than an inner emulsion phase. The enormous reduction in 
interfacial tension, enabling the large interface, is provided by high amounts of surfactant and co-
surfactant. This low interfacial tension also supports the spontaneous formation of such systems, 
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not requiring any energy input. Consequently, as thermodynamically stable systems, 
microemulsions do not exhibit stability problems such as phase separation or increase in particle 
size. Generally, with some exceptions [216], no single component alone is capable to provide the 
required low interfacial tension. A surfactant has to be mixed with another amphiphilic substance 
like low molecular alcohols or glycols to stabilize the interface. Besides, low molecular liquids 
as co-surfactants reduce the viscosity of the overall system. Depending on the volume ratio of the 
two immiscible liquids and molecular length, surface area and volume of the surfactants, 
microemulsions can be classified to be of either oil-in-water (O/W) or water-in-oil (W/O) type. 
However, many authors suggest a bicontinuous structure, especially if oil and water are present 
in similar amounts [216]. With an excess of either oil or aqueous phase, no transparent 
microemulsion is formed, but an opaque conventional emulsion, although without energy input. 
These preparations are also referred as self-emulsifying systems. 
Microemulsions have the advantages of being transparent, thermodynamically stable, fluid 
and they can be prepared applying simple production methods. They can also improve the 
solubility and the stability of incorporated drugs, increase the bioavailability and prolong drug 
effect. A special advantage of microemulsions is an improvement of the corneal permeability 
resulting in increased intensity and duration of drug action. At present, microemulsions are been 
investigated as potential carrier systems for topical use [214,217-220]. 
The use of these systems is also associated with some drawbacks, limiting their use to the 
application of problematic drugs rather than being universal tools [216]. These drawbacks are the 
required high amount of surfactant, which can decrease the in vivo tolerability, and the stability 
problems that can arise with the use of alcohols (because of their volatility) and oils (risk of 
rancidity). Incompatibilities between the oil phase and emulsifying agents can also be observed, 
possible incomplete solubilization of drug can lead to drug precipitation and only a limited 
amount of drug, approximately 10-15% can be incorporated. These systems are also susceptible 
to qualitative and quantitative changes in composition. 
Examples of commercially available microemulsions on the pharmaceutical market are 
Contrafungin®, Capsoft®, Capsoft® Cream and Sandimmun Neoral. 
2.3.5. Multiple emulsions 
Multiple emulsions are complex systems where droplets of the dispersed phase themselves 
contain even smaller droplets, identical with or different from the continuous phase [221]. There 
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are two basic types of multiple emulsions: water-in-oil-in-water (W/O/W) and oil-in-water-in-oil 
(O/W/O). 
Multiple emulsions are a challenge to the cosmetic and pharmaceutical technology [222]. To 
obtain optimum skin care effects that are as long-lasting as possible, well-formulated bases are 
needed that not only meet the requirements for the stability, purity and safety of the chosen 
ingredients imposed by quality management but additionally achieve a perceptible and 
measurable caring effect on the skin. Owing to their structure, multiple emulsions of the W/O/W 
type combine the classical properties of W/O emulsions with those of the lighter O/W emulsions 
and hence protect the skin's barrier and provide long-lasting care while actively moisturizing the 
skin. Immediately after application of a W/O/W emulsion to the skin, the water of the external 
aqueous phase is absorbed by the skin, cooling it and providing the same moisturizing care as 
that of a moisturizing cream with an O/W base. At the same time a protective film of coalescing 
oil droplets covers the skin, gradually releasing additional entrapped water droplets and thus 
moisturizing the skin long-term. A significant moisturizing effect can still be detected 18-24 
hours even after a single application of these products. 
This type of emulsion can also significantly improve the skin's moisture binding capacity 
[222]. For example, in long-term studies over an application period of 12 weeks a significant 
improvement in the water balance of the upper skin layers could be demonstrated. Regular 
application of W/O/W emulsions steadily increased the skin's moisture, with the maximum effect 
being reached after approximately 8 weeks and kept at this high level with continued use. Due to 
the variable electrolyte content, W/O/W technology also has a normalizing effect on extremely 
dry skin conditions as well as on sensitive but healthy skin. In addition, multiple emulsions 
especially of the W/O/W type can be used as dermal sustained release systems or to protect 
sensitive drugs. Hence lipophilic (e.g. some vitamins) and hydrophilic active substances of 
different origin can be incorporated in multi-lamellar phases in the internal or external aqueous 
phase. Also, incompatible drugs can be separated in different phases. 
Examples of commercially available multiple emulsions on the pharmaceutical market are 
Nivea® Visage Optimale 3, Nivea® Visage Optimale Eye Care, Eucerin® Hydro balance, 
Rejuven® Q10 and Rejuven® Q10 eye. 
2.3.6. Polymeric nanoparticles 
Almost 30 years of intensive research have been invested in nanoparticles since their 
development by Speiser et al. in the middle of the seventies [223]. Many review and research 
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articles report about the benefits of these systems for controlled drug delivery. However, as 
market products, they are practically non-existing. 
The reasons for the lack of products based on polymeric nanoparticles are many, such as the 
lack of large scale production methods yielding a product being acceptable by the regulatory 
authorities and simultaneously cost-effective, the organic solvent residues that can appear in the 
final product (depending on the method of preparation), the cytotoxicity of polymers and 
problems with polymer chemistry, as well as the need of y-irradiation for production of sterile 
formulations, which can cause decomposition of incorporated drug and/or polymer and 
formation of potentially cancerogenic radicals [224]. 
Several synthetic polymers, such as poly(lactic acid), poly(p-hydroxybutyrate) and 
poly(lactide-co-glycolide), have shown good histocompatibility and biodegradability, and their 
safety has been extensively documented. But even the ones which are accepted for use as 
microparticles and implants, can show cytotoxic effects when delivered as nanoparticles or as 
very small microparticles [225]. There are interesting data in academic research; however, they 
still fail as a benefit for the patient. 
The research and development of polymer-based formulations for controlled drug release is 
responsible for some registered preparations and trademarks for microparticles and implants 
approved for therapeutic use. Examples of commercially available polymer-based formulations 
on the pharmaceutical market are Enantone Depot®, Decapeptyl Depot®, Parlodel LA , Parlodel 
LAR®, Profact Depot®, Suprefact Depot® and Zoladex®. Concerning nanoparticulate products, 
just one - a diagnostic for magnetic resonance tomography (MRT) imaging - has been recently 
introduced on the market. 
2.3.7. Solid lipid nanoparticles (SLN) 
The first lipid microparticles were described by Speiser et al. at the beginning of the eighties 
[226]. The production method of these particles consisted of dispersing the melted lipid in a hot 
surfactant solution applying high speed stirring. The obtained emulsion was then cooled down 
and the lipid formed solid microparticles. Disadvantages of stirring techniques are the relatively 
broad size distribution, requiring high concentrations of surfactants to obtain a mean particle 
diameter in the nanometer range. The obtained products were called "Lipid nanopellets" and they 
have been developed for oral administration [3]. 
Similar systems have been described by Domb, as Lipospheres, which were produced by 
sonication [34,227,228]. The patent obtained by Speiser was not followed up by the owner 
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Rentschler and in a number of countries patent protection does not longer exist. The lipospheres 
found also no broad application in pharmaceutical products. 
At the beginning of the nineties, SLN have been developed as an alternative to the traditional 
systems, such as emulsions, liposomes and polymeric nanoparticles [5]. SLN are nanoparticles 
with a mean average size in the nanometer range, which means approximately between 50 nm 
and 1000 nm. They consist of a matrix composed of a lipid being solid at room temperature and 
at body temperature. 
The first patents for SLN were filed in 1991, one by Muller and Lucks [229] describing the 
production of SLN by high pressure homogenization, and another by Gasco [230] describing the 
production via microemulsions. 
As reported in Chapter I, a clear advantage of these particles is the fact that the lipid matrix is 
composed by physiological lipids (e.g. GRAS status for oral and topical administration), which 
decreases the danger of acute and chronic toxicity. The choice of the emulsifying agent depends 
on the administration route and is more limited for parenteral administration [5]. 
A major disadvantage of emulsions and liposomes is the lack of protection for chemically 
labile drugs, in addition drug release takes place as a burst (emulsions) or at least relatively fast 
(from liposomes). In contrast, SLN possess a solid lipid matrix identical to polymeric 
nanoparticles. In fact, SLN were idealized by simply exchanging the liquid lipid (oil) of the 
emulsions by a solid lipid [6], which can bring many advantages in comparison to a liquid core 
(Table IV) [231]. 
Table IV: Potential advantages of lipid suspensions over lipid emulsions due to the solid state properties. 
(Adapted from Siekmann and Westesen [231]). 
Solid state 
properties 
Potential 
advantages 
Solid particle core 
Strongly reduced mobility of incorporated 
drug 
Static interface solid/liquid 
No particle coalescence, 
Improved physical stability. 
Reduced drug leakage; 
Avoidance of drug protruding into emulsifying agent film; 
Sustained/controlled drug release. 
Facilitated surface modification. 
It can be stated that SLN possess major advantages over the previous carriers, and they also 
avoid some of their major disadvantages. In addition, SLN are "low cost" products. Excipients 
and production lines are relatively cheap and production costs are not much higher than to 
parenteral emulsion manufacture. 
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For topical delivery of SLN, the full range of excipients in cosmetic and pharmaceutical 
topical products can be exploited. For oral SLN, all lipids and surfactants used for tablets, 
capsules and other oral products, such as microemulsions can be used (see Tables I and II, 
Chapter I). For parenteral administration, the lipid matrix can be produced from acylglycerols 
being composed of fatty acids contained in the acylglycerols of parenteral nutrition emulsions. 
2.3.7.1. Preparation methods of SLN 
There are three main production methods for SLN described in scientific literature. These 
methods are the high pressure homogenization technique, the microemulsions based SLN 
preparations and the solvent emulsification-evaporation technique [232]. Recently, the solvent 
displacement and the emulsification-diffusion techniques, which have been used to prepare 
polymeric nanoparticles, where also tested for SLN preparation. 
2.3.7.1.1. High pressure homogenization technique 
As it has been reported before, the high pressure homogenization (HPH) technique was 
developed by Muller and Lucks [229]. 
HPH is a technique broadly used in different areas and it is also established in 
pharmaceutical production, e.g. the production of emulsions for parenteral nutrition {Intralipid®, 
Lipofundin®) [5], This technique overcomes a major problem of other nanoparticles, i.e. the large 
scale production line is possible. This technology also leads to nanoparticles having a relatively 
homogeneous size distribution, which increases the physical stability of the aqueous dispersion. 
The dispersion grade depends on the power density and the power distribution in the 
dispersion volume [7]. High power densities result in more effective particle disruption. High 
pressure homogenizers reach by far the highest power densities (1012 - 101 W/m ). A 
homogeneous distribution of the power density is necessary to obtain narrow size distribution. 
Otherwise, particles localized in different volumes of the sample will experience different 
dispersing forces and therefore, the degree of particle disruption will vary within the sample 
volume. Inhomogeneous power distributions are observed in high-shear homogenizers and 
ultrasonifiers. High pressure homogenizers are characterized by a homogeneous power 
distribution due to the small size of the homogenizing gap (25 - 30 um). 
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Production of SLN by HPH can be done using either the hot or the cold homogenization 
technique. For both techniques, the active compound is dissolved or dispersed in the melted lipid 
prior to HPH [5,6]. 
2.3.7.1.1.1. Hot HPH 
Figure 2.2 represents the schematic procedure of SLN preparation by hot HPH technique. 
The active compound-containing melted lipid (1) is dispersed in the hot surfactant solution (2) at 
the same temperature by high-speed stirring (3) [54,233,234] or by ultrasound (4) 
[36,54,233,234]. These procedures involve the break-up of large drops into smaller ones [54]. 
The obtained pre-emulsion (5) is then passed through a high pressure homogenizer (6). 
Typical production conditions are 500-1500 bar and 3 to 5 homogenization cycles. The obtained 
nanoemulsion is cooled down, solidifies and forms a SLN aqueous dispersion (7). 
This technique is the most frequently applied. It can be applied to lipophilic and insoluble 
drugs. In general, even temperature sensitive compounds can be processed because the exposure 
time to elevated temperatures is relatively short. The technique is not suitable for incorporating 
hydrophilic drugs into SLN. During the homogenization of the melted lipid phase the drug will 
partition to the water phase resulting in a too low encapsulation. 
2.3.7.1.1.2. ColdHPH 
In the cold HPH technique (Figure 2.3), the active compound-containing melted lipid (1) is 
cooled down by means of dry ice or liquid nitrogen (2). Dry ice or liquid nitrogen are used to 
increase the brittleness of the lipid and to ease the further milling procedure. The high cooling 
rate favours a homogeneous distribution of the drug within the lipid matrix [7]. After 
solidification, the lipidic mass is grounded by means of ball or mortar milling (3) [11,44,114] to 
yield lipid microparticles in a range between 50 and 100 urn (4) [6]. The lipid microparticles are 
then dispersed in cold surfactant solution by stirring, yielding a macro-suspension (5). This 
suspension is passed through a high-pressure homogenizer at/or below room temperature (6) and 
the microparticles are broken down to form SLN (7). The cavitation and shear forces in the 
homogenization gap are sufficiently high to break the microparticles and to yield SLN. These 
particles stay in their solid state. Note that low temperatures increase the fragility of the lipid and 
favour, therefore, particle comminution [7]. 
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Figure 2.2: Schematic procedure of SLN preparation by hot HPH technique. (1) Active compound 
-containing melted lipid; (2) hot surfactant aqueous solution; (3) high-speed stirring; 
(4) ultrasounds; (5) O/W pre-emulsion; (6) HPH; (7) aqueous dispersion of lipid particles. 
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Figure 2.3: Schematic procedure of SLN preparation by cold HPH technique. (1) active 
compound-containing melted lipid; (2) cooling down; (3) mortar milling; (4) lipid microparticles; 
(5) dispersion of lipid micropaticles in cold surfactant solution; (6) HPH; (7) aqueous dispersion 
of SLN. 
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The cold HPH technique minimizes the thermal exposure of the sample, but does not avoid it 
completely due to the melting of the lipid in the initial step of the process. Therefore, this 
technique is recommended for extremely temperature sensitive compounds and hydrophilic 
compounds, which might partition from the liquid lipid phase to the water phase during the hot 
HPH. To further minimize the loss of hydrophilic compounds to the aqueous phase of SLN 
dispersion, water can be replaced by liquids with low solubility for the drug, such as oils and 
PEG 600 [6]. 
SLN prepared by this procedure possess a slightly higher polydispersity in size distribution 
compared to particles obtained by hot HPH technique, the mean particle sizes are also slightly 
higher compared to hot processing of the same lipid at identical homogenization parameters 
(pressure, temperature, number of homogenization cycles). To further reduce the mean particle 
size and to minimize the polydispersity, a higher number of homogenization cycles can be 
applied. 
The cold HPH technique can be also employed when lipid matrix is composed by lipids with 
high melting points [93]. Note that this technique is less effective in dispersing the lipids. During 
the production process, the lipid matrix remains mainly in the solid state despite of possible high 
(but short) temperature peaks occurring in the high pressure homogenizer. The homogenization 
can be performed slightly below the melting point of the lipid (e.g. 5 to 10°C) which seems to 
lead to a softening of the lipid during the homogenization process. The softened lipid can be 
more easily dispersed leading to a more uniform product of smaller mean particle size. The 
homogenization temperature needs to be carefully selected because otherwise the loss of 
hydrophilic drugs to the water phase might be too high. 
2.3.7.1.2. Microemulsions based SLN preparations 
The microemulsion technique was developed by Gasco [230] and is represented in Figure 
2.4. For the production of SLN by this technique, the matrix lipid is melted (1) and an O/W 
surfactant/co-surfactant containing aqueous phase is prepared at the same temperature (2), 
approximately 60-70°C [24,30,71,72,89,90,120-122,125-128]. Both organic and aqueous phases 
are added and mixed (3) in such a ratio that a microemulsion results (4) [127], The size of the 
microemulsion region in the phase diagram is a function of temperature, which means that a 
microemulsion can convert to a different system when e.g. reducing the temperature. Therefore, 
the microemulsion needs to be kept at elevated temperatures during the production process. For 
nanoparticle formation, the hot microemulsion is poured into excess cold water (5) 
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[15,30,54,71,72,89,90,120-122,126,128]. This leads to a "breaking" of the microemulsion, 
converting it into an ultra-fine nanoemulsion, which recrystallizes forming SLN. 
Figure 2.4: Schematic procedure of SLN preparation by microemulsion technique. (1) lipid and 
drug containing organic phase; (2) O/W surfactant containing aqueous phase; (3) emulsification 
between the organic phase and aqueous phase in order to prepare the microemulsion; (4) 
thermodynamically stable O/W microemulsion; (5) dilution of microemulsion in cold water under 
mechanical stirring; (6) aqueous dispersion of SLN. 
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Reasons for the breaking of the emulsion are the dilution with water and the reduction in 
temperature narrowing the microemulsion region. A typical microemulsion composition is 10-
15% lipid, 15-25% surfactant, 2-10% co-surfactant and 50-73% water [127]. One disadvantage 
of the microemulsion method is the dilution of the particle suspension with water. Typically, the 
concentrations are distinctly below 1% particle content. In case of processing to a final dosage 
form, large amounts of water need to be removed, which is an inconvenient procedure. 
2.3.7.1.3. Solvent emulsification-evaporation technique 
Sjóstróm and Bergenstâhl described a production method for preparing SLN dispersions by 
solvent evaporation in O/W emulsions [142]. This procedure is represented in Figure 2.5. 
The lipid material is dissolved in a water-immiscible organic solvent, such as cyclohexane 
[65,142], chloroform [65] or methylene chloride [74], and then the drug is dissolved or dispersed 
producing an organic phase containing drug (1). This organic phase is emulsified in an O/W 
surfactant containing aqueous phase (2) by mechanical stirring (3). Upon evaporation of the 
organic solvent from the obtained O/W emulsion under mechanical stirring (4) [74] or reduced 
pressure (5) [65,142], a nanoparticle dispersion is formed by precipitation of the lipid in the 
aqueous medium (6). The solvent evaporation step must be quickly, in order to avoid particle 
aggregation [6]. 
This is a method analogous to the production of polymeric nanoparticles and microparticles 
by solvent evaporation [65]. The clear advantage of this procedure over the cold HPH technique 
described by Muller et al. [229], is the avoidance of any thermal stress. The major disadvantage 
is the use of organic solvents [7]. 
2.3.7.1.4. Solvent displacement technique 
The solvent displacement technique was first described and patented by Fessi et al. [235], for 
the preparation of polymeric nanoparticles from pre-formed polymers. This method has also 
been recently used to prepare SLN [88,154,155] and is represented in Figure 2.6. 
In this process, the lipid material is dissolved in a semi-polar water-miscible solvent, such as 
ethanol, acetone or methanol [88,154], and then the active compound is dissolved or dispersed in 
this phase (1). Simultaneously, an O/W surfactant containing aqueous phase is prepared (2). The 
organic phase is poured or injected into the aqueous phase under magnetic stirring (3). A violent 
spreading is observed because of the miscibility of both phases. Droplets of solvent of nanometer 
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size are torn from the O/W interface. These droplets are rapidly stabilized by the surfactant 
molecules presented in the aqueous phase, until diffusion of the solvent is complete and lipid 
precipitation has occurred. Removal of solvent can be performed by distillation (4). SLN are 
formed after total evaporation of the water miscible organic solvent (5). 
Figure 2.5: Schematic procedure of SLN prepared by solvent emulsification-evaporation 
technique. (1) lipid and drug containing organic phase; (2) O/W surfactant containing aqueous 
phase; (3) emulsification between the organic phase and aqueous phase; (4) evaporation of 
organic solvent under mechanical stirring; (5) evaporation of organic solvent under reduced 
pressure; (6) aqueous dispersion of SLN. 
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Figure 2.6: Schematic procedure of SLN preparation by solvent displacement technique. (1) lipid 
and drug containing organic phase; (2) O/W surfactant containing aqueous phase; (3) injection of 
the organic phase into the aqueous phase under magnetic stirring; (4) elimination of organic 
solvent by distillation; (5) aqueous dispersion of SLN. 
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2.3.7.1.5. Emulsification-diffusion technique 
The emulsification-diffusion technique patented by Quintanar-Gerrero and Fessi in 1999 
[236], is used to produce polymeric nanoparticles based on synthetic polymers. This method has 
also been recently used to prepare SLN [91,149] and is represented in Figure 2.7. 
This procedure involves the use of a partially water soluble solvent (1), such as benzyl 
alcohol [91] or tetrahydrofuran [149], which is previously saturate with water (2) to ensure the 
initial thermodynamic equilibrium between the two liquids (water and solvent). The lipid is 
dissolved in the saturated solvent producing an organic phase where the drug is added. This 
organic phase is then emulsified, under vigorous agitation, in an aqueous solution containing a 
stabilizer agent obtaining an O/W emulsion (3). The subsequent addition of water to the system 
(4), under moderate mechanical stirring, causes solvent diffusion into the external phase and the 
lipid starts precipitating. Depending on its boiling point, the solvent can be eliminated by 
distillation (5) or ultrafiltration (6). After the organic solvent being totally eliminated, an aqueous 
dispersion of SLN is formed (7). 
2.3.7.2. Models for incorporation of active compounds into SLN 
According to Mehnert et al. there are three different models for the incorporation of active 
compounds into SLN [9]. These models are represented in Figure 2.8 and consist of a 
homogeneous matrix model, a drug-enriched shell model and a drug-enriched core model. The 
obtained structure depends on the formulation composition, i.e. the chemical nature of active 
compound, lipid and surfactant, and on the production method. 
A homogeneous matrix with molecularily dispersed drug or drug being present in amorphous 
clusters (Figure 2.8, left) is thought to be mainly obtained when applying the cold HPH and 
when incorporating very lipophilic drugs in SLN with the hot HPH. In the former method, the 
bulk lipid contains the dissolved drug in molecularly dispersed form, mechanical breaking by 
HPH leads to nanoparticles having the homogeneous matrix structure. The same will happen 
when the oil droplets produced by the hot HPH is being cooled, crystallize and no phase 
separation between lipid and drug occurs during this cooling process. This model is assumed for 
drugs that can show prolonged release [27]. 
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Figure 2.7: Schematic procedure of SLN preparation by emulsification-diffusion technique. (1) 
partially water soluble solvent; (2) water; (3) emulsification between the organic phase and an 
O/W surfactant containing aqueous phase; (4) addition of water under moderate mechanical 
stirring; (5) elimination of organic solvent by distillation; (6) elimination of organic solvent by 
ultrafiltration; (7) aqueous dispersion of SLN. 
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An outer shell enriched with active compound (Figure 2.8, middle) can be obtained when 
phase separation occurs during the cooling process from the liquid oil droplet to the formation of 
SLN when applying the hot HPH. The lipid can precipitate first forming a practically compound-
free lipid core. At the same time, the concentration of active compound in the remaining liquid 
lipid increases continuously. Finally, the compound-enriched shell crystallizes. This model is 
valid for drugs that lead to a very fast release. A fast release can be highly desired when 
application of SLN to the skin should increase the drug penetration, especially when using the 
occlusive effect of SLN at the same time [27]. 
A core enriched with active compound (Figure 2.8, right) can be formed when the opposite 
occurs, which means the active compound starts precipitating first and the shell will have 
distinctly less drug. This leads to a membrane controlled release governed by the Fick law of 
diffusion [27]. This model is formed when the drug concentration is close to its saturation 
solubility in the lipid. 
matrix drag-enriched drug-enriched 
she! core 
Figure 2.8: Models of incorporation of active compounds into SLN. 
(Adapted from Midler et al. [6]). 
These three models of incorporation of active compounds into SLN described before 
represent ideal types. However, there are also mixed types which can be considered as a fourth 
type. 
It has been reported that drugs can also be linked with the outer layer of SLN composed of 
phospholipids and steric stabilizers [69]. Distribution of the drug depends strongly on the 
physicochemical characteristics of the drug and components of the SLN. It is most influenced by 
the partition coefficient of the drug [68,78]. 
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2.3.8. Nanostructured lipid carriers (NLC) 
SLN were the first generation of a solid lipid nanoparticulate carrier. These systems can be 
considered as a solid development with interesting applications, however there was still some 
room for improvements which were realized in the next generation, the so-called "nanostructured 
lipid carriers" (NLC) [26-29]. 
The basic difference between SLN and NLC is that in the NLC concept controlled 
nanostructuring of the lipid matrix is performed, in order to increase drug-loading and to prevent 
drug expulsion, which gives more flexibility in modulation of drug release. This section 
describes the features of the novel NLC and the improvements compared to the first generation 
SLN. 
SLN produced by hot HPH are formed during the cooling process of the hot O/W 
nanoemulsion as mentioned before. The solid nanoparticles are formed as a consequence of the 
lipid crystallization. As a result, a perfect crystal with little imperfections for drug 
accommodation can be formed immediately after production or during long-term storage leading 
to drug expulsion. To avoid this phenomenon, a less ordered lipid matrix with many 
imperfections is desirable. This approach was realized in the NLC. Figure 2.9 presents the 
differences between a perfect crystal in SLN in comparison to a structure with imperfections in 
NLC. 
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Figure 2.9: Differences between a perfect crystal in SLN in 
comparison to a structure with imperfections in NLC. Perfect crystal in 
SLN comparable with a brick all (1) and structure with imperfections 
due to spacially very different molecules in NLC (2). (Adapted from 
Millier eia/. [27]). 
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Note that SLN are made from solid lipids and sometimes even highly purified lipids. This 
means that the lipid molecules are relatively similar, allowing the formation of structures with 
little imperfections [27]. In contrast to this, NLC are produced from lipid blends made from 
chemically very different molecules, which means mixing solid lipids with liquid lipids, such as 
oils. Figure 2.10 presents the three types of NLC compared to the relatively ordered matrix of 
SLN [27]. 
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Figure 2.10: The three types of NLC compared to the relatively ordered matrix of 
SLN. (Adapted from Muller et al. [27]). 
Due to the different chain lengths of the fatty acids and the mixture of mono-, di- and 
triacylglycerols, the matrix of NLC is not able to form a highly ordered structure [27], There are 
many imperfections which are able to accommodate the drug. NLC based on this principle are 
called "imperfect crystal type" (type I, Figure 2.10 upper right) [27]. 
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The occurrence of crystallization was identified as the basic mechanism to lead to drug 
expulsion. This phenomenon can be avoided by minimizing lipid crystallization, which means 
creating solid particles of amorphous lipid structure. This can be achieved by mixing special 
lipids which do not recrystallize anymore after homogenization and cooling down, like 
hydroxyoctacosanylhydroxystearate and isopropylmyristate [237]. This is the "amorphous type" 
of NLC (type II, Figure 2.10 lower left) [27], 
For a number of drugs, the solubility in liquid lipids is higher than in solid lipids [56,107]. 
Therefore, the loading capacity for these drugs was improved by the development of the 
"multiple type" of NLC (type III, Figure 2.10 lower right). This type is derived from W/O/W 
emulsions, which consists of an oil-in-fat-in-water dispersion. In fact, tiny oil nanocompartments 
are created inside the solid lipid matrix of the lipid nanoparticles generated by a phase separation 
process [27]. A melted lipid and a hot oil are blended; therefore, the two lipids must show a 
miscibility gap at the used concentrations, approximately at 40°C. A hot O/W nanoemulsion is 
produced at higher temperature (80°C), the lipid droplets are cooled, when reaching the 
miscibility gap, the oil precipitates forming tiny oil droplets in the melted solid lipid. Subsequent 
solidification of the solid lipid as solid nanoparticle matrix leads to fixation of the oily 
nanocompartments. This is a procedure used to increase the solubility of a number of drugs in 
the particles [107]. 
Drug penetration into certain layers of the skin can be achieved using SLN or NLC as a 
consequence of the creation of a supersaturated system [27]. Supersaturation is a very useful 
method of enhancing the permeation of drugs across membranes such as skin, because unlike 
other methods, it does not interfere with the ultrastructure of the stratum corneum. Incorporation 
of lipid nanoparticles such as SLN and NLC into topical formulations (creams, ointments, 
emulsions, gels) can be performed to create supersaturated systems. The increase in saturation 
solubility will lead to an increased diffusion pressure of drug into the skin. Figure 2.11 shows the 
phenomenon of triggered drug release and supersaturation effect of NLC into a dermal 
preparation [27]. 
During storage, the drug remains in the NLC because these particles preserve their 
modification. After application to the skin, the increase in temperature and water loss observed 
lead to transformation to a more ordered lipid modification and are responsible for drug 
expulsion from the lipid matrix. The drug is expelled into the emulsion already saturated with 
drug and thus leading to supersaturation. This phenomenon increases the thermoactivity and 
leads to drug penetration into the skin. 
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In comparison to SLN, it can be stated that the novel NLC can be used for all purposes that 
the SLN have previously been exploited for. However, NLC can provide additional benefits such 
as higher drug loading capacity and avoidance or minimization of drug expulsion during storage. 
This is due to the less ordered structure of these new drug carrier systems. 
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Figure 2.11: Triggered drug release and supersaturation effect. Drug-loaded NLC are 
incorporated into a dermal preparation. On the shelf the drug stays inside the NLC 
(upper); after application to the skin, the increase in temperature and water loss initiate 
transition to higher ordered structure in the lipid particle, drug is being expelled, 
supersaturation occurs increasing the thermodynamic activity and leading to increased 
penetration of the drug into the skin. (Adapted from Millier et al. [27]). 
Chapter H 41 
2.4. Lipid polymorphism 
Polymorphism is the ability of a compound to crystallize in more than one distinct crystalline 
species with different internal lattices [238,239]. Lipid crystallization is an important point for 
the performance of the lipid nanoparticles. Therefore, polymorphism and the polymorphic 
transitions of acylglycerols are discussed in this section. 
The internal structure of the lipid matrix can appear in a variety of ways, as shown in Table 
V. Lipids can crystallize in different three-dimensional structures, which are represented in Table 
VI [240]. 
According to Larsson [241], short spacings of triacylglycerols can be described as following: 
1. a: Hexagonal (H) subcell with a lattice spacing of 0.415 - 0.42 nm; 
2. P': Orthorhombic perpendicular (Ox) subcell with strong lattice spacings of 0.42 - 0.43 
nm and 0.37 - 0.40 nm; 
3. p: Triclin parallel (T//) subcell with strong lattice spacings of 0.46 nm. 
Further polymorphic forms are found with complex acylglycerols like mixed acid 
triacylglycerols or partial acylglycerols. Multiple P' and P, sub-a or intermediate forms, usually 
mentioned as p;, have been described [242]. However, nomenclature and properties of monoacid 
triacylglycerols can also be used for these complex acylglycerols that have similar crystal 
packing [243]. 
Table V: Characterization of the crystal systems. (Adapted from 
Barrow [238]). 
Crystal system Elementar lattice 
Axle Angle 
Cubic a = b = c a = p = y = 90° 
Hexagonal a = b, c a = p = 90° 
y= 120° 
Rhomboedric a = b = c a = P = Y * 90° 
Tetragonal a = b, c a = P=Y = 90° 
Orthorhombic a, b, c a = p = Y = 90° 
Monoclinic a,b, c a = p = 90° 
Triclinic a, b, c a, P,y 
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Table VI: Three-dimensional structure of the crystal order in the three main polymorphs from monoacid 
triacylglycerols. (Adapted from [243,244]). 
a - Modification 3' - Modification P - Modification 
Crystal system Hexagonal Monoclin Triclin 
Subcell Orthorhombic Orthorhombic Triclin 
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Crystallization of bulk triacylglycerols from the melt after rapid cooling usually occurs in the 
less stable a-form, which transforms via the p'-form, into the more stable p-form upon heating 
or during storage time [36]. 
In colloidal dispersions such as SLN, these transformations of triacylglycerols are faster than 
in the bulk material, which leads to a change in the relative fraction of the polymorphic forms 
[63]. Depending on the chemical nature of the lipid and the production conditions, different 
fractions of a and P' modifications may occur. This phenomenon can lead to a reduction of the 
melting point, or more precisely, changes in form and shift of the melting peak. These created 
polymorphic forms are not long-term stable, leading to a gradual transformation to more stable 
modifications, which means increasing content of P'/Pi and finally p. This is not desired because 
the change in lipid structure is responsible for drug expulsion during storage and changes in the 
release profile of incorporated drug. 
Drug expulsion from suppository lipid matrices is a very well known phenomenon for many 
years [245]. There are many possibilities for incorporating drugs in the lipid matrix. In general, 
when a crystal is formed, foreign molecules can be incorporated by replacing host molecules in 
the lattice by a guest molecule or by being incorporated in between host molecules (however the 
guest molecule needs to be 20% smaller than the host molecule) [246]. 
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In addition, drugs can be localized in between the lipid lamellae, resulting an increase in the 
lattice spacing "d", detectable by x-ray diffraction studies [247]. The drug can also be present in 
form of amorphous clusters, mainly localized in the imperfections of the crystal. In this case, 
drug accommodation is improved when the lipid crystal has more imperfections [247]. Thus, 
drug loading can be increased by using rather crude lipid mixtures or by controlled 
nanostructuring of the lipid matrix, i.e. creating as many imperfections as possible. Depending 
on the nature of the lipids used for blending the lipid matrix, different types of NLC will be 
obtained, as it has been reported in Chapter II. 
It was found that the state of crystallinity of the lipid particles is also related to their physical 
stability in aqueous dispersions, i.e. absence or induction of particle aggregation and finally gel 
formation. It was observed that particle aggregation was accompanied, simultaneously, by 
transformation of high energetic polymorphic forms (i.e. mainly a) to more stable lipid 
modifications [98]. In general, the next step after particle aggregation is the increase of viscosity 
and the formation of soft and finally relatively rigid gels [66,97,248], 
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MATERIALS 
The raw materials used to prepare lipid nanoparticles represent a mixture of several chemical 
compounds [249]. 
In the context of this work, well-tolerated and in vivo biodegradable substances were selected 
for the preparation of lipid nanoparticles. The chosen lipids, emulsifying and gel-forming agents 
have GRAS status and are well accepted for human use. 
3.1. Lipids 
As matrix material for the lipid nanoparticles (either SLN or NLC) any lipid can be used 
since has a sufficiently high melting point, which normally should be higher than 37°C. 
3.1.1. Dynasan®\12,114,116 and 118 
Dynasan are market products from Sasol GmbH (Witten, Germany). These products consist 
of lipid materials with a high content of microcrystalline triacylglycerols (approximately 90%) 
and monocarboxilic acids (approximately 10%). The triacylglycerols are glycerol esters of 
selected, even-numbered and unbranched fatty acids of natural origin, are free from antioxidants 
and other stabilizing agents. In the present work, Dynasan®\\2, 114, 116 and 118 have been 
used. 
Dynasan®112 (triacylglycerol of lauric acid) is soluble in n-hexane and ether, and hardly 
soluble in ethanol [250]. 
Dynasan®I \4 (triacylglycerol of myristic acid) is slightly soluble in rc-hexane and ether, and 
is also hardly soluble in ethanol [250]. 
Dynasan®\\6 (triacylglycerol of palmitic acid) and 118 (triacylglycerol of stearic acid) are 
hardly soluble both in rc-hexane and ether as well in ethanol [250]. 
All Dynasan types are practically insoluble in water. If the individual Dynasan are rapidly 
cooled from the melt, glassy amorphous masses are initially formed which change on standing 
into crystalline modifications with volume expansion. The stable P-modification has a very sharp 
melting-point and is of triclinic structure. Dynasan®116 crystallizes in a P-modification (x-ray 
reflections at 4.6, 3.8 and 3.7 nm, long spacing dooi = 4.5 nm). 
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Dynasan should be stored in well-sealing containers and protected from light. Under these 
conditions, the product has a shelf life of at least 3 years. All products are stable against 
oxidation [251]. 
3.1.2. Softisan®\54 
Softisan®154 is a market product from Sasol GmbH (Witten, Germany), and belongs to the 
semi-synthetic acylglycerols, consisting of a mixture of di- (approximately 4%) and 
triacylglycerols (approximately 96%). It is defined as a special hard fat based on triacylglycerols 
with blends of natural, saturated even-numbered unbranched vegetable fatty acids with a chain 
length of Cio-Cig. It is free from antioxidants and stabilizers [150]. 
Softisan®154 is classified as "hydrogenated palm oil", with a melting point between 53 and 
55°C and a drop point2 between 53 and 55°C. It is characterized by an exceptional hardness at 
room temperature and a sharp melting range. The narrow interval between melting and 
solidification points allows a rapid and economic processing. This hard fat can be heated far 
beyond its melting point without its fast solidification and good contractibility being changed. It 
is exceptionally resistant against oxygen, so that there is no rancidity risk. This lipid is soluble in 
ether, toluol and acetone and is insoluble in water and ethanol. 
3.1.3. WitepsofYLS, S55, E75 and E85 
Witepsol bases are market products from Hiils AG (Witten, Germany), consisting mainly of 
mixtures of triacylglycerols of higher saturated fatty acids (C8Hi7COOH to C18H37COOH) along 
with mono- and diacylglycerols [253]. They are white, odourless hard fats containing 
acylglycerols of vegetable origin and type specific additives. 
In the present work, WitepsofVti, S55, E75 and E85 have been used. Table VII shows the 
main typical properties of the used Witepsol bases. 
Table VII: Main typical properties of some Witepsol bases. (Adapted from Kibbe [254]). 
Witepsol 
base 
Acid 
value 
Hydroxyl 
value 
Melting point 
(°C) 
Saponification 
value 
Solidification 
point 
H5 <0.2 5 34-36 235-245 33-35 
S55 <0.1 50-65 33.5-35.5 215-230 28-33 
E75 <1.3 5-15 37-39 220-230 32-36 
E85 <0.3 5-15 42-44 220-230 37-42 
2 Temperature at which the first drop of the melting substance to be examined falls from a cup under defined 
conditions [252]. 
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3.1.4. Imwitor9W and 191 
Imwitor®900 and 191 are market products from Htils AG (Witten, Germany), consisting of 
glyceryl stéarate. Imwitor®900 has a content of 40-50% of this lipid, while Imwitor 191 has a 
content of 90%. They are soluble in acetone and diethyl ether, hardly soluble in heptan and 
insoluble in water [253]. Imwitor®900 is used as surfactant, co-surfactant and viscosifying agent 
in dermatological preparations [251]. 
3.1.5. Compritot888 ATO 
Comprito^SSS ATO is a market product from Gattefossé GmbH (Weil am Rhein, Germany), 
based on glycerol esters of behenic acid (C-22). It consists of glycerol tribehenate (28-32%), 
glycerol dibehenate (52-54%) and glycerol monobehenate (12-18%). The main fatty acid is 
behenic acid (>85%) but other fatty acids (Ci6-C2o) are also present [255]. 
Due to the presence of partial acylglycerols, Comprito/®$$8 ATO has an amphiphilic 
character. Its hydrophilic-lipophilic balance (HLB) is approximately 2. The drop point is 69-
74°C and the density is 0.94 g/cm3 [256]. This lipid has a peroxide value lower than 6 meq 
02/kg, which gives a long stability character. It is soluble in chloroform, methylene chloride and 
xylene when heated and is insoluble in ethanol, ethyl ether, mineral oils and water. 
It is used as lubricating agent for tablets and capsules, as a binding agent for direct 
compression and as a lipophilic matrix in sustained release formulations. In dermal preparations 
this lipid is used as viscosifying agent for oil phases in W/O or O/W emulsions and improves 
heat stability of emulsions. It has to be stored below 35°C because of the risk of caking, avoiding 
the contact with air, light, heat and moisture in its original packing [255]. 
3.1.6. Precirof ATO 5 
Precirof'ATO 5 (glycerol palmitostearate) is a market product from Gattefossé GmbH (Weil 
am Rhein, Germany). It is composed of a blend of mono- (8-17%), di- (approximately 54%) and 
triacylglycerols (approximately 30%) of saturated fatty acids of mainly natural origin (C16H32O2) 
and (C18H36O2) [255]. The main components are palmitic acid and stearic acid (approximately 
48%). 
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This lipid has a melting point between 50 and 60°C, the HLB value is approximately 2 and 
the drop point is between 53 and 57°C [255]. It is soluble in chloroform and methylene chloride 
and is insoluble in mineral oils, ethanol and water. 
Precirof ATO 5 is a fine white powder used as taste-masking agent in wet granulation, melt 
granulation and hot-melt coating, as sustained release lipophilic matrix and as a lubricating agent 
with binding properties for tablets and powders filled into hard gelatine capsules. The storage 
must be below 35°C, avoiding the contact with air, light, heat and moisture. For storage above 1 
month it must be between 2 and 15°C. 
3.1.7. Precifac® ATO 5 
Precifac® ATO 5 (cetyl palmitate) is a market product from Gattefossé GmbH (Weil am 
Rhein, Germany). Cetyl palmitate is a wax, composed of cetyl alcohol ester of palmitic acid, 
which chemically is hexadecyl hexadecanoate (C32H04O2). 
Differential scanning calorimetry (DSC) investigations showed for Precifac® ATO 5 an onset 
temperature of 51.9°C and a peak maximum at 55.9°C [178]. Its drop point is between 52 and 
53°C. It is soluble in chloroform and acetone and practically insoluble in paraffin, water and 
ethanol [255]. 
In topical formulations, such as creams and fluid emulsions, Precifac® ATO 5 can be used as 
viscosifying agent [251]. 
3.1.8. Apifif 
Apifií® is non-ionic hydrophilic white beeswax obtained from Gattefossé GmbH (Weil am 
Rhein, Germany). The raw materials used in its production are waxes obtained from the 
honeycomb of the bee Apis mellifera Linné and polyethylene glycols from petrochemical origin. 
Chemically, this beeswax consists of 70-80% of a mixture of various esters composed of 
straight-chain monohydric alcohols with even-number carbon chains from C24-C36 esterified with 
straight-chain acids, which also have even-numbers of carbon atoms up to C26 together with 
some Ci8 hydroxyl acids [255]. The chief ester is myricyl palmitate. Also present are free acids 
(approximately 14%) and carbohydrates (approximately 12%), as well as approximately 1% of 
free wax alcohols and stearic esters of fatty acids. 
Apifif has a HLB lower than 5 and a drop point between 59 and 70°C [255], Its peroxide 
value is below 6 meq 02/Kg and its density is between 0.95 and 0.96 g/cm3 [254]. This structural 
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self-emulsifying base is insoluble in ethanol and water, slightly soluble in vegetable oils and 
soluble in chloroform and methylene chloride when heated at 60°C [255]. 
This lipid is used as a non-ionic O/W emulsifying agent, stiffening agent and controlled-
release vehicle. It is designed for emulsions in skincare, suncare and haircare, and for O/W 
masks in make-up applications. It can also be used as an additive for lipsticks and pencils due to 
its moisturizing and film forming properties [255]. During storage, the contact with air, light and 
heat must be avoided. 
3.1.9. Miglyofmi 
M/g/yo/®812 is a liquid triacylglycerol obtained from Caelo GmbH (Hilden, Germany). This 
lipid consists of middle-chain-triacylglycerols (C8-Cio), having a density between 0.945 and 
0.955 g/cm3 [257]. It is used as skin oil and dissolution medium for many substances [251]. 
3.2. Emulsifying agents 
The IUPAC3 defines the properties of an emulsifying agent as a surfactant which is positively 
adsorbed at interfaces and lowers the interfacial tension. When present in small amounts, it 
facilitates the formation of an emulsion or enhances its colloidal stability by decreasing either or 
both of the rates of aggregation and coalescence [258]. 
These properties are primarily attributed to the traditional emulsifying agents. They are 
characterized by an amphiphilic structure and are capable to form micellar aggregates. Polymers 
can function in the same manner, if they are sufficiently surface-active. The use of polymers as 
primary emulsifying agents is widely spread in food products but plays a minor role in 
pharmaceutical and cosmetic formulations [259]. 
As referred before, SLN and NLC are stabilized by surfactants or by polymers in aqueous 
dispersions. In the present work, a full range of emulsifying agents used either in cosmetic 
products or in pharmaceutical products was selected. 
3.2.1. Tween®80 
Tween®S0 or polyoxyethylene 20 sorbitan monooleate (polisorbate 80) is a market product 
from ICI Surfactants (Essen, Germany). It consists of a series of partial fatty acid esters of 
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sorbitol and its anhydrides copolymerized with approximately 20 moles of ethylene oxide for 
each mole of sorbitol and its anhydrides [254]. The resulting product is therefore a mixture of 
molecules of varying sizes rather than an uniform mixture of a single chemical. It is miscible 
with water, alcohol, dehydrated alcohol, ethyl acetate and methyl alcohol and it is insoluble in 
liquid paraffin and fixed oils [260]. It has a HLB of 15.3 [261]. 
Tween®$0 is a non-ionic surfactant widely used as emulsifying agent in the preparation of 
stable O/W pharmaceutical emulsions and can also be used as a solubilizing agent for a variety 
of substances, including essential oils and oil-soluble vitamins, and as wetting agents in the 
formulation of oral and parenteral suspensions. It is generally regarded as non-toxic and non-
irritant material widely used in cosmetics and topical pharmaceutical formulations. 
3.2.2. Span®85 
Span®%5 or sorbitan trioleate is a market product from ICI Surfactants (Essen, Germany). It 
consists of a series of mixtures of partial esters of sorbitol, and its mono- and dianhydrides with 
fatty acids [254]. It is widely used in cosmetics, food products and pharmaceuticals as lipophilic 
non-ionic surfactant. Span®85 is mainly used in pharmaceutical formulations as emulsifying 
agent in the preparation of creams, emulsions and ointments for topical application [261]. When 
used alone, produces stable W/O emulsions and microemulsions but is frequently used in 
combination with varying proportions of a polysorbate to produce either W/O or O/W emulsions 
or creams of varying consistencies. Span 85 has a HLB of 1.8. 
3.2.3. Lutrof*F68 
Lutroï®¥6S or poloxamer 188 is a non-ionic surfactant obtained from BASF AG 
(Ludwigshafen, Germany). It consists of polyoxyethylene-polyoxypropylene block copolymer 
used primarily in pharmaceutical formulations as emulsifying or solubilizing agent [262]. The 
polyoxyethylene segments are hydrophilic while the polyoxypropylene segments are 
hydrophobic. It is freely soluble in water and alcohol and it has a HLB of 29 [263]. 
3.2.4. Lipoitf S75 
LipoicfS75 or soybean lecithin is a market product from Lipoid KG (Ludwigshafen, 
Germany). It is described as a complex mixture of acetone-insoluble phosphatides, which consist 
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chiefly of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine and 
phosphatidylinositol, combined with various amounts of other substances such as 
triacylglycerols, fatty acids and carbohydrates as separated from a crude vegetable oil source 
(soja) [254]. 
It is partially soluble in water, but readily hydrates to form emulsions. The oil-free 
phosphatides are soluble in fatty acids, but are practically insoluble in fixed oils [264]. When all 
phosphatide fractions are present, lecithin is partially soluble in alcohol and practically insoluble 
in acetone. 
Lecithin is mainly used in food and pharmaceutical industry as dispersing, emulsifying and 
stabilizing agent [260]. 
3.2.5. TegoCare®450 
Tego Care®450 or polyglycerol-methylglucose distearate is a market product from 
Goldschmidt (Essen, Germany). It is described as a PEG-free, non-ionic O/W-emulsifying agent, 
with a HLB value of 11.5 [265]. 
3.2.6. Tyloxapot® 
Tyloxapof is a polymer of 4-(l,l,3,3-tetramethylbutil)-phenol with ethylene oxide and 
formaldehyde obtained from Caelo GmbH (Hilden, Germany) [257]. It is described as a non-
ionic surfactant which can be used to stabilize either O/W or W/O emulsions [260]. 
3.2.7. Lunette®^ 
Lanette®N is an anionic emulsifying wax obtained from Gattefossé (Weil am Rhein, 
Germany). It contains cetostearyl alcohol, purified water and either sodium lauryl sulphate or a 
sodium salt of similar sulfated higher primary aliphatic alcohol [254]. This wax is used in 
cosmetic and topical pharmaceutical formulations primarily as an emulsifying agent, and is 
added to fatty or paraffin bases in order to facilitate the production of O/W emulsions [255]. 
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3.3. Gel-forming agents 
Hydrogels are semi-solid systems consisting of highly swollen, hydrophilic polymer 
networks that can absorb large amounts of water and drastically increase in volume [266]. It is 
well known that physicochemical properties of the hydrogel depend not only on the molecular 
structure, the gel structure and the degree of cross-linking, but also on the content and state of 
water in hydrogel. 
In the present work, four different types of hydrogels were prepared, in order to incorporate 
aqueous dispersions of SLN and NLC. 
3.3.1. Xanthan gum 
Xanthan gum (XG) was obtained from Sigma Aldrich (Deisenhofen, Germany). It is a high 
molecular weight polysaccharide gum (MW ~ 2x106 g/mol) produced by a pure-culture 
fermentation of a carbohydrate with Xanthomonas campestris, then purified by recovery with 
isopropyl alcohol, dried and milled [260]. It contains D-glucose and D-manose as the dominant 
hexose units, along with D-glucuronic acid [254]. 
The backbone of this polysaccharide consists of four p-D-glucose units linked at the 1 and 4 
positions, and is therefore identical in structure to cellulose. Trisaccharide side chains on 
alternating anhydroglucose units distinguish XG from cellulose. Each side chain comprises a 
glucuronic acid residue between two manose units. At most of the terminal mannose units a 
pyruvate moiety is present; the mannose nearest the main chain carries a single group at C-6. The 
resulting stiff polymer chain may exist in solution, as a single, double or triple helix which 
interacts with other XG molecules to form complex, loosely bound network. It is soluble in hot 
and cold water [260]. 
This polymer is widely used in oral and topical pharmaceutical formulations, cosmetics and 
food products as suspending and stabilizing agent [267]. It is generally regarded as non-toxic and 
non-irritant at the levels usually employed. 
3.3.2. Hydroxyethylcellulose 4000 
Hydroxyethylcellulose (HEC) was obtained from Sigma Aldrich (Deisenhofen, Germany). It 
is a non-ionic, water-soluble polymer widely used in pharmaceutical formulations [254]. It is 
prepared by treating cellulose with NaOH and then reacted with ethylene oxide [260]. 
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It is primarily used as a thickening agent in ophthalmic and topical formulations, although it 
is also used as a binder and film coating agent for tablets [267]. 
The concentration of HEC used in a formulation is dependent upon the solvent used and the 
MW of the grade [254]. It is available in several grades, carrying in viscosity and degree of 
substitution and some grades are modified to improve their dispersion in water. The grades are 
distinguished by appending a number indicative of the apparent viscosity, in mPa.s, of a 2% 
im/V) solution measured at 20°C. 
This polymer is soluble either in hot or cold water, forming clear, smooth, viscous and 
uniform solutions [260], It is practically insoluble in acetone, ethanol, ether, toluene and most 
other organic solvents. In some polar organic solvents, such glycols, HEC swells or is partially 
soluble [254]. 
3.3.3. Carbopot®934 
Carbopofs>934 (polyacrylate, PA) was obtained from BF Goodrich (USA). It is a carbomer 
polymer, mainly used in liquid and semi-solid pharmaceuticals as a suspending or viscosifying 
agent [268]. It is a synthetic polymer with a high MW formed by repeating units of acrylic acid, 
crosslinked with either allylsucrose or allylethers of pentaerythritol [254]. It contains between 56 
and 68% of carboxylic acid (-COOH) groups as calculated on the dry basis. It forms a gel like 
structure in water, alcohol and glycerine when neutralized with alkali hydroxides or amines 
[260]. 
3.3.4. Chitosan 
Chitosan (CH, minimum 85% deacetylated) was obtained from Sigma Aldrich (Deisenhofen, 
Germany). It is a hydrophilic biopolymer, which chemically is p-(l,4)-2-amino-2-deoxy-D-
glucose [267]. Chitosan is industrially obtained by hydrolysing the aminoacetyl groups of chitin, 
which is the main component of the exoskeleton of crustaceans, by an alkaline treatment 
[269,270]. This polymer is insoluble in water, but can be solubilized in dilute acetic acid due to 
the formation of the acetate salt [271]. 
CH has a MW between 500 000 and 800 000 g/mol and it is considered to be biocompatible, 
biodegradable and non-toxic [270]. Its cationic character and potential functional groups make it 
an attractive biopolymer for many biomedical and pharmaceutical applications. In an acidic 
environment, CH swells into a hydrogel and has also been used to slow drug release [269]. 
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3.4. Water 
The water used in all experiments was Purified Water (European Pharmacopoeia, 4 ed.) 
obtained from a MilliQ Plus, Millipore (Schwalbach, Germany). It is mainly characterized by an 
osmotic resistance of 18 MOhm.cm and a total organic content equal or lower than 10 ppb [252]. 
3.5. Clotrimazole 
Clotrimazole, or (l-2-chlorphenyl-diphenylmethyl)-l-4-imidazole, was obtained from Caelo 
GmbH (Hilden, Germany). It is synthesized by the reaction of o-chlorotritylchloride with 
imidazole in the presence of a tertiary amine [257,272]. 
This drug is a synthetic derivative of imidazole with a broad-spectrum antifungal agent that 
inhibits growth of pathogenic dermatophytes [273], yeasts [188] and Pityrosporon obiculare 
(Malassezia furfur) [272]. It exhibits fungicidal activity in vitro against isolates of Plasmodium 
falciparum [274], Fusarium solam [275], Triadelphia pulvinata [276], Thrichophyton rubrum 
[277,278], Thrichophyton mentagrophytes [277], Epidermophyton floccosum [277], 
Mwrosporum canis [277,279] and Candida albicans [188]. It has a local antifungal effect, 
especially on the mucous membranes, which is widely used for the treatment of mycotic 
infections of the genitor-urinary tract [280]. It shares with econazole and miconazole the first 
choice status for topical treatment of tinea pedis, tinea crusis and tinea corporis due to any of the 
afore-mentioned organisms, candidiasis due to Candida albicans and Tinea versicolor due to 
Pityrosporon obiculare, as well as for local treatment of oropharyngeal candidiasis [190]. 
The structure of clotrimazole is represented in Figure 3.1. 
I N 
Figure 3.1: Structural formula of clotrimazole. 
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Clotrimazole is a colorless, odourless, tasteless and crystalline solid [272]. It is practically 
insoluble in water (<0.01 mg/ml), soluble in chloroform and methanol (>100 mg/ml), in ethanol 
(95 mg/ml) and in diethyl ether (14 mg/ml). It is freely soluble in acetone and methyl alcohol 
[260]. 
This drug is stable in the solid state under normal storage conditions [272]. It is unaffected by 
heat and by exposure to daylight for up two weeks. In solution, the stability of clotrimazole is pH 
dependent. It is stable in alkaline media, but it decomposes into o-chlorophenyl-
diphenylmethanol and imidazole in acid media [272]. A relative hydrolytic stability in solution in 
ethanol-water and isopropanol-water mixtures under acidic, neutral and alkaline conditions has 
been reported. 
DSC curve of clotrimazole shows a single sharp endotherm with an extrapolated onset 
temperature of 143°C and the molar melting enthalpy "AH" was calculated to be 7540 cal/mol 
[272]. A melting range between 141° and 145°C for this drug has been reported. 
After topical administration, clotrimazole undergoes rapid biotranformation into inactive 
metabolites. It has been found that when clotrimazole was applied in the skin as a cream, the 
drug penetrated the skin to a depth of 2000 urn and no drug substance or metabolites were 
detected in the serum [281]. A small quantity of the material (up to 0.4%) was detected in the 
urine over a five-day period. 
Several methods have been proposed for the identification of clotrimazole, such as 
titrimetric, spectrophotometric and chromatographic analysis [272]. Kráõmar et al. [282] have 
characterized the UV spectra of clotrimazole in methanol and in 0.1 N HC1 as an aid to the 
identification of this drug substance. 
3.6. Other materials 
3.6.1. Glycerol 85% 
Glycerol is an osmotic agent with lubricating and moisturising properties and has a wide 
range of pharmaceutical applications [260]. It is miscible with water and alcohol, slightly soluble 
in acetone, practically insoluble in chloroform, ether and in fixed and essential oils. 
Glycerol 85% is an aqueous solution containing not less than 83.5% (m/m) and not more than 
88.5% (m/m) of propane-1,2,3-triol [252]. In the present work, this product was used as 
humectant and emollient in the preparation of the hydrogels. 
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3.6.2. Sodium hydroxide 
Sodium hydroxide (NaOH) is a dry, very deliquescent, white or almost white strongly 
alkaline powder. It is completely soluble in water and freely soluble in alcohol [260]. An 
aqueous solution of NaOH at 5% (m/V) was used as a neutralizing agent of the PA in order to 
form a gel. 
3.6.3. Acetic acid 
Acetic acid (CH3COOH) is a clear colourless liquid with a pungent odour. This product is 
miscible with water, alcohol and glycerol [260]. An aqueous solution of CH3COOH at 4% (m/V) 
was used to start gel formation of CH. 
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CHAPTER IV 
METHODS 
4.1. Preparation of SLN and NLC 
The preparation of SLN and NLC was performed by the hot HPH technique, as described by 
Muller and Lucks [229]. The principle of HPH for the production of stable emulsions has been 
known for about 100 years [283]. The first homogenizer was introduced by Auguste Gaulin in 
1890. In spite of the numerous modifications that this technique has suffered, the basic principle 
of high-pressure relief has not changed. 
The high-pressure homogenizer consists of a high-pressure plunger pump with a subsequent 
relief valve [283]. The function of the plunger pump is to provide the energy level required for 
the relief. The relief valve (i.e. the homogenizing valve) consists of a valve seat, which is fixed, 
and an adjustable valve (Figure 4.1). Both parts form an adjustable radial precision gap. The gap 
conditions, the resistance and thus the homogenizing pressure, vary as a function of the force 
acting on the valve. An external impact ring forms a defined outlet cross section and prevents the 
valve casing from damage due to the flow. 
Homogenized 
Product 
Figure 4.1: The principle of HPH. (Adapted from Jahnke [283]). 
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Briefly, in order to prepare SLN and NLC, in the present work the lipid phase was melted at 
90°C. This hot lipid phase was dispersed in a hot surfactant aqueous solution (90°C), using an 
Ultra-Turrax T25 {Jahnke & Kunkel GmbH and Co KG, Staufen, Germany) at 8000 rpm for 1 
min. The obtained pre-emulsion was then homogenized at 90°C, using an APV Micron Lab 40 
{APV Deutschland GmbH, Lubeck, Germany) and applying a pressure of 500 bar. The obtained 
product was filled in siliconized glass vials, which were immediately sealed. Figure 4.2 shows a 
picture of the discontinuous APV Micron Lab 40 used for the preparation of SLN and NLC. 
Figure 4.2: Discontinuous APV Micron Lab 40 used for the 
production of SLN and NLC. 
4.2. Preparation of hydrogels-loaded SLN and NLC 
The SLN and NLC containing hydrogels were composed of 5% glycerol, 50% SLN or NLC 
aqueous dispersion, a sufficient amount of the gel-forming polymer and purified water. 
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Briefly, the gel-forming polymer, glycerol and water were weighed in a beaker and stirred 
with a high speed stirrer (Cito Unguator Konictzko, Bamberg, Germany) at approximately 1000 
rpm for 5 min. Finally, the SLN or NLC aqueous dispersion was added under continuous stirring 
at 1000 rpm for 3 min. 
4.3. Measurement of particle size and zeta potential 
4.3.1. Laser light diffraction 
Laser light diffraction (LD) is a technique used for determination of the sizes of particles in 
the range of 0.5 urn to 100 urn. 
In order to calculate the size distribution, the instrument uses Fraunhofer diffraction of laser 
scattered from particles in dispersion. These particles cause diffraction of laser light through 
different angles and create a diffraction pattern of light rings with varying radii (Figure 4.3). The 
diffraction patterns created by differently sized particles are detected on a ring detector and are 
used to calculate the size distribution. The diffraction pattern depends on the particle size, i.e. 
small particles create a large diffraction angle, while large particles create a small diffraction 
angle [284]. 
Large particle 
Multielement 
detector 
Small particle 
Figure 4.3: Principle of operation of a laser diffractometer. The diffraction angles and 
the diffraction pattern created are a characteristic function of particle size. The diffraction 
angle is small for large particles and large for small particles. (Adapted from Muller [2]). 
The laser diffractometers are constituted by a laser, an optical unit to expand the beam, and a 
Fourier Transform lens for focussing the scattered light onto a ring detector (Figure 4.4). 
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Figure 4.4: Schematic representation of a laser diffractometer. (Adapted from Miiller [2]). 
The particle dispersion is located in a measuring cell at a certain distance from the receiver 
lens. A great advantage of the laser diffractometers, is that any transparent dispersion medium 
can be used, such as aqueous or organic liquids and air. Size measurements can be performed 
maintaining the particles in their original dispersion medium, thereby minimizing changes in the 
sample due to modifications in the measurement conditions [2]. 
In the present work, LD was performed using a Coulter LS 230 (Coulter Electronics, 
Germany). LD data were evaluated using volume distribution, which means that a diameter 90% 
(d90%) value of 1 urn indicates that 90% of the particles possess a diameter of 1 um or less. 
Note that larger particles are overestimated in a volume distribution. 
In the case of hydrogels, prior to particle size analysis by LD, the semi-solid SLN and NLC 
formulations were diluted with double-distilled water to weak opalescence. All measurements 
were performed in triplicate. 
4.3.2. Photon correlation spectroscopy 
Photon correlation spectroscopy (PCS) is a technique employed to determine the mean 
particle size (PCS diameter) and size distribution (polydispersity index, PI) [2]. PCS consists of a 
laser light scattering technique suitable for application to particles ranging in size from 5 nm to 
approximately 3 um. The light scattered from the particle dispersion is used to calculate the 
correlation function "G(x)": 
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where "£>" is the diffusion coefficient of particles, "K" is the scattering vector of light and "x" is 
the sample time. 
The scattering vector of light "K" is given by: 
where "«" is the refractive index of the suspension medium, "A" is the wavelength of the light 
and "0" is the scattering angle. 
The diffusion coefficient "£>" obtained from the fit of the measured correlation function can 
be used to calculate the mean particle diameter "<f by application of the Einstein equation: 
3npD 
where " F is the Boltzmann's constant, "7" is the absolute temperature and "/?" is the viscosity of 
the medium. 
The schematic set up of a PCS apparatus is represented in Figure 4.5. The apparatus consists 
of a laser, a temperature controlled sample cell and a photomultiplier (PM) for detection of the 
scattered light at a certain angle (for example 90°) [2]. The PM signal is transferred to a 
correlator for calculation of the "G(T)". This "G(T)" is relayed to a microprocessor for calculation 
of "£>" and the correlated mean particle size. 
PCS does not exploit the absolute intensity of the scattered light, but rather fluctuations in 
intensity. Small particles diffuse faster than large ones causing a stronger fluctuation in the 
scattering signal and a more rapid decaying "G(T)'\ For a monodisperse particle population 
"G(T)" is a single exponential, in the presence of more than one size the function is 
polyexponential. 
Deviation from a single exponential is used to calculate the PI, as a measure of the width of 
the size distribution. An ideal, monodisperse formulation has a PI of zero. 
PCS diameter gives information about the average particle size (z-ave). The measured PCS 
diameter is based on the intensity of scattered light and therefore is not identical to the numeric 
diameter except in case of monodisperse particle suspensions. For polydisperse samples, PCS 
diameter is larger because it is based on the scattering intensity of the particles. The scattering 
intensity does not linearly depend on the particle size but is proportionally related to the 6 
power of the radius (Rayleigh scattering, I~r6A.4). Therefore, the broader the particle size 
distribution, the greater is the disparity between the PCS and number diameters. This 
phenomenon makes the measurements of PCS very sensitive for following aggregation or de-
aggregation processes in suspensions. 
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Figure 4.5: Principal set up of PCS. (Adapted from Muller [2]). 
In the present work, for PCS measurements, all samples were diluted with double-distilled 
water to suitable concentration and measured by a Malvern Zetasizer 4 apparatus {Malvern 
Instruments, UK). 
In the case of hydrogels, prior to particle size analysis by PCS, the semi-solid SLN and NLC 
formulations were diluted with double-distilled water to weak opalescence. All measurements 
were performed in triplicate. 
4.3.3. Zeta potential and electrophoretic mobility 
Most of the solid particles are electrically charged in aqueous dispersion media, a property 
that can be due either to the process of dispersing the particles in water, the existence of charged 
groups on the surface and/or adsorption of ions from the dispersion medium [2]. In electrolytic 
solutions, particles possess an adsorbed monolayer of ions on their surface (Figure 4.6). 
The adsorbed monolayer of ions at the particle surface consists of fixed, dehydrated and in 
most cases negatively charged ions (inner Helmholtz layer) [2]. These negative ions increase the 
surface potential (Nernst potential " W ) to the potential of the inner Helmholtz layer "¥". The 
next monolayer (outer Helmholtz plane) consists of fixed but hydrated positive ions reducing the 
Pump, filter unit 
1 1 
X 
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potential to the potential of the Stern plane "¥5" where "5" is the thickness of the Stern plane. In 
the diffuse layer the potential drops towards zero. During the movement of the particle a part of 
the diffuse layer will be stripped to reveal a potential at the shear plane. This potential is called 
zeta potential "Ç" and is an indirect measurement of the surface charge because its magnitude 
depends on the Nernst potential. 
Inner H el m hoi tz 
Outer Helraholtz 
plane I 
plane I 
Stern plane 
Figure 4.6: Schematic representation of different surface potentials associated to the 
particle in aqueous medium. Formation of Stern plane and diffuse layer on particle 
surface. %, Nernst potential; ¥j, potential of inner Helmholtz plane, Ts, Stern 
potential; 5, thickness of Stem plane; Ç, zeta potential at the surface of shear; d, 
distance from the particle surface. (Adapted from Miiller [2]). 
The Ç can be measured by determination of the movement velocity of the particles in an 
electric field (electrophoresis measurements). Conventional instruments use a light microscope 
to observe the particle movement, whilst modern zetameters use laser Doppler anemometry 
(LDA) to determine the particle velocity. 
A LDA set up consists of a laser, a beam splitter and a lens which focuses the beams into the 
measuring volume, forming a beam crossover. Particles move through the beam crossover and 
scatter laser light. The scattered light is detected in the forward direction and projected by 
collecting optics onto a PM. The frequency of the laser light scattered by the particles differs 
from the frequency of the incident beam. This frequency shift is caused by the Doppler effect 
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and it is a function of the particle velocity. As mentioned before, the Malvern Zetasizer 4 
apparatus uses the PM signal to calculate a "G(T)", which is transferred via Fourier Transform to 
the frequency spectrum of the scattered light. 
Particle velocity "v" is expressed in relation to the electrical field strength "E" as 
electrophoretic mobility '>" (um/s)/(V/cm): 
v 
E 
where "v" is the particle velocity and "E" is the field strength. The electrophoretic mobility '>" 
can be converted to a "Ç" DY u s m S t n e following equation of Helmholtz [285]: 
Avxri 
Es 
where "/7" is the viscosity of dispersion medium, "£" is the field strength and "e" is the dielectric 
constant. 
In the present work, for the Ç measurements a Malvern Zetasizer 4 apparatus {Malvern 
Instruments, UK) was used. Samples were previously diluted with double-distilled water 
adjusted to a conductivity 50 uS/cm with a solution of 0.9% NaCl (if not otherwise stated). 
4.4. Measurement of crystallinity and lipid modification 
4.4.1. Differential scanning calorimetry 
Differential scanning calorimetry (DSC) is frequently used in thermal analysis due to its 
ability to provide information on both physical and energetic properties of a compound [286]. 
DSC measures the heat loss or gain resulting from physical or chemical changes within a sample 
as a function of the temperature. 
Examples of heat-absorbing processes (endothermic measurements) are fusion, boiling, 
sublimation, vaporization, desolvation and solid-solid transitions. Crysallization is usually an 
exothermic process, i.e. energy is liberated. Qualitative measurements of these processes have 
many applications, such as the study of purity, polymorphism, solvation, degradation and 
compatibility of substances. 
If a thermodynamic event - either endothermic or exothermic - occurs, the power 
requirements for the coils maintaining a constant temperature will differ. This power difference 
is plotted as a function of the temperature recorded by the programming device [286]. 
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DSC analysis has been used to characterize the state and the degree of crystallinity of lipid 
dispersions, semi-solid systems, polymers and liposomes [287]. DSC measurements offer a close 
look at the melting and crystallization behaviour of crystalline material like lipid nanoparticles 
[83,226,288,289]. The breakdown or fusion of the crystal lattice by heating or cooling the sample 
yields inside information on polymorphism, crystal ordering, eutectic mixtures or glass transition 
processes [287]. DSC experiments are useful in order to understand solid dispersions like solid 
solutions, simple eutectic mixtures or, as in the case of SLN and NLC, drug and lipid interactions 
and the mixing behaviour of solid lipids with liquid lipids, such as oils [5,35,53,289,290]. 
In general, a melting point depression is observed when transforming the bulk lipid to 
nanoparticulate form. This melting point depression is described in the Gibbs-Thomson equation 
which itself is derived from the Kelvin equation [291]: 
In (T\2yV* 
To) r&H 
where "7" represents the melting point of the particle, and it is always smaller than the melting 
point of the bulk material "7b". The molar volume of the substance is characterized by "V", "r" 
is the radius of the particle, "A/7" is the molar melting enthalpy and "y" is the interfacial energy 
at the solid-lipid interface. For characterizing crystal forms, "ATT' can be obtained from the area 
under the DSC curve for the melting endotherm. 
An additional melting point depression occurs when a foreign compound is dissolved in the 
lipid matrix, such as surfactant molecules that will partition from the water phase to the lipid 
phase. Therefore, drug-loaded SLN will show a melting point depression in case of a molecularly 
dispersed drug is present. 
The recrystallization index (RI) is defined as the percentage of the lipid matrix that has 
recrystallized during storage time [98]. Its determination is useful for comparison of the 
crystallinity between the developed formulations. According to the literature [98], RI of the 
developed SLN and NLC formulations was calculated as follows: 
A I / 
DIÍO/\— SLN or NLC aqueousdispersion 1 OH 
&H Material x Concentration Hpld flmt 
where "ATT' is the molar melting enthalpy given by J/g"1 and the concentration is given by the 
percentage of lipid phase. 
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In the present work, DSC measurements were performed on a Mettler DSC 821e apparatus 
{Mettler Toledo, Gieften, Germany). Samples containing 1-2 mg of solid lipid were accurately 
weighed in 40 ml aluminium pans. DSC scans were recorded from 25°C to 85°C at a heating rate 
of 5 K/min, using an empty pan as reference. Melting points correspond to the maximum of the 
heating curve. Polymorphic forms were assigned by comparison with x-ray diffraction data. 
4.4.2. X-ray diffraction 
An important technique for establishing the reproducibility of a polymorphic form between 
different batches is x-ray diffraction, i.e. wide-angle x-ray scattering (WAXS) and small-angle x-
ray scattering (SAXS). Figure 4.7 shows the schematic representation of this technique. 
Figure 4.7: Schematic representation of x-ray diffraction. (Adapted from Krischner [292]) 
When a monochromatic x-ray beam is focused on a crystal, the scattered x-rays from the 
regularly placed atoms interfere with each other, giving strong diffraction signals in particular 
directions, since the interatomic distances are of the same order as the x-ray wavelength [292]. 
The directions of the diffracted beams are related to the shape and dimensions of the unit cell of 
the crystalline lattice. The diffraction intensity depends on the disposition of the atoms within the 
unit cell. This technique allows amorphous and crystalline materials to be differentiated. 
Crystalline materials display many diffractions bands whereas amorphous compounds present a 
more or less regular baseline. 
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The crystal diffracts x-rays similar to a diffraction grating, whose plane diffracts ordinary 
light. The three-dimensional crystal functions like a series of plane gratings stacked one above 
the other [292]. The wavelength of the x-rays "A" is related to the angle of incidence "0" and the 
interatomic distance "if' by Bragg's equation: 
n.A = 2dsm— 
2 
where "«" is the order of the diffraction. For a single crystal, the diffracted x-rays consist of a 
few lines. With powder, due to a random distribution of crystals, the diffraction pattern consists 
of a series of concentric cones with a common apex on the sample. The atoms in a crystal 
possess the power of diffracting the x-ray beam. Each substance scatters the beam in a particular 
diffraction pattern, producing a fingerprint for each atom crystal or molecule. 
If an unknown powder sample is to be identified, its diffraction pattern may be compared 
with those of known substances or its "if' values calculated from the diffraction diagram and 
compared with the "if' values of known compounds. 
If the diffraction pattern of a single crystal is to be determined, the crystal is mounted on a 
thin glass capillary and the capillary is fastened to a brass pin. A substance in powder form can 
be ground finely and transformed into a small rod using collodion as a binder or held in a 
specific device with an open cup. Samples like aqueous dispersions can be transformed into a 
paste, using a thickening agent, such as locust bean gum [29] and xanthan gum [107]. 
X-ray diffraction has been used for the study of molecular structure and polymorphism of 
lipid nanoparticles [29,36,56,63,74,103,107,293,294]. 
In the present work, x-ray studies were performed by WAXS (2 Theta = 4-40°) on a Philips 
PW 1830 x-ray generator (Philips, Amedo, The Netherlands) with a copper anode (Cu-Ka 
radiation, 1=0.15418 nm). SLN and NLC aqueous dispersions were previously transformed into 
a paste using locust bean gum as a thickening agent, and then mounted into a specific device 
before the measurement by WAXS. 
4.5. Light microscopy 
All substances that are transparent when examined under a microscope that has crossed 
polarizing filters are either isotropic or anisotropic [295]. Amorphous substances, such as 
supercooled melts and non-crystalline solid organic compounds, or substances with cubic crystal 
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lattices are isotropic materials, which have a single refractive index. Materials with more than 
one refractive index are anisotropic and appear bright with brilliant colours (birefringence) 
against a black polarized background. The interference colours depend upon the crystal thickness 
and the differences are either uniaxial, having two refractive indices, or biaxial, having three 
principal refractive indices. 
Most drugs are biaxial, corresponding to either an orthorhombic, monoclinic or triclinic 
crystal system. Therefore, in the present work polarized light microscopy was employed to detect 
drug crystals in suspension, as suggested by Westesen et al. [53]. Investigations were performed 
using a Leitz Orthoplan Microscope (Wetzlar, Germany) at lOOx, 400x and lOOOx with an oil 
immersion objective, in order to determine the presence/absence of drug crystals in the melted 
lipid. 
4.6. Assay of clotrimazole 
In the present work, the quantitative determination of clotrimazole was performed by 
ultraviolet (UV). 
As it is well known, UV and visible absorption bands are due to electronic transitions in the 
region of 200 nm to 800 nm [296,297]. In the case of organic molecules - such as clotrimazole -, 
the electronic transitions could be ascribed to a "a", "7t" or "n" electron transition from the 
ground state to an excited state (a*, 71* or n*). Since the "a" electron is firmly involved in the 
construction of a single bond, its transition requires much more energy (usually in far UV) than 
the "n" electron (non-bonding electrons) or less tightly bonded "JI" electrons [296]. 
According to Beer's law, the absorbance of a solution "A" is defined as the logarithm to base 
10 of the reciprocal of the transmittance "7" for monochromatic light and is expressed by the 
following equation: 
m , a. \ ^ = log10 - = log o 10 T ~lv\l 
where "70" is the intensity of incident monochromatic light, "7" is the intensity of transmitted 
monochromatic light and "7" is the ratio I/I0. 
In the absence of other physicochemical factors, the measured absorbance "A" is proportional 
to the path length "6" through which the light passes and to the concentration "c" of the 
substance in solution, in accordance to the equation: 
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A = s.cb 
where "e" is the molar absorptivity, if "6" is expressed in centimetres and "c" is expressed in 
moles per litre. 
The expression " Aj£, ", representing the specific absorbance of a dissolved substance, refers 
to the absorbance of a 10 g/1 solution in a 1 centimetre cell and measured at a defined 
wavelength, so that: 
Spectrophotometers suitable for measuring in the UV and visible range of spectrum consist 
of an optical system capable of producing monochromatic light in the range of 200 nm to 800 nm 
and a device suitable for measuring the absorbance. 
In the present work, two solutions of clotrimazole, using diethyl ether or a solution of 100 
mM acetate buffer pH 6.0 with 35% (V/V) of dioxane as dissolution medium, were scanned from 
300 nm to 200 nm, using an Uvikon 940 double-beam spectrophotometer (Kontron Instruments, 
Eching, Germany). In both media, the wide-band of clotrimazole shows a typical absorption 
pattern with two peaks at approximately 243 nm and 270 nm. 
4.6.1. Assay of clotrimazole in SLN and NLC aqueous dispersions 
For the assay of clotrimazole in the developed SLN and NLC aqueous dispersions, UV 
measurements were performed at 243 nm in a path length of 1 cm at 20±1°C, using diethyl ether 
as dissolution medium of the samples. 
Diethyl ether has shown to be an appropriate solvent for this assay, because it dissolves all 
the components of the formulations and the obtained peak at the prescribed wavelength (243 nm) 
is only due to the presence of clotrimazole, i.e. the excipients do not interfere with the 
measurement of the drug absorbance in this organic medium. 
Calibration curves were obtained from a series of standard solutions of clotrimazole in 
diethyl ether ranging from 25 to 150 ug/ml. Diethyl ether was used as blank. Figure 4.8 shows an 
obtained typical calibration curve. 
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Figure 4.8: Calibration curve of clotrimazole in diethyl ether. 
The total amount of clotrimazole was determined in the prepared aqueous dispersions of SLN 
or NLC, previously to the removal of non incorporated clorimazole. Briefly, 5 ul of an aqueous 
dispersion of SLN or NLC was introduced in a dilution-flask of 25 ml, completing the volume 
with diethyl ether in order to prepare a solution. The absorbance of the resulted solution was 
measured at 243 nm. 
For the determination of incorporated clotrimazole, the amount of free drug was firstly 
assessed by assaying clotrimazole in the obtained supernatant, after centrifugation of the SLN or 
NLC aqueous dispersions. The difference between total clotrimazole and free clotrimazole gives 
the amount of incorporated clotrimazole. Briefly, 1 ml of an aqueous dispersion of SLN or NLC 
was centrifuged at 32 000 rpm. 5 ul of the obtained supernatant was introduced in a dilution-
flask of 10 ml, completing the volume with diethyl ether in order to prepare a solution. The 
absorbance of the resulted solution was measured at 243 nm. 
4.6.2. Assay of clotrimazole in the release studies 
For the assay of clotrimazole in the release studies, UV measurements were also performed 
at 243 nm in a path length of 1 cm at 20±1°C, using a solution of 100 mM acetate buffer, pH 6.0 
with 35% (V/V) of dioxane as receptor medium in Franz diffusion cells. 
The 100 mM acetate buffer, pH 6.0 with 35% (V/V) of dioxane was chosen as receptor 
medium according to the studies carried out by Kast et ai, for the evaluation of the release 
profile of clotrimazole in bioadhesive systems based on chitosan-thioglycolic acid conjugates 
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[280]. The inclusion of 35% (V/V) of dioxane in the composition of the receptor medium is due 
to the insufficient solubility of clotrimazole in the 100 mM acetate buffer solution. 
Calibration curves were obtained from a series of standard solutions of clotrimazole in the 
receptor medium ranging from 25 to 150 ug/ml. The 100 mM acetate buffer pH 6.0 with 35% 
(V/V) of dioxane was used as blank. Figure 4.9 shows an obtained calibration curve. 
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Figure 4.9: Calibration curve of clotrimazole in a solution of 100 mM acetate buffer, pH 
6.0 with 35% (V/V) of dioxane. 
The amount of released clotrimazole was assessed by measuring the absorbance of the 
samples directly after their collection from Franz cells. 
4.7. Determination of the encapsulation parameters 
The E.E. was calculated as the percentage of the initial amount of drug which has been 
incorporated into lipid nanoparticles. The drug loading capacity, also called payload or drug 
content, is generally expressed in percentage of incorporated drug related to the lipid matrix [6]. 
The determination of the E.E. of clotrimazole in SLN and NLC and the drug loading capacity 
were calculated using the following equations: 
_ amount of clotrimazole in lipid nanoparticles 
initial amount of clotrimazole 
_ , , amount of clotrimazole in lipid nanoparticles Drug loading capacity = : x 1UU 
amount of lipid material 
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4.8. Evaluation of clotrimazole release profile from SLN and NLC aqueous dispersions 
In matrix systems like lipid nanoparticles the drug is incorporated in the lipid matrix either in 
dissolved or in dispersed form [6,7]. Therefore, the solubility of the drug in the lipid matrix 
becomes a very important controlling factor of the drug release from SLN and NLC. When the 
initial drug loading is below the solubility limit, release is achieved by simple diffusion through 
the lipid. However, when the drug loading is above the solubility limit, dissolution of the drug in 
the lipid becomes the limiting factor [27]. 
In the present work, static Franz glass diffusion cells were used in order to evaluate the 
release profile of clotrimazole from SLN and NLC. Static Franz glass structure is schematically 
represented in Figure 4.10. 
Exit of receptor fluid 
Entry of receptor fluid 
\ 
\S- Donor compartment 
Membrane 
Figure 4.10: Schematic representation of a Franz diffusion cell. (Adapted from Jenning [56]). 
These cells consist of donor and receptor chambers between which a membrane is positioned 
[298]. In the present work, the area for diffusion was 0.64 cm2 and the receptor chamber volume 
was approximately 5.5 ml. Cellulose nitrate membranes with an average pore size of 0.1 urn 
were used. The receptor chamber was maintained at 37°C, in order to ensure the surface skin 
temperature of 32°C on the surface of the membrane. 
As reported above, the receptor medium consisted of a solution of 100 mM acetate buffer, 
pH 6.0 with 35% (V/V) of dioxane. Since the receptor medium was not intended to mimic skin 
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conditions, it was suitable for the present in vitro investigations. Clotrimazole is well soluble in 
the chosen receptor medium. 
Briefly, 100 ul of a SLN or NLC aqueous dispersion (containing 1% of clotrimazole) was 
applied to the donor compartment. Samples (250 ul) were collected over 24h and analysed by 
spectrophotometric determination at 243 nm as described before. After each sample taking, the 
Franz cells were filled up with receptor medium. For each formulation, the release studies were 
performed in triplicate. 
4.9. Evaluation of Theological properties of SLN and NLC preparations 
Rheology (from the Greek rheos meaning flow and logos meaning science) is the study of 
the flow or deformation under stress. Rhéologie measurements are a valuable tool for quality 
control of ingredients and final products together with manufacturing processes, such as mixing, 
pumping, stirring, filling and sterilization [299]. 
Concerning liquid dispersions of lipid nanoparticles, they usually need to be incorporated in 
convenient topical dosage forms - like hydrogels or creams - to obtain a topical application form 
having the desired semi-solid consistency. However, when incorporated into a semi-solid base, 
the physicochemical characteristics of SLN and NLC can be modified as a result of interactions 
between the components of the final product, which can be evaluated using the so-called 
rhéologie measurements [300,301]. 
Semi-solid systems are characterized as materials that retain their shape when unconfmed, 
but flow or deform when an external force is applied. Essential components for a rhéologie 
observation are the tangential application of a force to a body and the resultant deformation of 
that body [302]. If this force is applied for a short period of time and then withdrawn, the 
deformation is defined as elastic if the shape is restored ox flow if the deformation remains. A 
fluid or liquid becomes a body that blows under the action of an infinitesimal force. In practice, 
gravity is generally regarded as the criterion of such a minimal force. 
Figure 4.11 represents the model demonstrating the components of classic viscous flow 
[302]. Two parallel planes are a distance "x" apart, and between these planes the viscous body is 
confined. The top plane "A" moves horizontally with the velocity "v" because of the action of 
force "F". The lower plane "B" is motionless. As a consequence, there exists a velocity gradient 
between the planes "dv/dx". This gradient is given by the definition of rate of shear "/)". The 
shear stress "5" is the force per unit of area creating the deformation. 
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A (mobile ptose) 
Velocity gradient 
dv/dx B (stationary phase) 
Figure 4.11; Schematic model for demonstrating the components of classic viscous flow. 
(Adapted from Wood [302]). 
The shear stress may be applied either momentarily or continuously. Elastic deformation 
occurs if, as the force is applied, the upper plate moves in the direction of the force only 
momentarily and then stops but returns to its original position when the deforming force is 
removed. On the other hand, pure viscous flow occurs if there is continuous movement during 
the applied force, and no restorative motion follows removal of the deforming force. 
Between the limits of elastic deformation and pure viscous flow, a continuum of 
combinations of these limits exists. Such behaviour is called viscoelastic flow. Knewtonian fluid 
is a fluid in which a direct proportionality exists between shear stress and shear rate, for all 
values of shear. 
Viscosity or coefficient of viscosity is the proportionality constant between shear stress "5°' 
and shear rate "/)". Conventionally, viscosity is represented by "//" and is given by: 
S 
D 
Fluidity is the reciprocal of the viscosity, usually designed by the symbol "<£>". Kinematic 
viscosity "v" is the Newtonian viscosity divided by density "d": 
n 
v = — 
d 
Non-newtonian fluids axe, those for which there is no direct linear relationship between shear 
stress and shear rate. Most systems of pharmaceutical interest fall into this category. A 
pseudoplastic material is one in which the stress increases at less than a linear rate with 
increasing shear rate, while a dilatant material is characterized by a more rapid increase. Thus, if 
viscosity is calculated at each of a series of shear rate points, by use of the ratio between shear 
rate and shear stress, then the resultant values decrease with increasing shear rate for 
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pseudoplastic materials and increase for dilatant ones. Measurements at such single points are 
frequently referred to as apparent viscosity to recognize clearly that the number quoted refers 
only to the condition of measurement. The fact that one number cannot characterize the viscous 
behaviour, however, requires the use of some equation of state. One such empiric one is the 
Power Law Equation: 
S = AD" 
where "5" and "£>" are the shear stress and shear rate, respectively, "A" is an appropriate 
proportionality constant and "«" is the Power Index. 
In this form, "«" is less than 1 for pseudoplastic materials and grater than 1 for dilatant 
materials. The Power Law Equation is also used with the index "n" associated with shear stress 
rather than shear rate. 
When the logarithm of both sides of the last equation is taken, the result is: 
log S = log A + n log D 
Compared with the equation of a straight line, a plot of "log 5" against "log D" results in a 
straight line of slope "«" and intercept "log A". 
When an initial finite force is necessary before any rhéologie flow can start, the initial stress 
is called yield value. A Bingham plastic is represented by a straight line or curve on the stress 
shear rate plot being displaced from the origin by a finite stress value. Thus, for Newtonian 
behaviour at stresses "5" greater than the yield value "f', it can be written: 
S-f = UD 
where "(7" is the plastic viscosity and "D" is the shear rate. Similarly, both pseudoplastic and 
dilatant curves may appear to exhibit yield values. The dimensional units of the yield value must 
be those of the shear stress. 
In general, Newtonian liquids are pure chemicals rather than of polymeric materials. All 
interactions are such that no structure is contributed to the liquid. Since by definition, shear stress 
and shear rate are directly proportional, a single viscometric point can characterize the liquid 
rheology. Increasing temperature decreases viscosity as it reduces intra-molecular forces of 
attraction. Such temperature viscosity relationships are quickly established, regardless of whether 
temperature is increased or decreased. 
Pseudoplastic behaviour is exhibited by polymer solutions and by most semi-solid systems 
containing some polymer components. 
Thixotropy is a phenomenon resulting from the time dependency of the breakdown or the 
rebuilding of structure. It is an empiric observation of good reliability that structure breakdown 
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or build-up is an exponential function time. Thus, if the observed shear stress for a given shear 
rate is followed with time, a plot of stress against time, both on the logarithmic scale, results in a 
straight line. A coefficient of thixotropic breakdown "B" can be calculated by the equation: 
B=Si-S2_ 
ln(t2/h) 
where "Si" and "S2" are the stress values at times "t" and ' V of continuous shear at any 
arbitrary shear rate chosen for comparison. 
Dilatant systems are essentially the opposite of pseudoplastic thixotropic ones. In dilactancy 
as shear continued, the fluid components contributing to lubricity between the shear planes so 
that the resulting structure develops increasing friction. Thus, stress increases with time in a 
logarithmic manner similar to that with thixotropy. A similar hysteresis loop of rheopexy is 
developed in dilatant systems. The last equation may be used with dilatant systems in the same 
way as with thixotropic ones to yield a coefficient of dilatant build-up. 
To sum up, Figure 4.12 represents the four basic types of rheograms or flow curves. 
D 
Newtonian Pseudo plastic 
D 
Dilatant Plastic 
Yield 
value 
Figure 4.12: The four basic types of rheograms. (Adapted from Strieker [303]). 
4 Hysteresis loop is a measure of the ihixotropy in area. 
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In the present work, evaluation of the Theological properties of SLN and NLC preparations 
were performed applying an oscillation frequency sweep test and continuous shear 
investigations. 
4.9.1. Oscillation frequency sweep test 
In the present work, oscillation tests were carried out in order to determine the rheological 
properties of the developed SLN and NLC aqueous dispersions. 
Oscillation tests are dynamic methods for determining the rheological properties of the 
material in its rheological ground state without altering its static structure and providing a so-
called fingerprint under non-destructive conditions [304,305]. 
In an oscillation experiment the material is subject to a sinusoidal stress, providing 
information on the inter-molecular and inter-particle forces in the material [306]. It can be used 
to differentiate between two samples which can not be distinguished by shear experiments, 
because this test is capable of separating elastic and viscous properties, while shearing leads to 
an integrated characterization only. The response of the tested material is measured as a function 
of frequency at constant stress amplitude. 
The selection of frequency that is applied has a strong influence on the testing time. The 
reciprocal of the frequency is the required time to run through one cycle. 
When applying stress "x" to a sample, it will deform. Dependent on the relationship of 
viscous and elastic properties, the amplitude of deformation "yo" is not necessary reached at the 
same time as the stress amplitude "to". There is a phase shift "<5" between stress and deformation. 
Pure elastic materials have a phase shift of 0°. Note that for these materials as soon as the 
force is lowered or released the deformation recovers. 
Pure viscous materials have a phase shift of 90° because when the applied force reaches its 
maximum, the material is pulled apart with its highest speed. 
Viscoelastic materials show phase shifts between 0 and 90°. 
For the evaluation of an oscillation experiment the following basic equation is used: 
TO = G yo 
where "G*" is the complex modulus. 
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By setting the stress amplitude and measuring the deformation amplitude, "G*" can be 
calculated. By knowing the frequency and measuring the time at which stress and strain 
(deformation) amplitudes are reached, the phase shift between both can be calculated, which is 
then used to determine the storage and the loss moduli. 
The storage modulus "G"' gives information about the elastic component and it can be 
determined using the following equation: 
G'=G*cos(ô) 
For a purely elastic material the phase shift is 0°, which makes "cos ((5)" equals to 1, and 
consequently, "G"' is 100%, reflecting the integral character "G*". 
The loss modulus " G" " is a measure of the viscous component and it can be determined 
using the following equation: 
G"=G* sin(S) 
For a purely viscous material the phase shift is 90°, which makes "sin (r))" equals to 1, and 
consequently, "G"" is 100%, reflects the integral character "G*". 
One might be interested in the ratio of viscous and elastic properties, which is given by the 
following equation: 
^ = ^ 1 = ^ ) 
G' cos(S) v ; 
The complex dynamic viscosity "?/*" is given by the equation: 
, G* 
7] = — 
CO 
where "co" is the frequency defined as sinus wave. 
In the present work, oscillation tests were performed at 20±0.1°C on a rheometer Rheo Stress 
RS 100 (Haake Instruments, Karlsruhe, Germany) equipped with a cone-and-plate test geometry 
(plate diameter 20 mm, cone angle 4°), schematically represented in Figure 4.13. 
Oscillation stress sweep tests were carried out at a constant frequency of 1 Hz in a stress 
range of 100 Pa and the oscillation frequency sweep test was performed over a frequency range 
from 0 to 10 Hz at constant stress amplitude of 5 Pa. 
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Figure 4.13: Schematic representation of a 
cone-and-plate rheometer. (Adapted from 
Reich [307]). 
4.9.2. Continuous shear investigations 
In the present work, the rheological properties of the developed hydrogels and hydrogels 
containing SLN and NLC were studied by continuous shear investigations which were performed 
in order to evaluate the shear rate as a function of shear stress. This study started applying 0 Pa 
up to a maximum shear stress of 50 Pa and the resulting shear rate was measured. 
In the present work this investigation was carried out at 20±0.1°C on a rheometer Rheo Stress 
RS 100 (Haake Instruments, Karlsruhe, Germany) equipped with a cone-and-plate test geometry 
(plate diameter 20 mm, cone angle 4°), schematically represented in Figure 4.13. 
4.10. Evaluation of the occlusive properties of SLN and NLC preparations 
It is well known that small particles, like lipid nanoparticles, possess an adhesive effect and 
this effect increases with the decrease of the diameter "if' of the particles [47]. But there are 
other factors influencing the adhesiveness, such as adhesion forces "F#", van-der-Waals forces 
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"/to", distance between adhesion partners "a", electric constant %", dielectric constant "e", 
contact potential of electric conductors "( / ' and the surface charge density of adhesion partners 
"ç>i <p2". The adhesive forces can be calculated by [308]: 
Van-der-Waals forces: 
hco d 
FH- 
16;r a 
In case of a conductor: 
FH=—80SU — 
2 a 
In case of an isolator: 
2 fOf 
In the present work, the occlusivity of SLN and NLC aqueous dispersions, as well as SLN 
and NLC containing hydrogels, was quantified by an in vitro occlusion test adapted by de 
Vringer [309]. Briefly, beakers of 100 ml volume were filled with 50 ml of water, covered and 
sealed with cellulose acetate filters of 90 mm diameter and 4-7 um cutoff size, obtained from 
Schleicher (Germany). Sample was spread with a spatula on the filter surface and then stored at 
32°C (skin temperature) and 50-55% of room humidity for 48 hours. 
After spreading the samples, the beakers were weighed after 6, 24 and 48 hours, giving the 
water loss due to evaporation at each time (water flux through the filter paper). Beakers were 
covered with filter paper but without applied sample served as reference values. Every 
experiment was performed in triplicate. The occlusion factor "F" was calculated according to the 
following equation: 
F = 100*[(A-B)/A] 
where "A" is the water loss in the absence of without sample (reference) and "B" is the water 
loss in the presence of sample. From this, an occlusion factor of 0 means no occlusive effect 
compared to the reference, the maximum occlusion factor is 100. 
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RESULTS AND DISCUSSION 
5.1. Clotrimazole-containing SLN and NLC preliminary studies 
Solubility of drug in the material of the carrier is one of the main limiting factors in the 
design of new carrier systems [310]. Poor solubility of drug can be due to a lack of affinity to the 
carrier matrix or to a specific stability of the drug into self-organized structures, such as 
crystalline structures. In fact, at the equilibrium, systems orientate towards minimum free energy, 
i.e. lower thermodynamic activity, which sometimes corresponds to crystalline structures 
forming a separate phase from the carrier. 
With regard to lipid nanoparticles - such as SLN and NLC -, the lack of affinity of the active 
compound to the lipid matrix is due to the increase of lipid packing density during the 
preparation process, resulting in a decrease of drug incorporation into the carrier, which is 
accompanied by a poor bioavailability [6]. 
The aim of the present preliminary studies was to assess the clotrimazole-lipid interaction, in 
order to select the best lipid or lipids for incorporating this drug in stable SLN and NLC 
formulations. 
After lipid screening for clotrimazole, a range of emulsifying agents were tested for each 
selected lipid and the composition of SLN and NLC formulations has been established. In 
addition, the optimum homogenization conditions, i.e. the number of homogenization cycles, 
were also assessed for each investigated nanoparticle system. 
5.1.1. Lipid screening for clotrimazole solubilization 
The solubility of clotrimazole in 15 different lipids was screened by mixing the drug in 
different concentrations (1%, 5%, 10% and 20% m/m) with the lipid and melting the mixture at 
90°C. The solubility was determined visually and microscopically at 90°C and at room 
temperature (20°C). 
Table VIII reports the melting point of the selected lipids and the obtained results for the 
solubility studies of clotrimazole in different lipids at 90°C and at 20°C. 
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Table VIII: Solubility studies of clotrimazole in different lipids at 90°C and at 20°C. 
Lipid Melting point Drug concentration 
%(m/m) 
Solubility at 90°C Solubility at 20°C 
Dynasan 112 43-47°C 
1% 
5% 
10% 
20% 
+++ 
++ 
+++ 
Dynasan®114 55-58°C 
1% 
5% 
10% 
20% 
+++ +++ 
Dynasan*116 61-65T 
1% 
5% 
10% 
20% 
+++ +++ 
Dynasan*'118 70-73°C 
1% 
5% 
10% 
20% 
+++ +++ 
Softisan*U5 53-58T 
1% 
5% 
10% 
20% 
+++ +++ 
WitepsoPWS 34-36T 
1% 
5% 
10% 
20% 
+++ +++ 
WitepsoPtt 33.5-35.5°C 
1% 
5% 
10% 
20% 
+++ 
++ 
++ 
+++ 
Witepso(*E15 37-39°C 
1% 
5% 
10% 
20% 
+++ 
+++ 
+++ 
Witepsof*E$5 42-44°C 
1% 
5% 
10% 
20% 
+++ 
-
Imwitor^OO 54-65°C 
1% 
5% 
10% 
20% 
-
-
Imwitor* 191 66-71°C 
1% 
5% 
10% 
20% 
+++ 
++ 
+++ 
CompritoflU ATO 72°C 
1% 
5% 
10% 
20% 
- -
Precirof MO 5 52-55°C 
1% 
5% 
10% 
20% 
+++ 
-
Precifac^klO 5 52-56°C 
1% 
5% 
10% 
20% 
++ 
-
Apiflf 59-70°C 
1% 
5% 
10% 
20% 
+++ +++ 
+++ soluble; ++ hardly soluble; - insoluble 
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Lipid screening showed that selection of the appropriated lipid for clotrimazole solubilization 
is extremely important. In order to ensure the success of incorporation process, the drug needs to 
be solubilized in the melted lipid, both at high and low temperatures. Therefore, microscopic 
observations were performed for confirming the presence/absence of drug crystals in the 
drug/lipid mixtures. 
Figure 5.1 shows a micrographical picture of 1% (m/m) clotrimazole-containing 
Witepso/®ES5 at 20°C, without using polarized light (a) and using polarized light (b). Crystals 
could be detected using polarized light (Figure 5.1, b). From this observation it could be 
concluded that clotrimazole is insoluble in this lipid at room temperature, in opposition to its 
solubility at 90°C (Table VIII). 
Figure 5.1: Micrographical picture of 1% (m/m) of clotrimazole-containing 
WilepsofiS at 20°C, (a) without using polarized light, and (b) using 
polarized light. The arrow identifies the presence of drug crystals. 
According to the obtained results, Dynasan®\\6, Soft isan®] 54, Witepsof^Yft, WitepsofS55, 
Witepsof^VJS and It7iwitor®\9\ were selected for SLN preparation. Clotrimazole appeared to be 
soluble in all these lipids, both at high and low temperatures. Note that no crystals were observed 
after lipid screening for clotrimazole using these lipids. 
5.1.2. Surfactant selection for SLN and NLC preparation 
The selection of an appropriate surfactant for SLN and NLC preparation is a very important 
procedure due to the risk of gelation phenomenon or formation of gel-like systems, which is 
associated with unstable dispersions. This phenomenon describes the transformation of a low-
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viscosity SLN or NLC dispersion into a viscous gel, which may occur very rapidly and 
unpredictably [7], In most cases, gel formation is an irreversible process which involves the loss 
of the colloidal particle size and it can be stimulated by intense contact of the SLN or NLC 
dispersion with other surfaces and shear forces, such as the contact with the syringe needle 
during preparatory steps of particle characterization or sample shaking. 
In the present work, several emulsifying agents were evaluated for the preparation of SLN 
containing 20% of lipid matrix, composed by different lipids, such as Dynasan 116, 
Soflisan®l54, WilepsofU5, WilepsofS55, WitepsotElS and Imwilor®\9\. The preparation of 
these systems was performed using a homogenization pressure of 500 bar and 3 homogenization 
cycles. The concentrations of lipid and emulsifying agent were selected according to the 
literature [48]. 
Table TX shows the first SLN formulations that were investigated and the obtained results on 
day 1 and day 7 after preparation. 
Table IX: First SLN formulations tested with 20% of lipid and the obtained results one 
day and one week after preparation, 
Lipid 
% (m/m) 
Emulsifiers 
% (m/m) 
Results 
Day 1 Day 7 
Dynasan*T16 
20% 
7Veen*80(1.2%) 
7teCTi*80/Spa»*85 (1.2%) 
Lipoi<fS15ILutrof>V6% (1.2%) 
Tego Care* 450(12%) 
Tyloxapof (3%) 
+ 
+ + 
So/ftW*154 
20% 
7VW80(1.2%) 
Tween^QISpan%5 (1.2%) 
Lipoicf^75/Lutro^F6% (1.2%) 
Tego Care*450 (1.2%) 
Tyloxapof (3%) 
+ 
+ 
-
WitepsoFm 
20% 
7Vmzw80 (1.2%) 
Tween**0/Span*i5 (1.2%) 
LipoicPS15ILutro{*YGl (1.2%) 
Tego Care^O (12%) 
Tyloxapof* (3%) 
+ 
+ 
+ 
+ 
+ 
+ 
(-) gelation of aqueous dispersion of SLN; (+) production of aqueous dispersion of 
SLN. 
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Table EX: First SLN formulations tested with 20% of lipid and the obtained results one 
day and one week after preparation. (Continuation). 
Lipid 
% (m/m) 
Emulsifiers 
% (m/m) 
Results 
Dayl Day 7 
7We»*80(1.2%) - -
Tween*WSpan*%5 (1.2%) - -
Witepsoí*S55 Z,^o/í/*S75/Z.wíra/*F68 (1.2%) + + 
20% TegoCare"450(l.2%) + -
Tyloxapof (3%) + -
Lanette®N (1.2%) - -
7Veew*80(1.2%) - -
7Ve<?«®80/,S>aH®85 (1.2%) - -
WitepsofKIS I^oíí/*S75/I«/ro/®F68 (1.2%) - -
20% Tego Care®450 (1.2%) - -
Tyloxapof (3%) + + 
Z.<wert<?®N(1.2%) - -
7Wen®80(1.2%) - -
7We«®80/S/w/7®85 (1.2%) - -
Imwitor*'191 LipoicfSlSILutrofVG?, (1.2%) - -
20% 7 ^ 0 07/-^450(1.2%) - -
Tyloxapof (3%) - -
Z^nete®N(1.2%) - -
(-) gelation of aqueous dispersion of SLN; (+) production of aqueous dispersion of 
SLN. 
Regarding to the formulations showing gelation, this phenomenon was observed either 
directly on cooling after preparation or during storage at room temperature. For most 
investigated solid lipid/emulsifying agent combinations, SLN preparation resulted in gel-like 
systems. 
It has been suggested that gelation phenomenon or formation of gel-like systems is 
associated to crystallization processes [36,289]. The crystal size of a modification of 
polycrystalline lipid aggregates is few microns or less [7]. A change of the a modification is 
associated with an increase in particle size ((3' is less than 5 um and p is between 20-100 urn) 
[294]. Westesen demonstrated by transmission electron microscopy (TEM) that tripalmitin and 
tristearin crystals have a spherical shape in a modification [66]. The P' modification is built up 
from stapled spheroids and the stable P modification is built up from long, coagulated platelets. 
Gelation process is connected with an increase of the particle surface due to the preferred 
formation of the more stable polymorph p, which is associated to a platelet form. The surfactant 
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molecules cannot longer provide sufficient coverage of the new surfaces and therefore, particle 
aggregation is observed. Gelation can be delayed or prevented by the addition of a co-surfactant 
agent with high mobility [66]. 
Other factors promoting gelation are the exposition to high temperatures, to the light and to 
mechanical stress [96]. Storage in darkness at 8°C can prevent particle growth for some SLN 
formulations. Freitas et al. found that fat samples stored under nitrogen atmosphere were more 
stable than samples filled under regular air [96]. This is attributed to the fact that nitrogen can 
inhibit the lipid hydrolysis [311]. High lipid concentrations and high ionic strengths can also 
promote gelation [97]. 
SLN obtained using Dynasan® 116, Witepsofm, Witepsof®S55 and Witepso^ElS were 
characterized by LD (d99% volume distribution) on day 1 and day 7 after preparation. The 
obtained results are shown in Figure 5.2. 
Figure 5.2: Particle size of the first SLN formulations measured by LD (d99%) on day 1 and day 7 
after preparation. 
Figure 5.2 shows that the best results, i.e. particle size below 500 nm, were obtained with 
20% (m/m) of Dynasan®\ 16 and 3% (m/m) of TyloxapoF. Witepso^R5 and Witepso^55 seem 
to be responsible for particle aggregation after 7 days of storage at 20°C. SLN obtained with 
Witepsof®E75 showed a mean particle size higher than 500 nm. 
5.1.3. Preparation of different elotrimazole-contaming SLN and NL€ formulations 
As observed before, the combination of 20% (m/m) of Dynasan®T16 and 3% (m/m) of 
Tyloxapof was responsible for the lowest particle size value measured by LD on day 1 and day 
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7 after SLN preparation, i.e. the SLN particle size remained lower than 490 nm during the first 
week. 
According to the obtained results, Dynasan®\ 16 appears to be the best lipid for preparation 
of SLN using Tyloxapof as emulsifying agent. Therefore, this lipid and emulsifying agent were 
selected in order to prepare SLN and NLC containing 5% (m/m) of clotrimazole (with regard to 
the lipid matrix). The composition of the investigated SLN and NLC formulations are listed in 
Tables X and XI, respectively. 
Table X: Composition of prepared SLN formulations. 
Formulation 
code 
Dynasaif\\6 
% (m/m) 
MiglyofSU 
% (m/m) 
Tyloxapof 
% (m/m) 
Clotrimazole 
% (m/m) 
Water ad 
% (m/m) 
D10% 10 - 3 - 100 
D10%C 9.5 - 3 0.5 100 
D20% 20 - 5 - 100 
D20%C 19.5 - 5 1 100 
Table XI: Composition of prepared NLC formulations. 
Formulation 
code 
Dynasan^llô 
% (m/m) 
Migtyofsn 
% (m/m) 
Tyloxapof 
% (m/m) 
Clotrimazole 
% (m/m) 
Water ad 
% (m/m) 
DM20% 14 6 5 - 100 
DM20%C 13.5 5.5 5 1 100 
5.1.4. Optimizing the homogenization conditions 
The optimum homogenization conditions need to be assessed for each nanoparticle system. It 
is known that the particle size distribution strongly depends on the amount and the type of 
emulsifying agent [233]. Therefore, the effect of the number of homogenization cycles on the 
particle size was investigated, keeping the homogenization pressure and the type of emulsifying 
agent constant. 
In order to optimize the number of homogenization cycles, special batches D10%, D20% and 
DM20% were produced at 500 bar, applying 1 to 5 cycles and their diameter was evaluated by 
LD (d95%) and PCS on day 0 and after 7,14 and 30 days of storage at 20°C. 
Figures 5.3 and 5.4 show the results obtained by LD and PCS analysis, respectively, for 
D10% formulation. 
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N° of homogenization cycles 
5 cycles 
Figure 5.3: Particle size of SLN formulation D10% measured by LD (d95%) after 1 to 5 
homogenization cycles, on day 0 and after 7, 14 and 30 days of storage at 20°C. 
IPCS- ■PI 
N° of homogenization cycles 
Figure 5.4: Mean particle size and PI of SLN formulation D10% measured by PCS after 1 
to 5 homogenization cycles, on day 0 and after 7, 14 and 30 days of storage at 20°C. 
Figures 5.5 and 5.6 show the results obtained by LD and PCS analysis, respectively, for 
D20% formulation. 
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1 cycle 2 cycles 3 cycles 4 cycles 
N° of homogenization cycles 
5 cycles 
Figure 5.5: Particle size of SLN formulation D20% measured by LD (d95%) after 1 to 
5 homogenization cycles, on day 0 and after 7, 14 and 30 days of storage at 20°C. 
300 ­, 
1 250 ■ 
— PCS — - Pi 
r 0,35 
0,3 . 
jjj 200 ­ 1V_ (k m 3k I ■ 0,25 H Tfl­fl B n\n » n '­ iiSt fl ki Bv__ 0,2 1 15° " i f f * ­ nBnll n nHH n Mhff Im ■ 0.15 E •° 100 ­ 1111 1II1 "J1if I 1111 l l l l 0,1 i 50­i l l l 1111 1111 HIS 8818 l 0,05 
o t­» r f O O r­ Tf o o r . •«t o o ^ ■«* O o ^ ■ * o 
;•­. ;>­. >; p>i > ­ i > i >> p i to >, >, í 1 n td 03 n n M ca Q D S f 1 í l ta oa í 1 í l M P P u U 1 Q Q 1 Q Q l Q a 
1 cycle 2 cycles 3 cycles 4 cycles 5 cycles 
N° homogenization cycles 
Figure 5.6: Mean particle size and PI of SLN formulation D20% measured by PCS after 
1 to 5 homogenization cycles, on day 0 and after 7, 14 and 30 days of storage at 20"C. 
Figures 5.7 and 5.8 show the results obtained by LD and PCS analysis, respectively, for 
DM20% formulation. 
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Figure 5.7: Particle size of NLC formulation DM20% measured by LD (d95%) after 1 to 5 
homogenization cycles, on day 0 and after 7, 14 and 30 days of storage at 20°C. 
IPCS' ■ PI 
N° of homogenization cycles 
Figure 5.8: Mean particle size and PI of NLC formulation DM20% measured by PCS 
after 1 to 5 homogenization cycles, on day 0 and after 7, 14 and 30 days of storage at 
20°C. 
For all tested formulations LD and PCS measurements showed the decrease of the mean 
diameter by increasing the number of homogenization cycles from 1 to 3 cycles. Considering LD 
results, Figures 5.3, 5.5 and 5.7 show that SLN and NLC remain in their colloidal particle size 
during a period of 30 days. With regard to PCS results, Figures 5.4, 5.6 and 5.8 reveal similar 
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mean diameters from 3 to 5 homogenization cycles for all samples and a smallest PI after 3 
homogenization cycles, which indicates a narrow size distribution. The observed particle growth 
after 4 and 5 homogenization cycles might be due to the high energy input originating particle 
fusion. 
It is known that increasing the homogenization pressure or the number of homogenization 
cycles often results in an increase of the particle size due to particle coalescence, which occurs as 
a result of the high kinetic energy of the particle [64]. 
According to the obtained results, 3 homogenization cycles and a pressure of 500 bar were 
selected for preparation of all SLN and NLC formulations. 
5.2. Physicochemical characterization of developed SLN and NLC formulations 
Physicochemical characterization of formulations is an important tool used to assess the 
properties of the developed systems, considering the intended therapeutic purposes. 
E.E. of clotrimazole in SLN and NLC formulations, as well as loading capacity were 
evaluated. In addition, particle size and zeta potential measurements, as well as DSC and X-ray 
analysis were performed for prepared SLN and NLC aqueous dispersions. 
5.2.1. Encapsulation parameters 
It was found that clotrimazole was successfully incorporated into physically stable lipid 
nanoparticle dispersions. Table XII shows the E.E. and the loading capacity of clotrimazole into 
SLN and NLC, one day after nanoparticles preparation. 
Table XII: E.E. and loading capacity of clotrimazole into SLN and 
NLC one day after preparation. 
Formulation E.E. (%) Loading capacity (%) 
D10%C 64.189 ±0.020 3.335 ±0.004 
D20%C 67.219 ± 0.040 2.623 ± 0.001 
DM20%C 71.367 ±0.004 3.860 ±0.001 
As Table XII shows, DM20%C revealed the highest E.E. (approximately 71.4%), probably 
due to the liquid oil content (M/g/yo/®812), which can better solubilize the clotrimazole. For 
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SLN samples, D10%C revealed a lower E.E. (approximately 64.2%) than D20%C 
(approximately 67.2%), which is probably due to the lower lipid content of the former. 
With regard to drug loading capacity, Table XII shows the percentage of clotrimazole-loaded 
lipid nanoparticles (D10%C, D2G%C and DM20%C), calculated on day 1 of storage at room 
temperature. Obtained results confirm the higher loading capacity of NLC samples 
(approximately 3.9% m/m) in comparison to SLN with the same lipid content (approximately 
2.6% m/m). For SLN samples, D10%C revealed a higher loading capacity (approximately 3.3% 
m!m) in comparison to D20%C (approximately 2.6% m/m), in spite of being responsible for a 
lower E.E.. 
5.2.2. Particle size 
Tables XIII and XIV show the PCS diameter, PI and d99% diameter of SLN and NLC 
formulations, respectively, on day 1 of storage at room temperature. 
Table XIII: PCS diameter, PI and d99% diameter of SLN formulations on day 1 of storage at 20°C. 
Formulation PCS diameter 
(nm) 
PI d99% diameter 
(jim) 
D10% 195.167± 1.150 0.224 ± 0.027 0.466 ± 0.007 
D10%C 189.533 ±4.750 0.208 ±0.040 0.577 ± 0.002 
D20% 203.600 ±1.840 0.219 ±0.004 0.492 ± 0.000 
D20%C 214.400 ±0.260 0.241 ±0.024 0.725 ± 0.000 
Table XIV: PCS diameter, PI and d99% diameter of NLC formulations on day 1 of storage at 20°C 
Formulation PCS diameter 
(nm) 
PI d99% diameter 
(um) 
DM20% 181.167 ±2.630 0.175 ±0.027 0.573 ± 0.002 
DM20%C 182.333 ±1.930 0.182 ±0.021 0.645 ± 0.002 
On day 1 after preparation, both drug-free and drug-loaded SLN and NLC aqueous 
dispersions showed a narrow particle size distribution measured by LD (d99%), which was 
completely in the nanometer range (Tables XTTT and XTV). 
The presence of clotrimazole was not responsible for an increase in the mean particle size 
measured by PCS. NLC formulations revealed a lower PI (< 0.182) in comparison to SLN 
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formulations with the same lipid content (< 0.241). In addition, NLC showed a smaller mean 
particle size (approximately 180 nm). 
5.2.3. Zeta potential 
The determination of Ç was performed in SLN and NLC aqueous dispersions stored at room 
temperature. Tables XV and XVI show the Ç values of SLN and NLC formulations, respectively, 
one day after samples preparation. pH of all tested SLN and NLC aqueous dispersions ranged 
between 4 and 5. 
Table XV: Zeta potential of SLN 
formulations on day 1 of storage at 20°C. 
Formulation UmV) 
D10% -37.367 ±0.057 
D10%C -11.333 ±0.472 
D20% -23.400 ±0.608 
D20%C -9.533 ± 0.208 
Table XVI: Zeta 
formulations on day 1 
potential of NLC 
of storage at 20°C. 
Formulation Ç(roV) 
DM20% -16.767 ±0.153 
DM20%C -8.433 ± 0.379 
On day 1 of storage at room temperature, Ç of drug-free samples was between -17 mV and 
-37 mV, while Ç of drug-loaded samples was between -8 mV and -11 mV. It could be observed 
that the clotrimazole-containing formulations showed Ç lowers than the drug-free formulations. 
In addition, drug-free NLC formulations also showed lower Ç values in comparison to SLN 
samples. 
5.2.4. DSC studies 
DSC investigations afford an insight into the melting point and recrystallization behaviour of 
crystalline materials, like SLN and NLC. The breaking down of the crystal lattice by heating the 
sample yields inside information on polymorphism and crystal ordering [287]. Therefore, the 
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bulk lipid (glyceryl tripalmitate), as well as clotrimazole-free and clotrimazole-loaded SLN and 
NLC were investigated by DSC. 
DSC curves have been displaced along the ordinate for better visualization. 
5.2.4.1. Crystalline status of bulk material 
Figure 5.9 shows the DSC curves of glyceryl tripalmitate (Dynasan'116) bulk material and 
of a mixture of Dynasan® 116 with 5% (m/m) of clotrimazole. 
Figure 5.9: DSC curves of glyceryl tripalmitate (Dynasan® 116) bulk material and of a 
mixture of Dynasan® \ 16 with 5% (m/m) of clotrimazole. 
The bulk material melted between 53°C and 68°C with the melting point at 63°C. When 
analysing Figure 5.9 it should be pointed out that a simple mixture of the Dynasan 116 with 
clotrimazole elicited only one thermal event at 63°C, indicating that the clotrimazole does not 
interfere with the melting point of the lipid. 
The lower area under the curve observed for drug-lipid mixture is due to its lower solid lipid 
content in comparison to the bulk material. The transition temperature suggests that the 
endotherm is due to the melting of tripalmitin. 
5.2.4.2. Crystalline status of lipid matrix 
In order to assess possible interactions between clotrimazole and the lipid matrix of SLN and 
NLC aqueous dispersions DSC assays were performed for all tested formulations. 
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Figure 5.10 shows the DSC curves of D10% (clotrimazole-free) and D10%C (clotrimazole-
loaded) SLN formulations, after 7 days of storage at 20°C. The sample containing 5% of 
clotrimazole (with regard to the lipid matrix) exhibited a thermal event at 59°C, exactly at the 
same value as the clotrimazole-free sample. This result indicates that clotrimazole does not 
interfere with the crystallinity of SLN containing 10% of Dynasan 116 as lipid matrix. 
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Figure 5.10: DSC curves of D10% (clotrimazole-free) and D10%C 
(clotrimazole-loaded) SLN formulations, after 7 days of storage at 20°C. 
Figure 5.11 shows the DSC curves of D20% (clotrimazole-free) and D20%C (clotrimazole-
loaded) SLN formulations, after 7 days of storage at 20°C. The sample containing 5% of 
clotrimazole (with regard to the lipid matrix) exhibited a thermal event at 60°C, exactly at the 
same value as the clotrimazole-free sample. This result also indicates that clotrimazole does not 
interfere with the crystallinity of SLN containing 20% of Dynasan®'116 as lipid matrix. 
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Figure 5.11: DSC curves of D20% (clotrimazole-free) and D20%C 
(clotrimazole-loaded) SLN formulations, after 7 days of storage at 20°C. 
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As it has been reported before, polymorphic transformations of triacylglycerols in colloidal 
dispersions, such as SLN, are faster than in the bulk material, leading to changes in the 
crystallinity of the lipid matrix [63]. Crystallization of the lipid in nanoparticles is different from 
the bulk material because the former recrystallizes at least in a form, whereas the bulk material 
tends to crystallize preferentially in the (3' modification and transforming rapidly into the P form. 
Depending on the chemical nature of the lipid and on the production conditions, different 
fractions of a and P' modifications can be obtained in lipid nanoparticles. This phenomenon 
leads to a reduction of the melting point, i.e. changes in form and shift of the melting peak, 
which can be observed by DSC measurements. 
Figure 5.12 shows the DSC curves of DM20% (clotrimazole-free) and DM20%C 
(clotrimazole-loaded) NLC formulations, after 7 days of storage at 20°C. The sample containing 
5% of clotrimazole (with regard to the lipid matrix) exhibited a thermal event at 58°C, exactly at 
the same value as the clotrimazole-free sample. This result indicates that clotrimazole does not 
interfere with the crystallinity of NIX containing 14% of Dynasan®\ 16 and 6% of Migly of %\2. 
In comparison to SLN formulations, DM20% and DM20%C exhibited a lower melting point 
due to the liquid oil (MiglyofSU) inside their lipid matrix, indicating that a fat fraction might be 
liquid. The presence of liquid phases promotes the crystallization in the stable form because 
unstable crystals might redissolve and crystallize in the stable modification [312]. 
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Figure 5.12: DSC curves of DM20% (clotrimazole-free) and DM20%C 
(clotrimazole-loaded) NLC formulations, after 7 days of storage at 20°C. 
The obtained DSC data are in agreement with particle size and Ç measurements showing that 
clotrimazole has no effect on physicochemical stability of the lipid matrix. In comparison to the 
bulk material, the melting point of the lipid matrix of SLN and NLC formulations slightly 
decreased (from 63°C to 58°C). 
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The melting behaviour of triacylglycerol nanoparticles strongly depends on the particle size, 
irrespective of matrix material and stabilizer composition [44]. From thermodynamic point of 
view it is expected that the melting temperature of colloidal substances would decrease with 
particle size. 
The Gibbs-Thompson equation (Chapter IV, section 4.4.1) has been used to explain the 
melting point depression of triacylglycerol nanoparticles compared to their bulk phase. The 
melting point of lipid nanoparticles (T) is always smaller than the melting point of the bulk 
material (T0). When a foreign compound is dissolved in the lipid matrix, e.g. drug or surfactant 
molecules, the lipid nanoparticles will show a melting point depression. Defects in the crystal 
lattice may also contribute to the depression of the DSC melting temperature, and the small size 
of these nanoparticles may be an additional reason for their low melting temperature [53]. 
5.2.5. X-ray diffraction studies 
The existence of only one additional, low-melting structure in very fine particles is, however, 
not sufficient to explain the complex melting behaviour of the solid lipid dispersions at higher 
temperatures [44]. According to the x-ray measurements, the complex melting behaviour is due 
to a stepwise melting of the |3 stable form. For the 0 modification of triacylglycerols, several sub-
modifications, which differ in angle of chain tilt and thus in their long spacings, have been 
described. 
Therefore, bulk material, as well as lipid nanoparticles without drug and clotrimazole-loaded 
were also characterized by WAXS-experiments. Scattering angles were transformed into short 
spacings using Bragg's equation (Chapter IV). These measurements were performed after 7 days 
of storage at room temperature. 
By means of WAXS it is possible to assess the length of the long and short spacings of the 
lipid lattice. It is highly recommended to measure solid lipid dispersions themselves because 
solvent removal is able to lead to polymorphic changes [7]. 
The x-ray diffractograms of the bulk material display reflections due to the crystalline state 
of tripalmitin. The x-ray diffractograms of drug-free and drug-loaded dispersions also contain 
only the diffraction pattern of the stable p-polymorph of tripalmitin but no reflections of drug 
when incorporated [73]. 
In the following WAXS curves plots have been displaced vertically for better visualization. 
The units of intensity are arbitrary. 
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As it can be observed in Figure 5.13 bulk material (Dynasari^X 16) showed the typical signals 
of the P-modification of triacylglycerols [293,294]. 
3000 
O V Û M O O - s l - O O ^ Û C S O O - S - V O M S r M O O ' * - * ^ ^ 
— \r~ v\ c* O oi "Ï ^- °- "^ t^ ^ ""■ ■ ■ ^0 ""■ ■ 
^ m t r i r - ' — ò r - í T t i n í S C T v ^ - t N - ^ - m o o a N 
^ , PH p « H C N C N C N C S CN f ) m m m m 
2 Theta 
Figure 5.13: WAXS curve of glyceryl tripalmitate (Dynasatfl 16) bulk material. 
Figures 5.14 and 5.15 show the WAXS curves of SLN prepared with 10% of lipid without 
drug and clotrimazole-loaded, respectively. These curves show the characteristic peaks for P'/p 
modifications, which are marked with arrows. They display x-ray peaks in the wide angle 
regions pointing to the crystalline nature of these particles. 
These dispersions also exhibit melting endotherms in DSC heating runs. DSC and x-ray 
diffraction data indicate that solidification of the freshly O/W nanoemulsion under investigation 
results in crystalline material, i.e. SLN and NLC. The incorporation of drug into these particles 
did not influence lipid crystallinity, as reported after DSC analysis. Note that the position of the 
peak maxima did not change noticeably with the presence of clotrimazole. 
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Figure 5.14: WAXS curve of SLN formulation D10%. The arrows identify the 
characteristic peaks of p/ p" modifications. 
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Figure 5.15: WAXS curve of SLN formulation D10%C. The arrows identify the 
characteristic peaks of p/ P' modifications. 
Figures 5.16 and 5.17 show the WAXS curves of SLN prepared with 20% of lipid without 
drug and clotrimazole-loaded, respectively. As it could be observed for samples containing 10% 
of lipid matrix, these curves also show the characteristic peaks for p'/p modifications, which are 
marked with arrows, showing the crystalline nature of these particles. The incorporation of 
clotrimazole into these SLN did not influence the lipid crystallinity, as reported after DSC 
analysis. 
In comparison to SLN formulations containing 10% of lipid matrix, the peak intensity is 
higher for SLN containing 20% of lipid matrix, as it could be expected. 
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Figure 5.16: WAXS curve of SLN formulation D20%. The arrows identify the 
characteristic peaks of p/ P' modifications. 
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Figure 5.17: WAXS curve of SLN formulation D20%C. The arrows identify the 
characteristic peaks of p7 p" modifications. 
Figures 5.18 and 5.19 show the WAXS curves of NLC formulations. No peak could be 
detected for both formulations, i.e. clotrimazole-free (Figure 5.18) and clotrimazole-loaded 
(Figure 5.19), which means that lipid might contain dissolved clotrimazole in the molecularly 
dispersed form. 
None of the NLC formulations (clotrimazole-free and clotrimazole-loaded) displayed any 
wide angle reflection in their x-ray patterns. Although, these samples display a thermal event 
(melting endotherm) in DSC heating runs (Figure 5.12). Note that, whereas x-ray diffraction data 
only allow differentiation between crystalline data and amorphous material, DSC data can be 
used to differentiate between amorphous solids and liquids [53]. 
In comparison to SLN with the same lipid content, NLC formulations evidence lower lipid 
crystallinity in agreement with the obtained DSC data. These x-ray crystallization studies 
confirm that the transition rates of liquid oils are lower than solid lipids. These differences may 
be due to the more ordered structure of SLN in comparison to NLC. 
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Figure 5.18: WAXS curve of NLC formulation DM20%. 
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Figure 5.19: WAXS curve of NLC formulation DM20%C 
According to the x-ray results it can be stated that clotrimazole does not interfere with the 
lipid matrix. In fact, the incorporation of drug in SLN and NLC formulations led to similar 
results as the ones obtained without drug. In addition, no drug peaks are visible in WAXS curves 
of clotrimazole-loaded formulations; therefore, it can be concluded that drug is still inside the 
lipid nanoparticles. 
In comparison to the bulk material, SLN and NLC seem to transform more rapidly into the 
stable p-polymorph, confirming the DSC data. The faster polymorphic transitions in lipid 
nanoparticles have been attributed to the presence of small crystallization nuclei [53,289]. Note 
that, x-ray peaks of SLN formulations are less intense in comparison to the bulk material pattern. 
This is due to lattice imperfections of incomplete crystallization of the dispersed lipid 
nanoparticles. 
It has been reported that the degree of crystallinity has an effect on the long-term stability of 
aqueous dispersions of SLN [96]. In general, dispersions with a highly recrystallized lipid phase 
showed an increased particle size growth. SLN and NLC were produced by hot HPH of the 
melted lipid dispersed in a surfactant aqueous solution. The obtained O/W nanoemulsion was 
cooled down, recrystallized and formed the lipid particles. Depending on the nature of the lipid, 
this process can take place very quickly, in fact within minutes [98]. However, it has also been 
reported that the recrystallization of the lipid fraction can be retarded up to weeks or months 
[289]. In general, the degree of crystallinity of lipid nanoparticles is below the crystallinity of the 
bulk material used for SLN production and increases with increasing storage time [98]. 
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5.3. Stability of developed SLN and NLC formulations 
Ideally, SLN and NLC should be physically stable in aqueous dispersion. Optimized 
compositions of lipid nanoparticle aqueous dispersions proved to be stable for more than 3 years 
[48]. 
in the present work, the stability of prepared SLN and NLC formulations was evaluated 
concerning the encapsulation parameters, particle size, Ç and the crystalline status of SLN and 
NLC. 
5.3.1. Encapsulation parameters 
The evaluation of the E.E. of clotrimazole and the drug loading capacity during storage time 
are very important tools for the development of a colloidal carrier system [6]. Therefore, for all 
developed clotrimazole-containing SLN and NLC aqueous dispersions the E.E. and the loading 
capacity were evaluated over a period of 21 days. 
Figures 5.20 and 5.21 show, respectively, the variation of E.E. of clotrimazole and drug 
loading capacity of D10%C, measured after 1, 3, 7, 14 and 21 days of storage at room 
temperature. 
I Free drug nwwa Incorporated drug E.E. 
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Figure 5.20: Variation of E.E. of clotrimazole in D10%C, measured after 1, 3, 7, 14 and 
21 days of storage at room temperature (20°C). 
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Figure 5.21: Variation of drug loading capacity of D10%C, measured after 1, 3, 7, 14 
and 21 days of storage at room temperature (20°C). 
Concerning the E.E., D10%C revealed a higher decrease between day 1 and day 3 of storage 
(approximately 7%), while from day 7 onwards, the decrease in E.E. became smaller. During 21 
days the value of E.E. decreased from 60% to 58%. With regard to drug loading capacity, it was 
also observed a decrease of drug content in D10%C between day 1 and day 3 (approximately 
0.3%). Between day 7 and day 21 the loss of drug was neglected. 
Figures 5.22 and 5.23 show, respectively, the E.E. of clotrimazole and the drug loading 
capacity of D20%C, measured after 1, 3, 7, 14 and 21 days of storage at room temperature. 
I Free drug i M a Incorporated drag E.E. 
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Figure 5.22: Variation of E.E. of clotrimazole in D20%C, measured after 1, 3, 7, 14 and 
21 days of storage at room temperature (20°C). 
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Figure 5.23: Variation of drug loading capacity of D20%C, measured after 1, 3, 7, 14 
and 21 days of storage at room temperature (20°C). 
Concerning the E.E., D20%C also revealed a higher decrease between day 1 and day 3 of 
storage (approximately 3%), in comparison to the period of time between day 7 and day 21. 
However, the decrease in E.E. during storage time was lower in D20%C than in D10%C. With 
regard to drag loading capacity, D20%C also showed drug loss during, approximately 0.3%, 
during 21 days of storage at room temperature. 
Figures 5.24 and 5.25 show, respectively, the E.E. of clotrimazole and the drug loading 
capacity of DM20%C, measured after 1, 3, 7, 14 and 21 days of storage at room temperature. 
I Free drug Incorporated drug E.E. 
Day 1 
75 
- 70 
65 
60 
55 
Day 3 Day 7 Day 14 
Days of storage 
Day 21 
Figure 5.24: Variation of E.E. of clotrimazole in DM20%C, measured after 1, 3, 7, 14 
and 21 days of storage at room temperature (20°C). 
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Figure 5.25: Variation of drug loading capacity of DM20%C, measured after 1, 3, 7, 14 
and 21 days of storage at room temperature (20°C). 
Concerning the E.E., DM20%C was responsible for the higher obtained value for E.E.. This 
formulation also revealed a decrease in E.E. between day 1 and day 3 of storage (approximately 
2%), while from day 7 onwards, the decrease in E.E. became smaller. With regard to drug 
loading capacity, DM20%C also showed drug loss during, approximately 0.3%, during 21 days 
of storage at room temperature. 
The obtained results confirm the higher loading capacity of NLC formulation (approximately 
3.5% m/m) in comparison to SLN formulation prepared with the same lipid content 
(approximately 2.3% m/m). 
For SLN formulations, D10%C revealed a higher loading capacity (approximately 3% m/m) 
in comparison to the D20%C (approximately 2.3% m/m), in spite of being responsible for a 
lower E.E.. 
According to Mûller et al. [6], factors determining drug loading capacity are: (i) the 
solubility of drug in melted lipid, (ii) the miscibility of melted lipid and drug, (iii) the chemical 
and physical structure of solid lipid matrix, and (iv) the polymorphic state of the lipid material. 
The prerequisite for obtaining a sufficient loading capacity is a sufficiently high solubility of the 
drug in the melted lipid. Typically, the solubility should be higher than required because it 
decreases when cooling down the melt and might even be lower in the solid lipid. It needs also to 
be considered that during solidification of the lipid an expulsion of the drug from the lipid matrix 
might occur [5]. 
To enhance the solubility of the active compound in the melted lipid one can add solubilizers, 
emulsifying agents or use mono- and diacylglycerols as matrix material, which promotes drug 
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solubilization [6]. In addition, the presence of a liquid lipid can enhance both E.E. and drug 
loading capacity, which has been observed for DM20%C formulation. 
The chemical nature of the lipid is also important, because lipids which form highly 
crystalline particles with a perfect lattice, such as monoacid tri acyl glycerol s like Dynasan 116 
[293], lead to drug expulsion [53]. In the present work, during 21 days of storage at room 
temperature, all SLN and NLC developed formulations showed some drug expulsion from the 
lipid matrix. During this period of time, all clotrimazole-loaded formulations revealed a drug loss 
of approximately 10% (m/m). More complex lipids, such as mixtures of mono-, di- and 
triacylglycerols form less perfect crystals with many imperfections, offering space to 
accommodate the drugs [9]. Also chemically polydisperse lipids, such as those used in 
cosmetics, show very good drug incorporation capabilities. 
Figure 5.26 shows the E.E. of clotrimazole-loaded lipid nanoparticles (D10%C, D20%C and 
DM20%C) on day 21 of storage at room temperature (20°C), as a function of E.E. obtained on 
day 1. 
Figure 5.26: E.E. of clotrimazole-loaded lipid nanoparticles (D10%C, D20%C and 
DM20%C) on day 21 of storage at room temperature (20°C), as a function of E.E. 
obtained on day 1. 
DM20%C showed the highest E.E. with regard to the results obtained on day 1 
(approximately 94%), probably due to the liquid oil content, which can better solubilize the 
lipophilic drug. Although D10%C revealed a lower E.E., in comparison to D20%C after 21 days 
of storage at room temperature (Figures 5.20 and 5.22), the former was responsible for a lower 
loss of drug during this period of time. In fact, after 21 days of storage at room temperature the 
E.E. of D10%C was approximately 90% and of D20%C was approximately 88% (Figure 5.26). 
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With regard to drug loading capacity, Figure 5.27 shows loading capacity of clotrimazole-
loaded lipid nanoparticles (D10%C, D20%C and DM20%C) on day 21 of storage at room 
temperature (20°C), as a function of loading capacity obtained on day 1. 
Figure 5.27: Loading capacity of clotrimazole-loaded lipid nanoparticles (D10%C, 
D20%C and DM20%C) on day 21 of storage at room temperature (20°C), as a function of 
loading capacity obtained on day 1. 
The obtained results for loading capacity of clotrimazole-loaded lipid nanoparticles are in 
agreement with the obtained results for E.E. exposed above (Figure 5.26). Figure 5.27 shows that 
DM20%C is responsible for the lowest drug loss observed during 21 days of storage at room 
temperature. In comparison to NLC formulation, SLN formulations revealed a higher drug loss 
during storage time. The loading capacity of D10%C was higher than the value obtained for 
D20%C, probably due to the lower lipid content of the former in comparison to D20%C. 
Crystalline structure which is related to the chemical nature of the lipid is the responsible 
factor to decide whether the drug will be expelled or firmly incorporated during long-term 
storage [6]. The polymorphic form is also a parameter determining drug incorporation. As 
reported before, crystallization of the lipid in nanoparticles is different from the bulk material. In 
fact, lipid nanoparticles recrystallize at least partially in the a-form, whereas bulk lipids tend to 
recrystallize preferentially in the p'-form and transforming rapidly into the (3-form [63]. With 
increasing formation of the more stable modifications during storage, the lattice is getting more 
perfect and the number of imperfections decreases, which means the formation of p7p-
modifications and promotion of drug expulsion. In general, the transformation is slower for long-
chain than for short-chain triacylglycerols [36]. 
114 Chapter V 
In order to avoid drug loss during storage time, complex acylglycerols, like hard fats as lipid 
matrix, can be used because the incorporation of lipophilic drugs is facilitated [289]. However, 
these hard fats reveal tendency to form supercooled melts instead of solid nanoparticles. Even if 
they are solidified at room temperature, these particles melt at body temperature. Therefore, 
these later are not suitable for controlled release applications and could not be used for the 
purpose of the present work. 
An optimal lipid nanoparticle carrier can be produced in a controlled way when a certain 
fraction of a-form can be created and preserved during the storage time [27]. This can be 
achieved by preparation of NLC aqueous dispersions. These later systems are characterized by 
having a built-in trigger mechanism to initiate transformation from a to P-forms and 
consequently controlled drug release upon application to the skin [103,106]. 
As reported before, SLN formulations revealed a higher drug loss that NLC formulation 
during storage time (Figures 5.26 and 5.27). A potential disadvantage of SLN over NLC is the 
transformation of the lipid matrix from a P'-modification to a more stable one, p, leading to drug 
expulsion. This triggered release theory described by Mûller et al. [27] is schematically 
represented in Figure 5.28. 
SLN problem: 
control process 
perfect 
crystallization 
drug 
expulsion 
NLC trick: 
set trigger impulse 
start 
crystallization 
drug release 
Figure 5.28: Triggered release of active compounds by controlling the transformation from p 
and p' to p. (Adapted from Muller et al. [27]). 
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In comparison to NLC, in spite of having lower E.E. and loading capacity SLN have a solid 
lipid matrix and should therefore theoretically be suitable for controlled release [107]. This 
property becomes important in dermal application, concerning to drugs that are irritating at high 
concentrations. Furthermore, it provides the possibility to supply an active compound over a 
period of time and can reduce systemic absorption. Controlled triggered release of drugs is 
feasible due to polymorphic transitions of the lipids induced by water evaporation from the 
dosage form after application to the skin. In addition, electrolytes present in the upper skin 
surface can initiate polymorphic transitions accompanied by drug expulsion due to the formation 
of a stable polymorph [103]. 
5.3.2. Particle size 
Regarding to hot HPH technique, the parameters influencing the product quality are the 
power density, i.e. the homogenization pressure, the number of homogenization cycles, the 
percentage of solid content and the nature and concentration of the emulsifying agent. 
Physical stability of SLN and NLC developed formulations was evaluated as a function of 
lipid concentration, presence of clotrimazole, and as a function of time and temperature of 
storage. The effect of the packing conditions was minimized and neglected. After production, 
aqueous dispersions were stored and sealed in siliconized glass vials. Immediate sealing avoids 
water evaporation from the freshly prepared aqueous dispersions, and siliconization of the vials 
almost eliminates particle growth [96,98]. By optimizing the storage conditions, the tendency of 
particle growth for each nanoparticle system can be achieved. 
LD data were characterized by the diameter d99% and the mean particle size and PI were 
investigated by PCS during a period of 90 days. 
5.3.2.1. Particle size stability of clotrimazole-free SLN and NLC formulations 
It was possible to produce SLN and NLC dispersions having an extremely narrow particle 
size distribution, similar to emulsions for parenteral nutrition (Lipofundin®, Intralipid*'). Note 
that commercial fat emulsions possess mean diameters ranging from about 200-400 nm [313]. 
Figure 5.29 shows that clotrimazole-free SLN and NLC dispersions revealed a narrow 
particle size distribution measured by LD analysis, which was completely in the nanometer range 
during 90 days of storage at room temperature. During the same period of time and storage 
conditions, the PI remained lower than 0.3 (Figure 5.30) for all drug-free formulations. 
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Figures 5.29 and 5.30 show that despite the increasing lipid content of the formulations, 
nanoparticles retained their colloidal particle size. Due to the narrow size distribution, their 
colloidal particle size can be maintained during storage time. If the particle size distribution was 
inhomogeneous, smaller particles would be able to dissolve and recrystallize on the surface of 
larger particles leading to an increase in particle size of already larger particles [117]. This 
phenomenon is based on the Kelvin equation (Chapter IV, section 4.4.1), which describes the 
increased vapour pressure over small liquid particles with a strong curvature of the surface. 
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Figure 5.29: Particle size of clotrimazole-free SLN and NLC formulations (D10%, 
D20% and DM20%) measured by LD (d99%), after 1, 30, 60 and 90 days of storage at 
room temperature (20°C). 
Figure 5.30: Mean particle size and PI of clotrimazole-free SLN and NLC formulations 
(D10%, D20% and DM20%) measured by PCS, after 1, 30, 60 and 90 days of storage at 
room temperature (20°C). 
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5.3.2.2. Particle size stability of clotrimazole-loaded SLN and NLC formulations 
Figures 5.31 and 5.32 show the results obtained by LD and PCS analysis of SLN and NLC 
formulations containing clotrimazole, during a period of 90 days of storage at room temperature. 
Incorporation of the antifungal agent in the lipid matrix was successful in concentrations of 5% 
(m/m) with respect to the lipid content. 
Figure 5.31 shows that 99% of clotrimazole-loaded SLN and NLC remained lower than 750 
nm after three months of storage at room temperature. During this period, the particle size of the 
clotrimazole-loaded samples containing 20% of lipid matrix remained higher than drug-loaded 
samples containing 10% of lipid matrix. 
It can also be observed that D10%C showed a decrease in particle size measured by LD 
during 3 months of storage at room temperature. This interesting observation might probably be 
due to the repartitioning effect of Tyloxapof at the surface of the SLN and to the lower content 
of lipid in comparison to D20%C and DM20%C. One day after production, D20%C sample 
exhibited the highest particle size probably due to the higher solid lipid content of this 
formulation. 
Figure 5.32 shows that the mean particle size of clotrimazole-loaded SLN and NLC remained 
between 150 and 250 nm, during 90 days of storage at room temperature. D20%C formulation 
showed a higher mean particle size (> 200 nm), in comparison to D10%C and DM20%C, during 
the investigation time. 
Figure 5.31: Particle size of clotrimazole-loaded SLN and NLC formulations (DlO%C, 
D20%C and DM20%C) measured by LD (d99%), after 1, 30, 60 and 90 days of storage 
at room temperature (20°C). 
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Figure 5.32: Mean particle size and PI of clotrimazole-loaded SLN and NLC 
formulations (D10%C, D20%C and DM20%C) measured by PCS, after 1, 30, 60 and 90 
days of storage at room temperature (20°C). 
5.3.2.3. Particle size stability of clotrimazole-free and clotrimazole-loaded SLN and 
NLC formulations as function of temperature of storage 
When judging the suitability of SLN and NLC aqueous dispersion for therapeutic purposes, 
the long-term stability of these systems needs to be considered. It might be possible that a solid 
lipid formulation appears highly attractive with regard to toxicological aspects. However, it 
proves to be physically unstable during storage as aqueous dispersion. In such cases, lipid 
nanoparticles can be transferred to a dry product by lyophilization [15,20-22] or by spray-drying 
[21]. 
Physical integrity of SLN and NLC, i.e. absence or minimization of particle aggregation and 
quantitative preservation of solid lipid content during storage, has to be confirmed. However, a 
low extent of particle aggregation which is well below the perception limit has to be regarded as 
non-critical. 
In the present work, storage stability of SLN and NLC aqueous dispersions was assessed by 
monitoring particle size as a function of time, for 3 months stored at 4°C, 20°C and 40°C. 
Figures 5.33 and 5.34 show the results obtained for clotrimazole-free SLN formulation 
D10% analysed by LD and PCS, respectively. 
For all three batches of this formulation, particle size remained below 0.8 urn during 90 days 
of storage at different temperatures. When stored at 4°C, a slight increase in particle size 
measured by LD could be observed. At 40°C particle size remained below 0.4 urn during 3 
months, probably due to the lower viscosity of the medium in comparison to the samples stored 
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at 4°C and 20°C. Mean particle size measured by PCS was around 200 nm during the same 
period of storage. The PI obtained by PCS analysis remained around 0.3 throughout the observed 
storage time. 
20°C 
Temperature of storage 
Figure 5.33: Particle size of clotrimazole-iree SLN formulation D10% measured by LD 
(d99%), after 1, 7, 14, 30, 60 and 90 days of storage at 4°C, 20°C and 40°C. 
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Figure 5.34: Mean particle size and PI of clotrimazole-free SLN formulation D10% 
measured by PCS, after 1, 7, 14, 30, 60 and 90 days of storage at 4°C, 20°C and 40°C. 
Figures 5.35 and 5.36 show the results obtained for clotrimazole-loaded SLN formulation 
D10%C analysed by LD and PCS, respectively. 
The incorporation of clotrimazole did not influence the particle size of the SLN aqueous 
dispersion when stored at different temperatures. 
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For all three batches of this formulation particle size remained below 0.7 urn during 90 days 
of storage at different temperatures. When stored at 4°C, a slight increase in particle size 
measured by LD could be observed. At 40°C the particle size remained below 0.6 urn during the 
first week but showed a decrease between 7 and 90 days of storage. Mean particle size measured 
by PCS was around 200 nm during the same period of storage. The PI obtained by PCS analysis 
remained around 0.3 throughout the observed storage time. 
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Figure 5.35: Particle size of clotrimazole-loaded SLN formulation D10%C measured by 
LD (d99%), after 1, 7, 14, 30, 60 and 90 days of storage at 4°C, 20°C and 40°C. 
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Figure 5,36: Mean particle size and PI of clotrimazole-loaded SLN formulation D10%C 
measured by PCS, after 1, 7, 14, 30, 60 and 90 days of storage at 4°C, 20°C and 40°C. 
Figures 5.37 and 5.38 show the results obtained for clotrimazole-free SLN formulation 
D20% analysed by LD and PCS, respectively. 
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When stored at 4°C, samples were not able to be analysed by LD and PCS once they were 
congealed. Thus, particle size analysis was only performed for batches stored at 20°C and 40°C. 
It could be observed that particle size remained below 0.5 urn during storage time and at 
40°C from day 7 onwards it remained around 0.3 um. The PI obtained by PCS analysis remained 
below 0.25 throughout the observed storage period. 
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Figure 5.37: Particle size of clotrimazole-free SLN formulation D20% measured by LD 
(d99%), after 1, 7, 14, 30, 60 and 90 days of storage at 20°C and 40°C. 
Figure 5.38: Mean particle size and PI of clotrimazole-free SLN formulation D20% 
measured by PCS, after 1, 7, 14, 30, 60 and 90 days of storage at 20°C and 40°C. 
Figures 5.39 and 5.40 show the results obtained for clotrimazole-loaded SLN formulation 
D20%C analysed by LD and PCS, respectively. 
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As it can be observed, the presence of clotrimazole did not change significantly the particle 
size distribution. When stored at 20°C, particle size oscillated between 0.7 and 0.5 urn during the 
3 months of storage. When stored at 40°C, a decrease in particle size, probably due to the lower 
viscosity of the medium, could be observed. For this sample (D20%C), the mean diameter 
remained approximately at 200 nm and the PI around 0.2. 
Figure 5.39: Particle size of clotrimazole-loaded SLN formulation D20%C measured by LD 
(d99%), after 1, 7, 14, 30, 60 and 90 days of storage at 20°C and 40°C. 
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Figure 5.40: Mean particle size and PT of clotrimazole-loaded SLN formulation D20%C 
measured by PCS, after 1, 7, 14, 30, 60 and 90 days of storage at 20°C and 40°C. 
Figures 5.41 and 5.42 show the results obtained for clotrimazole-free NLC formulation 
DM20% analysed by LD and PCS, respectively. 
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For all three batches of this formulation particle size measured by LD remained below 0.6 
urn during 90 days of storage at different temperatures. Mean particle size measured by PCS was 
below 190 nm during the same period of storage. At 4°C a slight increase in mean diameter could 
be observed, although it remained below 190 nm. The PT obtained by PCS analysis was below 
0.25 throughout the observed storage time. 
Figure 5.41: Particle size of clotrimazole-free NLC formulation DM20% measured by 
LD (d99%), after 1, 7, 14, 30, 60 and 90 days of storage at 4°C, 20°C and 40°C. 
195 -, 
— P C S - « - P I 
r 0,35 
,-, 190 -
I 185 ■ 
IB 18° 1 
0,3 
0,25 
t 175 . ■ 0,2 
| 170 0,15 K 
a 1 6 5 " I 160 • 111111 I I I I I I III III 0,1 S 155 -in in in in min - 0,05 150 r_ ■ * o o o i-~ -^ o o o r. - t o o o 
vo CT\ o <j\ ^o CT> is1 to ; > i i». >, > i <0 >• >, a a) K - , > i >> f 1 ' 1 CYI f ) Í ) a ( 1 f 1 Q a a a a a Q a a Q Q ID 
4X' 20¾ 40¾ 
Temperature of storage 
Figure 5.42: Mean particle size and PI of clotrimazole-free NLC formulation DM20% 
measured by PCS, after 1, 7, 14, 30, 60 and 90 days of storage at 4°C, 20°C and 40°C. 
Figures 5.43 and 5.44 show the results obtained for clotrimazole-loaded NLC formulation 
DM20%C analysed by LD and PCS, respectively. 
124 Chapter V 
As expected, the presence of clotrimazole was not responsible for changes in particle size 
distribution. During 90 days of storage at different temperatures, particle size remained around 
0.6 urn. Mean particle size measured by PCS was below 190 nm and the PI obtained by PCS 
analysis was below 0.25 throughout the observed storage time. 
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Figure 5.43: Particle size of clotrimazole-loaded NLC formulation DM20%C 
measured by LD (d99%), after 1, 7, 14, 30, 60 and 90 days of storage at 4°C, 20°C and 
40°C. 
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Figure 5.44: Mean particle size and PI of clotrimazole-loaded NLC formulation 
DM20%C measured by PCS, after 1, 7, 14, 30, 60 and 90 days of storage at 4°C, 20°C 
and 40°C. 
In comparison to oil-free formulations (i.e. SLN formulations), samples containing 
Miglyofzn (DM20% and DM20%C) showed a lower variation in size distribution during 
storage time. 
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5.3.3, Zeta potential 
Determination of Ç was carried out in SLN and NLC aqueous dispersions stored at room 
temperature. Figure 5.45 shows the results after 1, 30 and 90 days of storage. All samples 
showed a pH between 4 and 5, during 3 months. 
Figure 5.45: Zeta potential of clotrimazole-free and clotrimazole-loaded SLN and NLC 
formulations, after 1, 30 and 90 days of storage at room temperature (20°C). 
On day 1 of storage at room temperature, the Ç of drug-free samples was between -17 mV 
and -37 mV, while the Ç of drug-loaded samples was between -8 mV and -11 mV. 
After 30 days of storage in the same conditions, the Ç of drug-free samples was between -16 
mV and -31 mV, while the C, of drug-loaded samples was between -12 mV and -13 mV. 
After 90 days, the Ç of drug-free samples was between -16 mV and -24 mV, while the Ç of 
drug-loaded samples was between -14 mV and -15 mV. 
It could be observed that samples with 10% of lipid matrix showed higher Ç than samples 
containing 20% of lipid. In addition, samples containing MiglyorS 12 showed the lowest Ç value. 
On day 1 of storage, clotrimazole-loaded formulations showed lower Ç than drug-free 
formulations. On the contrary, after 3 months of storage, the Ç of the samples without drug was 
lower than clotrimazole-loaded systems. 
A low Ç could be expected for all tested formulations, once these lipid particles are made of a 
non-ionic lipid and a non-ionic emulsifying agent. The Ç must be sufficiently high (in absolute 
value) for electrostatic stabilization of the nanoparticle dispersions [314]. In general, a Ç of 
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approximately -30 mV is considered as the lowest edge of the Ç range required for adequate 
stabilization [315]. 
Although all tested samples exhibited a Ç lower than -25 mV after 90 days of storage at room 
temperature, these samples remained physically stable during this period of time. 
From these results it can be concluded that incorporated clotrimazole can take part in the 
improvement of long-term stability. Note that all produced clotrimazole-containing SLN and 
NLC aqueous dispersions presented higher Ç than clotrimazole-free aqueous dispersions. 
5.3.4. DSC studies 
Polymorphic transformations may occur during preparation of lipid drug delivery systems 
and during the subsequent storage time [53,83,226]. 
During solidification of the melt or the solution, the triacylglycerol can crystallize in different 
polymorphic forms (Chapter II), depending on the composition of the lipid and the cooling rate. 
Nanoparticles made from mixed triacylglycerols are characterized by more imperfections in the 
crystal lattice, while the ones made from monoacid triacylglycerols have a higher degree of 
crystalline order and are connected to lower loading capacities [9,53]. Concerning cooling rate, it 
is known that due to a fast solidification during the preparation of lipid nanoparticles the instable 
a modification is formed. During a slow process, the lipid molecules can arrange in the 
thermodynamically most stable P modification [294]. 
Thermodynamic stability and lipid packing density increase, while drug incorporation rates 
decrease in the following order: supercooled melt, a modification, P' modification and P 
modification [6]. 
Supercooled melts are not lipid suspensions, rather systems similar to O/W emulsions [7]. 
They describe a phenomenon that lipid crystallization may not occur although the sample is 
stored at temperature below the melting point of the lipid. These systems are not unusual in SLN 
preparation [316]. Therefore, special attention must be paid because the potential advantages of 
SLN over nanoemulsions are linked to the solid state of the lipid. 
The main reason for the formation of supercooled melts is the size dependence of 
crystallization processes. Crystallization requires a critical number of crystallization nuclei to 
start [317]. This critical number of molecules is less likely to be formed in small droplets and 
therefore, the tendency of the formation of supercooled melts increase with decreasing droplet 
size. The range of supercooling (temperature difference between the melting and crystallization 
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points) can reach 30 to 40°C in lipid dispersions [35]. In addition to size, crystallization can be 
affected by surfactants, incorporated drugs and other factors. 
Lipid nanoparticles, such as SLN and NLC, present a solid matrix and, therefore, are able to 
entrap drug molecules. On the contrary, supercooled melts immobilize more difficulty the active 
compound. Therefore it is necessary to evaluate the solid state of the lipid by DSC and by x-ray 
diffraction. 
The phenomenon of crystallization may cause differences in solubility and melting point of 
active compounds and excipients, and especially the conversion of one polymorph to another 
may change the physical properties of the incorporated drug [83]. 
5.3.4.1. Maintenance of crystalline status at room temperature 
It is not sufficient to describe the physical state of the lipid as crystallized or non-crystallized, 
because the crystallized lipid may be present in several modifications of the crystal lattice. In 
general, lipid molecules have higher mobility in thermodynamically unstable configurations, 
which are characterized by a lower density and a higher capacity for incorporation of active 
compounds [6,7]. 
The advantage of higher incorporation rates in unstable modifications is paid off by an 
increase mobility of the drug [7]. During storage, rearrangements of the crystal lattice might 
occur in favour of thermodynamically stable configurations and this is often associated to 
expulsion of the drug molecules. The performance of the system will be determined to a large 
extent by the lipid modification, because this parameter triggers drug incorporation and drug 
release. Aspects of reproducibility and drug safety demand the assurance of systems with defined 
and reliable characteristics. Therefore, DSC investigations during storage time are an important 
tool, in order to evaluate the performance of SLN and NLC as a function of time. 
Figures 5.46 and 5.47 show the DSC curves of clotrimazole-free and clotrimazole-loaded, 
respectively, of SLN formulations containing 10% of lipid matrix, measured after 7 and 90 days 
of storage at room temperature. 
It could be observed that during storage the crystallinity of lipid matrix increased, which is 
indicated by a higher melting point. On day 7 the clotrimazole-free and clotrimazole-loaded 
samples showed a melting point at 60°C while on day 90 the lipid matrix melted at 61°C. The 
melting enthalpy remained almost the same. 
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Figure 5.46: DSC curves of clotrimazole-free SLN formulation D10% after 7 
and 90 days of storage at room temperature (20°C). 
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Figure 5.47: DSC curves of clotrimazole-loaded SLN formulation D10%C after 
7 and 90 days of storage at room temperature (20°C). 
Figures 5.48 and 5.49 show the DSC curves of clotrimazole-free and clotrimazole-loaded, 
respectively, of SLN formulations containing 20% of lipid matrix, measured after 7 and 90 days 
of storage at room temperature. 
For these formulations an increase in lipid crystallinity during storage time could also be 
observed. On day 7 the clotrimazole-free and clotrimazole-loaded samples showed a melting 
point at 60°C while on day 90 the lipid matrix melted at 62°C. The melting enthalpy remained 
almost the same for clotrimazole-loaded sample, while it decreased for clotrimazole-free sample. 
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Figure 5.48: DSC curves of clotrimazole-free SLN formulation D20% after 7 
and 90 days of storage at room temperature (20°C). 
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Figure 5.49: DSC curves of clotrimazole-loaded SLN formulation D20%C after 
7 and 90 days of storage at room temperature (20°C). 
Figures 5,50 and 5.51 show the DSC curves of clotrimazole-free and clotrimazole-loaded, 
respectively, of NLC formulations containing 20% of lipid matrix, measured after 7 and 90 days 
of storage at room temperature. 
For both drug-free and drug-loaded NLC formulations the melting point increased from 58°C 
to 6 PC upon 90 days of storage at room temperature. Similarly to the clotrimazole-loaded SLN 
formulations, clotrimazole-loaded NLC formulations also evidenced an increase in lipid 
crystallinity during storage time. However, this increase was higher than the registered for SLN 
formulations. 
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Figure 5.50: DSC curves of clotrimazole-free NLC formulation DM20% after 7 
and 90 days of storage at room temperature (20°C). 
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Figure 5.51: DSC curves of clotrimazole-loaded NLC formulation DM20%C 
after 7 and 90 days of storage at room temperature (20°C). 
To sum up, for all studied samples, either clotrimazole-free or clotrimazole-loaded, it could 
be observed that crystallinity of the solid matrix increased during storage time. Tables XVII and 
XVIII show the DSC results of clotrimazole-free and clotrimazole-loaded SLN and NLC 
aqueous dispersions, respectively, as a function of storage time at room temperature. 
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Table XVII: DSC results of clotrimazole-free SLN and NLC aqueous dispersions, as a function of storage time 
at room temperature (20°C). 
Formulation Days of 
storage 
Melting point 
(°Q 
Onset 
(°C) 
Integral 
(mJ) 
Enthalpy 
(J/R) 
RI 
(%) 
D10% 7 59.33 55.12 479.25 13.51 69.8 
90 60.27 55.53 494.14 13.10 67.7 
D20% 7 59.46 55.53 330.87 33.67 87.0 
90 60.69 55.74 362.64 30.70 79.4 
DM20% 7 58.04 54.22 623.07 17.88 46.2 
90 59.83 56.54 665.00 16.74 43.3 
Table XVTTT: DSC results of clotrimazole-loaded SLN and NLC aqueous dispersions, as a function of storage 
time at room temperature (20°C). 
Formulation Days of 
storage 
Melting point 
(UC) 
Onset 
<"C) 
Integral 
(mJ) 
Enthalpy 
(J/g) 
RI 
(%) 
D10%C 7 58.95 54.65 411.36 15.86 81.2 
90 59.70 55.42 372.97 17.35 89.7 
D20%C 7 59.07 54.97 339.08 32.85 84.9 
90 60.19 55.94 327.94 33.95 87.8 
DM20%C 7 58.12 54.57 705.54 15.79 40.8 
90 60.21 56.53 576.80 19.32 49.9 
The obtained results indicate that drug can be expelled from the lipid matrix during storage. 
Therefore, crystallinity of the lipid matrix is a parameter determining drug incorporation and it is 
also responsible for the drug release profile. As reported before, triacylglycerols are known to 
crystallize mainly in three polymorphic forms, which transform monotrophically from a to P via 
P' with increase of thermodynamic stability and lipid packing density and decrease of drug 
incorporation [244]. 
5.3.4.2. Maintenance of crystalline status at different temperatures 
Figures 5.52 and 5.53 show the DSC curves of clotrimazole-free and clotrimazole-loaded 
SLN formulations containing 10% of lipid matrix, respectively, obtained after 90 days of storage 
at 4°C, 20°C and 40°C. 
Lipid crystallinity remained practically as the same at the three different temperatures of 
storage. All clotrimazole-free and clotrimazole-loaded batches evidenced a thermal event 
between 60°C and 61°C, corresponding to melting of the lipid. 
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Figure 5.52: DSC curves of clotrimazole-free SLN formulation D10% after 90 
days of storage at 4°C, 20°C and 40°C. 
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Figure 5.53: DSC curves of clotrimazole-loaded SLN formulation D10%C after 
90 days of storage at 4°C, 20°C and 40°C. 
Figures 5.54 and 5.55 show the DSC curves of clotrimazole-free and clotrimazole-loaded 
SLN formulations containing 20% of lipid matrix, respectively, obtained after 90 days of storage 
at 4°C, 20°C and 40°C. 
For all these samples, it could also be stated that lipid crystallinity remained practically 
constant at the three different temperatures of storage. All clotrimazole-free and clotrimazole-
loaded batches revealed a thermal event between 60°C and 62°C. 
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Figure 5.54: DSC curves of clotrimazole-free SLN formulation D20% after 90 
days of storage at 4°C, 20°C and 40°C. 
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Figure 5.55: DSC curves of clotrimazole-loaded SLN formulation D20%C after 
90 days of storage at 4°C, 20°C and 40°C. 
Figures 5.56 and 5.57 show the DSC curves of clotrimazole-free and clotrimazole-loaded 
NLC formulations containing 20% of lipid matrix, respectively, obtained after 90 days of storage 
at 4°C, 20°C and 40°C. 
For NLC formulations, thermal behaviour showed significant differences between samples 
stored at room temperature and samples stored at 4°C and 40°C. For both clotrimazole-free and 
clotrimazole-loaded formulations stored at 20°C, the matrix showed the highest crystallinity with 
a melting point at 6FC. When stored at 4°C and 40°C the melting point decreased to 58°C. At 
40°C the observed melt enthalpy was lower than at 4°C. 
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These results may be due to the presence of the liquid oil inside the solid matrix, showing 
that NLC remain in a more unstable polymorph during storage, which can be associated to a 
higher drug payload in comparison to SLN prepared with the same lipid content. 
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Figure 5.56: DSC curves of clotrimazole-free NLC formulation DM20% after 
90 days of storage at 4°C, 20°C and 40°C. 
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Figure 5.57: DSC curves of clotrimazole-loaded NLC formulation DM20%C 
after 90 days of storage at 4°C, 20°C and 40°C, 
To summarise, for all studied samples, either clotrimazole-free or clotrimazole-loaded, it 
could be observed that crystallinity of the solid matrix did not change significantly when samples 
were stored at different temperatures, except for DM20% when stored at 4°C and 40°C. Tables 
XLX and XX show the DSC results of clotrimazole-free and clotrimazole-loaded SLN and NLC 
aqueous dispersions, respectively, as a function of storage temperature, obtained after 90 days of 
storage. 
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Table XIX: DSC results of clotrimazole-free SLN and NLC aqueous dispersions as a function of storage 
temperature, obtained after 90 days of storage. 
Formulation Temperature 
of storage (°C) 
Melting point 
(°C) 
Onset 
(°C) 
Integral 
(mJ) 
Enthalpy 
(J/g) 
RI 
(%) 
D10% 4 59.21 55.03 499.33 12.96 67.0 
20 60.27 55.53 494.14 13.10 67.7 
40 60.70 56.32 503.11 12.86 66.5 
D20% 4 60.14 55.36 330.19 33.72 87.2 
20 60.69 55.74 320.95 34.70 89.7 
40 61.03 57.07 326.36 34.14 88.2 
DM20% 4 57.45 52.29 594.67 18.74 48.4 
20 59.83 56.54 418.12 28.09 67,4 
40 58.27 56.78 660.49 16.85 43.6 
Table XX: DSC results of clotrimazole-loaded SLN and NLC aqueous dispersions as a function of storage 
temperature, obtained after 90 days of storage. 
Formulation Temperature 
of storage (°C) 
Melting point 
(°C) 
Onset 
(°C) 
Integral 
(mJ) 
Enthalpy 
(J/g) 
RI 
(%) 
D10%C 4 59.22 54.73 374.61 17.28 89.3 
20 59.70 55.42 372.97 17.35 89.7 
40 60.10 55.72 368.84 17.55 90.7 
D20%C 4 60.11 54.51 337.90 32.96 85.2 
20 60.19 55.94 327.94 33.95 87.8 
40 60.36 55.92 338.30 32.92 85.1 
DM20%C 4 57.83 52.72 603.48 18.46 47.7 
20 60.21 56.53 400.43 27.81 71.9 
40 57.02 52.24 672.50 16.57 42.8 
5.4. Clotrimazole release profiles of developed SLN and NLC formulations 
Drug release profiles of clotrimazole from the developed SLN and NLC formulations were 
determined using static Franz glass diffusion cells. The receptor medium consisted on a solution 
of 100 mM acetate buffer, pll 6.0 with 35% (V/V) of dioxane. Samples were taken after 1, 2, 4, 
6, 8, 10 and 24 h. 
Figure 5.58 shows the release profiles of clotrimazole from three different SLN and NLC 
formulations containing 5% of drug, with regard to the lipid matrix. 
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Figure 5.58: In vitro release profiles of clotrimazole from SLN and NLC formulations 
containing 5% of drug, with regard to the lipid matrix. 
Clotrimazole is clearly more easily released from the NLC formulation (DM20%C). 
Regarding the SLN formulations - D10%C and D20%C -, it can be stated that after 1 hour the 
percentage of drug released from D10%C formulation (7% m/rri) was almost doubled in 
comparison to D20%C (4% nv'm). After the same period, the percentage of drug released from 
the NLC formulation was almost 10% (m/m). 
As it was referred before, in NLC formulations lipid nanoparticles have a liquid core 
(Miglyo/®$12) and clotrimazole is incorporated in the oil less tightly in comparison to the solid 
lipid matrix of SLN formulations. In these later, drug molecules are incorporated into the 
crystalline matrix and their diffusional mobility is decreased. 
Tt was also observed that the release rate of clotrimazole also depends on the E.E. of the 
systems. In fact, clotrimazole was faster released by the D10%C formulation, which showed the 
lowest E.E. (approximately 64%). 
DSC measurements and x-ray diffraction studies demonstrated that the drug was present in 
the form of a solid solution in SLN formulations or dissolved in the oil core in NLC 
formulations. The existence of pure drug crystals inside the lipid nanoparticles could not be 
detected. Drug crystals in the water phase of the aqueous dispersions, a reason for fast release, 
could also be excluded. A possible explanation for the observed faster clotrimazole release from 
D10%C in comparison to D20%C is the enrichment of drug in the outer shell of the nanoparticle 
(Figure 2.8, Chapter II). 
As it was referred in Chapter II, SLN formulations may present different drug incorporation 
and drug release mechanism models, such as the core-shell model with drug-enriched shell and 
the core-shell model with drug-enriched core [6]. The drug-enriched shell model is formed 
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during the production process when the drug in the melted lipid is well below its saturation 
solubility. During the cooling process after hot HPH, the lipid solidifies and the drug re-
partitions into the shell of the particles. A drug-enriched core is formed when the drug in the 
melted lipid is close to its saturation solubility in the lipid. The cooling process leads to 
supersaturation of the drug and subsequently to drug crystallization prior to lipid crystallization 
[6]. 
In the present study, the SLN formulation D10%C corresponds to the drug-enriched shell 
model, while the SLN formulation D20%C corresponds to the drug-enriched core model. For 
SLN formulations corresponding to the drug-enriched shell model, burst release can be observed, 
whereas sustained release can be obtained by choosing a suitable formulation which forms drug-
enriched core [6]. 
Generally, diffusion through the carrier is the main mechanism of controlled release as 
described by Fick's law of diffusion [27]. However, drug diffusion coefficient cannot be 
considered constant, but it is dependent upon drug concentration. Due to a large drug loading, the 
degree of diffusion can be decreased. There are too many molecules trying to diffuse and they 
limit their own permeation (hindering effects). Also, the previously described incorporation 
models for SLN (drug-enriched core or shell) underline these findings. 
Drug loading is very important with regard to release characteristics [6]. Generally, the 
increase of drug loading leads to an acceleration of the drug release. However, in particular 
cases, increasing the drug loading may slow down the release, which can be explained by 
possible drug crystallization inside the nanoparticles, but in this particular investigation this 
phenomenon was not observed. 
In the present work, it has been found that SLN and NLC are suitable systems for controlling 
the release of clotrimazole. The release profiles are determined by drug characteristics and the 
properties of the lipid carriers, i.e. particle size, loading capacity, structure of the lipid matrix and 
obviously the drug localization inside this matrix. Dominant factors for the shape of the profiles 
are the production parameters, such as the concentration of the emulsifying agent, the 
temperature and the nature of the lipid matrix [6]. 
Obtained profiles (Figure 5.58) could be explained by partitioning effects of the drug 
between the melted lipid phase and the aqueous surfactant solution during particle production, 
i.e. phase separation effect [11]. 
This phase separation effect is schematically represented in Figure 5.59. During hot HPH 
technique, drug moves from the liquid oil phase (melted lipid) to the aqueous phase. The amount 
of drug partitioning to the water phase will increase with the increase of drug solubility in this 
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phase, which happens when both temperature and surfactant concentration of the aqueous phase 
increase. The higher the temperature and the surfactant concentration, the greater is the 
saturation solubility of the drug in the water phase. During the cooling step of the produced O/W 
nanoemulsion solubility of the drug in the water phase decreases continuously with decreasing 
temperature of the water phase, which means a repartitioning of the drug into the lipid phase. 
When reaching the recrystallization temperature of the lipid, a solid lipid core starts forming 
including the drug, which is present at this temperature in the lipid phase. Reducing the 
temperature of the dispersion further increases the pressure on the drug because of its reduced 
solubility in water to further repartition into the lipid phase. The already crystallized core is not 
accessible anymore for the drug. As a consequence, drug concentrates in the still liquid outer 
shell of the SLN and/or on the surface of the particles. 
HOT HOMOGENIZATION COOLING TO ROOM TEMPERATURE 
Drug distribution D™g distribution 
to water phase at the particle surface 
Liquid lipid Solidification of the lipid dropplet 
droplet and SLN formation 
Figure 5.59: Partitioning effects on drug during the production of SLN by the hot HPH technique. 
Partitioning of drug from the lipid phase to the water phase at increased temperature, and repartitioning of 
the drug to the lipid phase during cooling of the produced O/W nanoemulsion. (Adapted from Mûller et al. 
[6]). 
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Due to the morphological types of SLN, the amount of drug in the outer shell and on the 
particle surface is released in the form of a burst, while the drug incorporated into the particle 
core is released in a prolonged way [27]. 
This phenomenon of burst release of the drug has been described for a number of SLN 
formulations [6]. However, prolonged release is also possible as described by many examples in 
the literature [107,129,136]. Therefore, to achieve prolonged release, special production 
conditions are recommended [11]. The extent of burst release can be controlled via the solubility 
of the drug in the water phase during production, which means via the temperature employed and 
the surfactant concentration used. Higher temperatures and higher surfactant concentrations 
increase the burst. Thus, production at room temperature avoids partitioning of drug into the 
water phase and subsequently repartitioning from the oil phase [6]. If no initial dose is desired, 
the burst release can be avoided [50]. However, despite applying such production conditions for 
some drug and lipid mixtures the burst release cannot be avoided [29]. Applying the NLC 
technology, especially the imperfect type and amorphous type (Figure 2.10, Chapter II), provides 
much more flexibility to achieve the desired controlled drug release profile. 
The reasons and the mechanism why certain drugs are very efficiently incorporated while 
others are not still remain poorly understood. One hypothesis that can be used to explain this 
phenomenon is based on different melting points of the drugs [318]. It is believed that drugs with 
higher melting points than the lipid precipitate first after the hot homogenization production 
process, and the drug, therefore, forms a core in the lipid phase. These systems show sustained 
release and a good E.E. [319]. In the case of drugs with lower melting points than the lipid, the 
lipid recrystallizes first and forms a lipid core, and the drug can only distribute to the surface. 
Thus, poor encapsulation and burst release results. However, this hypothesis, derived from 
release studies, was not investigated experimentally [75]. 
5.5. Incorporation of SLN and NLC into hydrogels 
As reported before, SLN and NLC aqueous dispersions might be interesting systems in 
dermatological pharmaceutical formulations [9,47,56,104,107,113,119,175,177,183,187,320, 
321]. These lipid particles are able to act as drug reservoirs, providing a controlled release profile 
of the incorporated drug. In addition, they can act as carriers for active substances, which prove 
to be chemically unstable in aqueous formulations, such as creams or lotions. 
Therefore, in the present work clotrimazole-loaded SLN and NLC topical formulations were 
produced and investigated. Four different hydrogel types were prepared using an optimal 
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stabilizer combination of water, gel forming polymer (XG, HEC, PA and CH) and glycerol as 
hydrating agent, and finally adding the SLN and NLC aqueous dispersion into freshly prepared 
hydrogels. Table XXI and XXII resume the final composition of developed SLN and NLC-
containing hydrogels formulations, respectively. 
Table XXI: Composition of the investigated SLN-containing hydrogels formulations. 
Formulation 
code 
Dynasan®\\6 
% (m/m) 
Tyloxapof 
% (m/m) 
MiglyofUl 
% (m/m) 
Clotrimazole 
% (m/m) 
Gel-forming agent 
% (m/m) 
Glycerol 
% (m/m) 
Water 
ad 
% (m/m) 
D10%-XG 5% 1.5% - - 1% Xanthan gum 5% 100% 
D10%-HEC 5% 1.5% - - 1.75% HEC 4000 5% 100% 
D10%-PA 5% 1.5% - - 0.5% CarbopoP934 5% 100% 
D10%-CH 5% 1.5% - - l%Chitosan 5% 100% 
D10%C-XG 4.75% 1.5% - 0.25% 1% Xanthan gum 5% 100% 
D10%C-HEC 4.75% 1.5% - 0.25% 1.75% HEC 4000 5% 100% 
D10%C-PA 4.75% 1.5% - 0.25% 0.5% Carbopof93<\ 5% 100% 
D10%C-CH 4.75% 1.5% - 0.25% 1% Chitosan 5% 100% 
D20%-XG 10% 2.5% - - 1% Xanthan gum 5% 100% 
D20%-HEC 10% 2.5% - - 1.75% HEC 4000 5% 100% 
D20%-PA 10% 2.5% - - 0.5% Carhopof934 5% 100% 
D20%-CH 10% 2.5% - - 1% Chitosan 5% 100% 
D20%C-XG 9.5% 2.5% - 0.5% 1% Xanlhan gum 5% 100% 
D20%C-HEC 9.5% 2.5% - 0.5% 1.75% HEC 4000 5% 100% 
D20%C-PA 9.5% 2.5% - 0.5% 0.5% Carbopo^m 5% 100% 
D20%C-CH 9.5% 2.5% - 0.5% 1% Chitosan 5% 100% 
Table XXII: Composition of the investigated NLC-containing hydrogels formulations. 
Formulation 
code 
Dvnasan"\\k 
%(m/m) 
Tyloxapof 
% (m/m) 
Miglyof%\l 
% (m/m) 
Clotrimazole 
% (m/m) 
Gel-forming agent 
% (m/m) 
1% Xanthan gum 
Glycerol 
% (m/m) 
5% 
Water 
ad 
% (m/m) 
DM20%-XG 7% 2.5% 3% - 100% 
DM20%-HEC 7% 2.5% 3% - 1.75% HEC 4000 5% 100% 
DM20%-PA 7% 2.5% 3% - 0.5% Carbapot
K934 5% 100% 
DM20%-CH 7% 2.5% 3% - 1% Chitosan 5% 100% 
DM20%C-XG 6.75% 2.5% 2.75% 0.5% 1% Xanthan gum 5% 100% 
DM20%C-HEC 6.75% 2.5% 2.75% 0.5% 1.75% HEC 4000 5% 100% 
DM20%C-PA 6.75% 2.5% 2.75% 0.5% 0.5% Carbopof 934 5% 100% 
DM2()%C-CH 6.75% 2.5% 2.75% 0 3 % 1% Chitosan 5% 100% 
CTotrimazole-containing SLN and NLC hydrogels having a drug content of 5% (m/m) with 
regard to the lipid matrix could be prepared. In order to investigate the physicochemical stability 
of the lipid particles into hydrogels the mean particle size, the Ç and the state of crystallinity were 
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characterized and evaluated during a period of 3 months. Results will be presented in the 
following sections. 
5.6. Characterization of developed hydrogel formulations 
In order to physically characterize the developed SLN and NLC-containing hydrogel 
formulations particle size measurements, Ç and DSC studies were performed. 
5.6.1. Particle size of SLN and NLC 
For particle size measurement of SLN and NLC into hydrogels, aqueous dispersions were 
previously diluted with double-distilled water to weak opalescence and then the PCS diameter 
and Pi and the LD diameter (d99%) were determined. 
Table XXIII and XXIV show the PCS diameter, PI and LD (d99%) diameter of SLN and 
NLC-containing hydrogel formulations, respectively, one day after hydrogel preparation. 
Table XXIII: PCS diameter, PI and LD (d99%) diameter of SLN-containing hydrogel formulations on day 
1 of storage at 20°C. 
Formulation PCS diameter 
(nm) 
PI LD (d99%) diameter 
(um) 
D10%-XG 191.000 ±3.819 0.355 ±0.015 0.504 ±0.005 
D10%-HEC 179.391 ±0.666 0.246 ± 0.027 0.581 ±0.002 
D10%-PA 177.400 ±3.955 0.217 ±0.030 0.315 ±0.003 
D10%-CH 288.790 ±7.262 0.427 ±0.011 0.475 ± 0.006 
D10%C-XG 182.788 ±2.571 0.419 ±0.009 0.610 ±0.004 
D10%C-HEC 169.098 ± 1.102 0.263 ±0.031 0.510 ±0.008 
D10%C-PA 181.297 ±1.677 0.186 ±0.035 0.344 ± 0.058 
D10%C-CH 230.500 ±1.514 0.365 ± 0.024 0.458 ± 0.007 
D20%-XG 239.600 ±3.233 0.294 ±0.020 0.574 ±0.002 
D20%-HEC 227.897 ±6.782 0.239 ±0.016 0.577 ±0.001 
D20%-PA 230.291 ±0.300 0.240 ±0.045 0.554 ±0.028 
D20%-CH 330.490 ±11.310 0.416 ±0.023 0.686 ±0.058 
D20%C-XG 201.100 ±8,778 0.421 ±0.035 1.937 ±0.107 
D20%C-HEC 171.400 ±2.157 0.247 ± 0.044 0.554 ±0.004 
D20%C-PA 173.380 ± 1.789 0.235 ±0.011 0.568 ±0.006 
D20%C-CH 257.890 ±5.381 0.467 ±0.017 0.568 ±0.005 
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Table XXIV: PCS diameter, PI and LD (d99%) diameter of NLC-containing hydrogel formulations on day 
1 of storage at 20°C. 
Formulation PCS diameter 
(nm) 
PI LD (d99%) diameter 
(um) 
DM20%-XG 192.100 ±1.026 0.385 ±0.031 0.703 ± 0.006 
DM20%-HEC 185.769 ±2.329 0.274 ±0.038 0.643 ± 0.001 
DM20%-PA 175.290 ±0.611 0.191 ±0.019 0.632 ±0.007 
DM20%-CH 207.900 ± 4.530 0.376 ±0.011 0.607 ± 0.004 
DM20%C-XG 169.311 ±2.344 0.304 ± 0.004 0.731 ±0.006 
DM20%C-HEC 172.890 ±2.524 0.264 ± 0.023 0.763 ± 0.002 
DM20%C-PA 167.198 ±1.411 0.237 ±0.033 0.710 ±0.004 
DM20%C-CH 220.703 ± 2.386 0.303 ± 0.009 0.721 ±0.002 
One day after preparation, both drug-free and drug-loaded SLN and NLC-containing 
hydrogel formulations showed a narrow particle size distribution measured by LD analysis 
(d99%), which was completely in the nanometer range (Table XXTTI and XXIV). 
The presence of clotrimazole was not responsible for an increase in the mean particle size 
measured by PCS. For all tested formulations the mean particle size was lower than 300 nm. XG 
and CH hydrogels were responsible for a higher PI in comparison to HEC and PA hydrogels. 
Sample D20%C-XG revealed a d99% higher than 1 um, probably due to a poor effective 
dilution of XG hydrogel with double-distilled water. 
5.6.2. Zeta potential of SLN and NLC 
Determination of Ç was carried out in SLN and NLC-containing hydrogel formulations stored 
at room temperature. Tables XXV and XXVI show the Ç values of SLN and NLC formulations, 
respectively, one day after hydrogel preparation. 
SLN and NLC were negatively charged when incorporated into XG, HEC and PA hydrogels. 
The same was not observed after incorporation into CH hydrogels. 
On day 1 of storage at room temperature, clotrimazole-containing formulations, either SLN 
or NLC, showed a lower Ç than drug-free formulations. 
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Table XXV: Zeta potential of SLN-
containing hydrogel formulations on day 1 
of storage at 20°C. 
Formulation C 
D10%-XG -50.402 ± 1.082 
D10%-HEC -22.414 ±0.153 
D10%-PA -21.290 ±0.058 
D10%-CH 45.881 ±0.100 
D10%C-XG -40.900 ±2.835 
D10%C-HEC -9.600 ±0.231 
D10%C-PA -12.301 ±0.346 
D10%C-CH 41.498 ±0.577 
D20%-XG -30.000 ±1.054 
D20%-HEC -14.399 ±0.252 
D20%-PA -15.004 ±0.058 
D20%-CH 39.500 ±0.451 
D20%C-XG -39.323 ±2.203 
D20%C-HEC -18.711 ±0.289 
D20%C-PA -19.701 ±1.100 
D20%C-CH 28.214 ±1.026 
Tabic XXVI: Zeta potential of NLC-
containing hydrogel formulations on day 1 
ofstorageat20°C. 
Formulation ç 
DM20%-XG -17.500 ±0.404 
DM20%-HEC -10.732 ±0.361 
DM20%-PA -12.222 ± 0.603 
DM20%-CH 36.901 ±0.321 
DM20%C-XG -40.600 ± 2.800 
DM20%C-HEC -11.532 ±0.208 
DM20%C-PA -19.818 ±0.200 
DM20%C-CH 35.500 ±0.550 
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5.6.3. DSC studies 
In order to assess interactions between lipid nanoparticles and the gel forming polymer, as 
well as investigate the solid state of SLN and NLC particles, DSC measurements were carried 
out. The samples (pure SLN and NLC aqueous dispersions and SLN and NLC-containing 
hydrogels) were heated from 25°C to 85°C and the respective melting enthalpies were recorded. 
The components used for the preparation of the hydrogels do not melt at this temperature 
range (25°C-85°C). Therefore, it is possible to determine the crystallinity of SLN and NLC after 
their incorporation into the different developed semi-solid systems by DSC measurements. The 
melting peaks of pure SLN and NLC aqueous dispersions and of SLN and NLC incorporated 
into hydrogels were obtained on day 1 after production. 
Figures 5.60 and 5.61 show the DSC curves of clotn'mazole-free and clotrimazole-loaded 
SLN containing 10% of lipid matrix, respectively, as pure aqueous dispersion and when 
incorporated into four different hydrogels recorded after 1 day of storage at room temperature. 
The melting point recorded for SLN containing 10% of lipid matrix (D10% and D10%C) as 
pure aqueous dispersion did not change significantly after incorporation into the four different 
hydrogels. It could be detected an increase from 60°C to 61°C when D10% was incorporated into 
HEC hydrogels. 
D10% 
D10%-XG 
D10%-HEC 
D10%-PA 
D10%-CH 
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Temperature (°C) 
Figure 5.60: DSC curves of clotrimazole-free SLN formulation D10% as pure aqueous 
dispersion and when incorporated into four different hydrogels recorded after 1 day of 
storage at 20°C. 
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Figure 5.61: DSC curves of clotrimazole-loaded SLN formulation D10%C as pure 
aqueous dispersion and when incorporated into four different hydrogels recorded after 1 
day of storage at 20°C. 
Figures 5.62 and 5.63 show the DSC curves of clotrimazole-free and clotrimazole-loaded 
SLN containing 20% of lipid matrix, respectively, as pure aqueous dispersion and when 
incorporated into four different hydrogels recorded after 1 day of storage at room temperature. 
It could also be observed that the melting point recorded for SLN containing 20% of lipid 
matrix (D20% and D20%C) as pure aqueous dispersion did not change after incorporation into 
four different hydrogels. In fact, the presence of clotrimazole did not change thermal behaviour 
of the formulations when incorporated into hydrogels. 
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Figure 5.62: DSC curves of clotrimazole-free SLN formulation D20% as pure aqueous 
dispersion and when incorporated into four different hydrogels recorded after I day of 
storage at 20°C. 
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Figure 5.63: DSC-curves of clotrimazole-loaded SLN formulation D20%C as pure 
aqueous dispersion and when incorporated into four different hydrogels recorded after 1 
day of storage at 20°C. 
Figures 5.64 and 5.65 show the DSC curves of clotrimazole-free and clotrimazole-loaded 
NLC containing 20% of lipid matrix, respectively, as pure aqueous dispersion and when 
incorporated into four different hydrogels recorded after 1 day of storage at room temperature. 
The melting point recorded for NLC containing 20% of lipid matrix as pure drug-free 
aqueous dispersion (DM20%) increased from 59°C to 60°C after incorporation into four different 
hydrogels. When the clotrimazole-loaded NLC formulation (DM20%C) was incorporated into 
HEC, PA and CH hydrogels an increase from 58°C to 60°C was observed. Nevertheless, the 
same was not observed when DM20%C formulation was incorporated into XG hydrogels. In 
fact, the melting point of this later formulation remained approximately at 58°C. 
Temperature (°C) 
-DM20% 
-DM20%-XG 
DM20%-HKC 
DM20%-PA 
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Figure 5.64: DSC curves of clotrimazole-free NLC formulation DM20% as pure aqueous 
dispersion and when incorporated into four different hydrogels recorded after 1 day of 
storage at 20°C. 
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Figure 5.65: DSC curves of clotrimazole-loaded NLC formulation DM20%C as pure 
aqueous dispersion and when incorporated into four different hydrogels recorded after 1 
day of storage at 20°C. 
For both clotrimazole-free and clotrimazole-loaded SLN and NLC aqueous dispersions, lipid 
content of the hydrogel is always preserved. As figures show, the DSC curves of incorporated 
SLN and NLC aqueous dispersions into hydrogels revealed identical peaks compared to pure 
aqueous dispersions. This indicates that SLN and NLC particles remained chemically stable 
when incorporated and did not interfere with the gel forming polymer when stored at room 
temperature. 
The decreased area under the curve observed for SLN and NLC-containing hydrogels is due 
to the lower solid lipid content of these samples in comparison to pure aqueous solid lipid 
dispersions. However, the melting enthalpy standardized on 1 g lipid remains constant. 
To sum up, for all studied samples, either clotrimazole-free or clotrimazole-loaded, it could 
be observed that crystallinity of the solid matrix did not change significantly upon their 
incorporation into the four different hydrogels. Tables XXVII and XXVIII show the DSC results 
of clotrimazole-free and clotrimazole-loaded SLN and NLC aqueous dispersions, respectively, 
after 1 day of storage at 20°C. 
Table XXVTI: DSC results of clotrimazole-free SLN and NLC aqueous dispersions 
before and after incorporation into different four hydrogels recorded after 1 day of 
storage at 20°C. 
Formulation Melting point 
(°C) 
Onset 
CO 
Integral 
(mJ) 
Enthalpy 
ÍJ/R) 
RI 
(%) 
D10% 59.33 55.12 479.25 13.51 69.8 
D10%-XG 59.01 56.15 772.22 8.38 43.3 
D10%-HEC 60.18 56.12 724.66 8.93 46.2 
D10%-PA 59.33 55.11 764.92 8.46 43.7 
D10%-CH 59.27 55.16 775.00 8.35 43.2 
D20% 59.46 55.53 330.87 33.67 87.0 
D20%-XG 59.59 55.71 425.18 15.22 78.7 
D20%-HEC 59.58 55.63 424.07 15.26 78.9 
D20%-PA 59.52 55.68 423.23 15.29 79.0 
D20%-CH 59.63 55.44 426.02" 15.19 78.5 
DM20% 58.04 54.22 623.07 17.88 46.2 
DM20%-XG 59.14 55.74 521.45 12.41 64.2 
DM20%-HEC 59.08 55.59 522.72 12.38 64.0 
DM20%-PA 58.93 55.29 522.30 12.39 64.1 
DM20%-CH 59.12 55.97 526.54 12.29 63.5 
Table XXVIII: DSC results of clotrimazole-loaded SLN and NLC aqueous dispersions 
before and after incorporation into different four hydrogels recorded after 1 day of 
storage at 20°C. 
Formulation Melting point 
(°C) 
Onset 
(°C) 
Integral 
(mJ) 
Enthalpy 
(J/8) 
RI 
(%) 
D10%C 58.95 54.65 411.36 15.86 81.2 
D10%C-XG 59.08 56.22 737.88 8.77 45.3 
D10%C-HEC 59.21 55.43 744.68 8.69 44.9 
D10%C-PA 59.17 55.72 748.99 8.64 44.7 
D10%C-CH 59.27 55.31 737.04 8.78 45.4 
D20%C 59.07 54.97 339.08 32.85 84.9 
D20%C-XG 59.14 55.07 424.07 15.26 78.9 
D20%C-HEC 59.01 56.11 425.46 15.21 78.6 
D20%C-PA 59.21 55,46 423.23 15.29 79.0 
D20%C-CH 59.25 55.14 424.62 15.24 78.8 
DM20%C 58.12 54.57 705.54 15.79 40.8 
DM20%C-XG 58.81 55.42 563.21 11.49 59.4 
DM20%C-HEC 58.87 55.17 566.16 11.43 59.1 
DM20%C-PA 58.80 55.59 564.68 11.46 59.2 
DM20%C-CH 58.76 55.18 568.15 11.39 58.9 
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5.7. Stability of developed hydrogel formulations 
The stability of developed SLN and NLC-containing hydrogel formulations was evaluated 
concerning to particle size, Ç and crystalline status of lipid nanoparticles. 
5.7.1. Particle size 
For the analysis of physical stability of SLN and NLC incorporated into the hydrogels (e.g. 
nanoparticle aggregation), particle size has been evaluated. Aqueous dispersions were previously 
diluted with double-distilled water to weak opalescence and then LD diameter (d50%, d95% and 
d99%), PCS diameter and PI were determined. 
5.7.1.1. SLN-containing hydrogel formulations 
Figures 5.66 and 5.67 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded SLN containing 10% of lipid matrix incorporated into 
XG hydrogels, which were stored at room temperature during 3 months. 
Figure 5.66: Particle size of clotrimazole-free and clotrimazole-loaded SLN formulations 
D10% and D10%C incorporated into XG hydrogels measured by LD (d50%, d95% and 
d99%), after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
150 Chapter V 
I PCS ■ ■ P I 
Day 1 Day 30 Day 60 
Days of storage 
Day 90 
Figure 5.67: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded SLN formulations D10% and D10%C incorporated into XG 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Incorporation of D10% and D10%C into XG hydrogels did not result in aggregation of SLN. 
Upon incorporation of clotrimazole-free and clotrimazole-loaded SLN containing 10% of lipid 
matrix into XG hydrogels, 99% of volume distribution remained lower than 0.7 urn. For all 
formulations, 50% of volume distribution was lower than 100 mn. PCS analysis shows a mean 
particle size lower than 190 mn and a PI between 0.3 and 0.4 during 90 days of storage at room 
temperature. 
Figures 5.68 and 5.69 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded SLN containing 10% of lipid matrix incorporated into 
HEC hydrogels, which were stored at room temperature during 3 months. 
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Figure 5.68: Particle size of clotrimazole-free and clotrimazole-loaded SLN formulations 
D10% and D10%C incorporated into HEC hydrogels measured by LD (d50%, d95% and 
d99%), after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
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Figure 5.69: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded SLN formulations D10% and D10%C incorporated into HEC 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Incorporation of D10% and D10%C into HEC hydrogels did not result in aggregation of 
SLN. Upon incorporation of clotrimazole-free and clotrimazole-loaded SLN containing 10% of 
lipid matrix into HEC hydrogels, 99% of volume distribution remained lower than 0.6 um. The 
presence of clotrimazole did not change significantly the particle size distribution. PCS data 
revealed a mean particle size of approximately 180 nm for clotrimazole-free SLN, while for 
clotrimazole-loaded SLN the mean particle size was 170 nm during 90 days of storage at room 
temperature. PI remained lower than 0.3 for both formulations. 
Figures 5.68 and 5.65 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded SLN containing 10% of lipid matrix incorporated into 
PA hydrogels, which were stored at room temperature during 3 months. 
152 Chapter V 
Figure 5.70: Particle size of clotrimazole-free and clotrimazole-loaded SLN formulations 
D10% and D10%C incorporated into PA hydrogels measured by LD (d50%, d95% and 
d99%), after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Figure 5.71: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded SLN formulations D10% and D10%C incorporated into PA 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Incorporation of D10% and D10%C into PA hydrogels did not result in aggregation of SLN. 
Upon incorporation of clotrimazole-free and clotrimazole-loaded SLN containing 10% of lipid 
matrix into PA hydrogels, 99% of volume distribution remained lower than 0.4 um. It could not 
be observed any significant difference between clotrimazole-free and clotrimazole-loaded 
samples during 90 days of storage at room temperature. The mean particle size measured by PCS 
was lower 180 nm and the PI remained approximately 0.25. 
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Figures 5.66 and 5.67 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded SLN containing 10% of lipid matrix incorporated into 
CH hydrogels, which were stored at room temperature during 3 months. 
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Figure 5.72: Particle size of clotrimazole-free and clotrimazole-loaded SLN formulations 
D10% and D10%C incorporated into CH hydrogels measured by LD (d50%, d95% and 
d99%), after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
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Figure 5.73: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded SLN formulations D10% and D10%C incorporated into CH 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
The incorporation of D10% and D10%C into CH hydrogels increased the mean particle size 
of SLN in comparison to XG, HEC and PA hydrogels. From LD data, 99% of volume 
distribution remained below 0.5 um, which is lower than the obtained after incorporation of these 
particles into XG. However, by PCS analysis a growth of particle size could be observed. The 
154 Chapter V 
mean particle size oscillated between 200 and 350 nm during 90 days of storage at room 
temperature and the PI remained between 0.4 and 0.5 during the same period of time. 
Figures 5.74 and 5.75 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded SLN containing 20% of lipid matrix incorporated into 
XG hydrogels, which were stored at room temperature during 3 months. 
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Figure 5.74: Particle size of clotrimazole-free and clotrimazole-loaded SLN formulations 
D20% and D20%C incorporated into XG hydrogels measured by LD (d50%, d95% and 
d99%), after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
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Figure 5.75: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded SLN formulations D20% and D20%C incorporated into XG 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Analysis of clotrimazole-free and clotrimazole-loaded SLN containing 20% of lipid matrix 
incorporated into XG hydrogels revealed peaks in the micrometer range. It could be observed that 
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99% of volume distribution remained lower than 2 um. For all formulations 50% of volume 
distribution was lower than 500 nm. PCS analysis showed a mean particle size between 200 and 
250 nm and a PI between 0.3 and 0.4 during 90 days of storage at room temperature. 
Figures 5.76 and 5.77 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded SLN containing 20% of lipid matrix incorporated into 
HEC hydrogels, which were stored at room temperature during 3 months. 
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Figure 5.76: Particle size of clotrimazole-free and clotrimazole-loaded SLN formulations 
D20% and D20%C incorporated into HEC hydrogels measured by LD (d50%, d95% and 
d99%), after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Figure 5.77: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded SLN formulations D20% and D20%C incorporated into HEC 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
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Upon incorporation of clotrimazole-free and clotrimazole-loaded SLN containing 20% of 
lipid matrix into HEC hydrogels, LD analysis did not exhibited peaks in the micrometer range. Tn 
fact, 99% of volume distribution was below 0.6 urn as obtained for samples with 10% of lipid 
matrix. The presence of clotrimazole did not change the particle size distribution. PCS data 
revealed a mean particle size of approximately 200 nm for SLN without drug and a PI of 0.35, 
while for drug-loaded SLN the mean particle size was 170 nm and the PI oscillated between 0.25 
and 0.3 during 90 days of storage at room temperature. 
Figures 5.78 and 5.79 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded SLN containing 20% of lipid matrix incorporated into 
PA hydrogels, which were stored at room temperature during 3 months. 
Figure 5.78: Particle size of clotrimazole-free and clotrimazole-loaded SLN formulations 
D20% and D20%C incorporated into PA hydrogels measured by LD (d50%, d95% and 
d99%), after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Figure 5.79: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded SLN formulations D20% and D20%C incorporated into PA 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
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Upon incorporation of clotrimazole-free and clotrimazole-loaded SLN containing 20% of 
lipid matrix into PA hydrogels, 99% of volume distribution remained lower than 0.6 urn. it could 
not be observed any significantly difference between samples without drug and clotrimazole-
loaded during 90 days of storage at room temperature. The mean particle size measured by PCS 
remained approximately 230 nm for samples without drug, while it remained lower than 170 nm 
for samples with clotrimazole. PI oscillated between 0.2 and 0.25 for both formulations. 
Figures 5.80 and 5.81 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded SLN containing 20% of lipid matrix incorporated into 
CH hydrogels, which were stored at room temperature during 3 months. 
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Figure 5.80: Particle size of clotrimazole-free and clotrimazole-loaded SLN formulations 
D20% and D20%C incorporated into CH hydrogels measured by LD (d50%, d95% and 
d99%), after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Figure 5.81: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded SLN formulations D20% and D20%C incorporated into CH 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
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The incorporation of D20% and D20%C into CH hydrogels increased the mean particle size 
of SLN in comparison to XG, HEC and PA hydrogels, as reported for SLN containing 10% of 
lipid matrix. From LD data, 99% of volume distribution remained below 0.7 um, which is lower 
than the obtained after incorporation of these particles into XG. However, after PCS analysis it 
could be observed a growth in particle size. PCS data revealed a mean particle size of 
approximately 400 nm for SLN without drug and a PI higher than 0.5, while for SLN with 
clotrimazole the mean particle size was 250 nm and the PI was approximately 0.3 during 90 days 
of storage at room temperature during 3 months. 
5.7.1.2. NLC-containing hydrogel formulations 
Figures 5.82 and 5.83 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded NLC containing 20% of lipid matrix incorporated into 
XG hydrogels, which were stored at room temperature during 3 months. 
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Figure 5.82: Particle size of clotrimazole-free and clotrimazole-loaded NLC 
formulations DM20% and DM20%C incorporated into XG hydrogels measured by LD 
(d50%, d95% and d99%), after 1, 30, 60 and 90 days of storage at room temperature 
(20°C). 
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Figure 5.83: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded NLC formulations DM20% and DM20%C incorporated into XG 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Upon incorporation of clotrimazole-free and clotrimazole-loaded NLC containing 20% of 
lipid matrix into XG hydrogels, analysis by LD did not reveal peaks in the micrometer range, it 
could be observed that 99% of volume distribution remained lower than 0.7 um and for all 
formulations 50% of volume distribution was lower than 200 nm. PCS analysis shows a mean 
particle size around 200 nm and a PI between 0.25 and 0.4 during 90 days of storage at room 
temperature. 
Figures 5.84 and 5.85 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded NLC containing 20% of lipid matrix incorporated into 
HEC hydrogels, which were stored at room temperature during 3 months. 
Figure 5.84: Particle size of clotrimazole-free and clotrimazole-loaded NLC 
formulations DM20% and DM20%C incorporated into HEC hydrogels measured by LD 
(d50%, d95% and d99%) after 1, 30, 60 and 90 days of storage at room temperature 
(20°C). 
160 Chapter V 
Figure 5.85: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded NLC formulations DM20% and DM20%C incorporated into HEC 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Upon incorporation of clotrimazole-free and clotrimazole-loaded NLC containing 20% of 
lipid matrix into HEC hydrogels, analysis by LD did not reveal peaks in the micrometer range. In 
fact, 99% of volume distribution was below 0.8 urn. The presence of clotrimazole did not change 
the particle size distribution. PCS data revealed a mean particle size of approximately 170 nm 
and a PI of 0.25 for both drug-free and drug-loaded formulations, during 90 days of storage at 
room temperature. 
Figures 5.86 and 5.87 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded NLC containing 20% of lipid matrix incorporated into 
PA hydrogels, which were stored at room temperature during 3 months. 
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Figure 5.86: Particle size of clotrimazole-free and clotrimazole-loaded NLC 
formulations DM20% and DM20%C incorporated into PA hydrogels measured by LD 
(d50%, d95% and d99%), after 1, 30, 60 and 90 days of storage at room temperature 
(20°C). 
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Figure 5.87: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded NLC formulations DM20% and DM20%C incorporated into PA 
hydrogels, after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
Upon incorporation of clotrimazole-free and clotrimazole-loaded NLC containing 20% of 
lipid matrix into PA hydrogels, 99% of volume distribution remained lower than 0.7 urn. It could 
not be observed any significant difference between clotrimazole-free and clotrimazole-loaded 
samples during 90 days of storage at room temperature. The mean particle size measured by PCS 
remained below 175 nm and PI was approximately 0.25 for both formulations. 
Figures 5.88 and 5.89 show the results after LD and PCS analysis, respectively, of 
clotrimazole-free and clotrimazole-loaded NLC containing 20% of lipid matrix incorporated into 
CH hydrogels, which were stored at room temperature during 3 months. 
Figure 5.88: Particle size of clotrimazole-free and clotrimazole-loaded NLC 
formulations DM20% and DM20%C incorporated into CH hydrogels measured by LD 
(d50%, d95% and d99%), after 1, 30, 60 and 90 days of storage at room temperature 
(20°C). 
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Figure 5.89: Mean particle size measured by PCS and PI of clotrimazole-free and 
clotrimazole-loaded NLC formulations DM20% and DM20%C incorporated into CH 
hydrogels after 1, 30, 60 and 90 days of storage at room temperature (20°C). 
The incorporation of clotrimazole-free and clotrimazole-loaded NLC containing 20% of lipid 
matrix into CH hydrogels increased the mean particle size of NLC, in comparison to XG, HEC 
and PA hydrogels, as reported for SLN containing 10% and 20% of lipid matrix. From LD data, 
99% of volume distribution remained approximately 0.7 um, which is the same as the obtained 
after incorporation of these particles into XG However, after PCS analysis a growth of particle 
size could be observed. PCS data revealed a mean particle size of between 200 and 300 nm and a 
PI between 0.3 and 0.5 for both drug-free and drug-loaded formulations during 90 days of 
storage at room temperature during 3 months. 
Analysis of the different hydrogels developed in this study revealed no peak in the 
micrometer range, except for SLN formulations D20% and D20%C containing XG, probably 
caused by insoluble residues of this polysaccharide. 
The lowest particle size obtained after incorporation of SLN and NLC into four different 
hydrogels was observed for SLN with the lowest lipid content (D10% and D10%C) when 
incorporated into PA hydrogels. 
PA hydrogels were also responsible for the lowest PI value obtained for all tested 
formulations, while CH hydrogels showed the highest PI, especially for SLN samples containing 
10% of lipid matrix. 
CH was also responsible for the highest mean particle size for all tested SLN and NLC 
formulations. This result is probably due to the use of a solution of 4% im/V) acetic acid in order 
to start gel formation of CH. The use of acetic acid might affect the Ç at the surface of SLN and 
NLC being responsible for particle aggregation. 
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5.7.2. Zeta potential of SLN and NLC 
Figure 5.90 shows the Ç of clotrimazole-free and clotrimazole-loaded SLN formulations 
containing 10% of lipid matrix incorporated into XG, HEC, PA and CH hydrogels, measured on 
day 1 and day 90 after production and stored at room temperature. 
Lipid nanoparticles remained negatively charged upon incorporation into XG, HEC and PA 
hydrogels. The same could not be observed when lipid nanoparticles were incorporated into CH 
hydrogels. In fact, the Ç of these later particles arose from -37 mV to 45.9 mV for samples 
without drug and from -11.3 mV to 41.5 mV for drug-loaded SLN formulations, one day after 
preparation. 
The incorporation of D10% and D10%C SLN formulations into XG hydrogels revealed the 
highest Ç, either on day 1 or on day 90 of storage at room temperature. Incorporation of these 
particles into HEC and PA hydrogels showed similar Ç values. 
In comparison to clotrimazole-free SLN containing 10% of lipid matrix, a decrease of Ç value 
could be observed for clotrimazole-loaded SLN formulations upon incorporation into four 
different hydrogels, both on day 1 and day 90 of storage at room temperature. 
Figure 5.90: Zeta potential of clotrimazole-free and clotrimazole-loaded SLN containing 10% of 
lipid matrix when incorporated into four different hydrogels, measured on day 1 and day 90 after 
production and stored at room temperature (20°C). 
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Figure 5.91 shows the Ç of clotrimazole-free and clotrimazole-loaded SLN formulations 
containing 20% of lipid matrix incorporated into XG, HEC, PA and CH hydrogels, measured on 
day 1 and day 90 after production and stored at room temperature. 
The incorporation of D20% and D20%C SLN formulations into XG, HEC and PA hydrogels 
also revealed negatively charged, while when incorporated into CH hydrogels the Ç value was 
positive. The Ç of these later arose from -37 mV to 39.5 mV for drug-free particles and from 
-11.3 mV to 28.2 mV for drug-loaded SLN formulations, one day after preparation. 
Figure 5.85: Zeta potential of clotrimazole-free and clotrimazole-loaded SLN containing 20% of 
lipid matrix when incorporated into four different hydrogels, measured on day 1 and day 90 after 
production and stored at room temperature (20°C). 
Figure 5.92 shows the Ç of clotrimazole-free and clotrimazole-loaded NLC formulations 
containing 20% of lipid matrix incorporated into XG, HEC, PA and CH hydrogels, measured on 
day 1 and day 90 after production and stored at room temperature. 
As it could be expected, the incorporation of DM20% and DM20%C into XG, HEC and PA 
hydrogels also revealed particles negatively charged, while when incorporated into CH hydrogels 
the Ç value was positive. The Ç of these later arose from -37 mV to 36.8 mV for drug-free 
particles and from -11.3 mV to 32.5 mV for drug-loaded SLN formulations one day after 
preparation. 
In comparison to SLN formulations with the same lipid content, all NLC formulations 
revealed lower Ç values on day 1 and 90 of storage at room temperature, except the D20%C 
when incorporated into XG hydrogels. 
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Figure 5.92: Zeta potential of clotrimazole-free and clotrimazole-loaded NLC containing 20% of 
lipid matrix when incorporated into four different hydrogels, measured on day 1 and day 90 after 
production and stored at room temperature (20°C). 
As expected, for all tested formulations a decrease of Ç during the 90 days of storage could be 
observed. CH hydrogels were responsible for particles having a positive Ç value. These results 
are probably due to the cationic character of this bioadhesive polymer. Its positively charged 
amine groups are capable of neutralizing the negative charge at the surface of the particles 
changing their Ç As a consequence of the positive value of Ç, aggregation is facilitated, as it 
could be observed after particle size analysis. In addition, one needs to use acetic acid in order to 
start gel formation of CH, which can also be a reason for the observed Ç. 
In order to exhibit gel-forming properties, the carboxylic groups of PA have to be neutralized 
with NaOH. This neutralizing agent could enhance aggregation due to the action of sodium ions, 
which can reduce the Ç of the particles [322]. As a consequence of this lower Ç value, 
aggregation is facilitated. This phenomenon is well known for lipid nanoemulsions [97], as well 
as for SLN when incorporated into PA hydrogels [311]. However, the tested lipid nanoparticles 
made from Dynasan®! 16 and Tyloxapof* revealed no sensitivity to exposure of sodium ions. 
In general terms, SLN and NLC aqueous dispersions can be incorporated into hydrogels 
consisting of more or less uncharged polymers without significant changes in the particle size 
characteristics and Ç values [107], which has been observed after incorporation of SLN and NLC 
aqueous dispersions into XG, HEC and PA. In the case of gel forming polymers with very polar 
groups, like CH, possible interactions between negative surface charge of lipid nanoparticles and 
polar groups of this polymer must be taken into account. 
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5.73. DSC studies 
DSC studies during storage were performed in clotrimazole-containing samples, in order to 
evaluate the chemical stability of clotrimazole-loaded SLN and NLC into different hydrogels as 
a function of time. 
Figure 5.93 shows the DSC curves of D10%C incorporated into XG hydrogel, obtained after 
1 and 90 days of storage at room temperature. 
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Figure 5.93: DSC curves of D10%C SLN formulation incorporated into XG hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.94 shows the DSC curves of D10%C incorporated into HEC hydrogel, obtained 
after 1 and 90 days of storage at room temperature. 
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Figure 5.94: DSC curves of D10%C SLN formulation incorporated into HEC hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
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Figure 5.95 shows the DSC curves of D10%C incorporated into PA hydrogel, obtained after 
1 and 90 days of storage at room temperature. 
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Figure 5.95: DSC curves of D10%C SLN formulation incorporated into PA hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.96 shows the DSC curves of D10%C incorporated into CH hydrogel, obtained after 
1 and 90 days of storage at room temperature. 
-Day 1 Day 90 
0.6 
0,5 -i 
-SP 0,4 
0,3 -*— 
•a 
t 0,2 
w 
0,1 
' í{WMiliinlWíM^iWUlnmiíUtiU)MMEini!iiuiifliilliMiM)iiil!il!tiinlll!ii 
*n ao »— •*& r- o *tf 
<N cs r-i m r^i -s- ^r 
tSÍ!Ml!!l!ÍHItnMr 
O fl \Q 0\ m MD tri in u"i in vo vo \0 
Temperature (W/g) 
Figure 5.96: DSC curves of D10%C SLN formulation incorporated into CH hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.97 shows the DSC curves of D20%C incorporated into XG hydrogel, obtained after 
1 and 90 days of storage at room temperature. 
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Figure 5.97: DSC curves of D20%C SLN formulation incorporated into XG hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.98 shows the DSC curves of D20%C incorporated into HEC hydrogel, obtained 
after 1 and 90 days of storage at room temperature. 
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Figure 5.98: DSC curves of D20%C SLN formulation incorporated into HEC hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.99 shows the DSC curves of D20%C incorporated into PA hydrogel, obtained after 
1 and 90 days of storage at room temperature. 
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Figure 5.99: DSC curves of D20%C SLN formulation incorporated into PA hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.100 shows the DSC curves of D20%C incorporated into CH hydrogel, obtained 
after 1 and 90 days of storage at room temperature. 
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Figure 5.100: DSC curves of D20%C SLN formulation incorporated into CH hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.101 shows the DSC curves of DM20%C incorporated into XG hydrogel, obtained 
after 1 and 90 days of storage at room temperature. 
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Figure 5.101: DSC curves of DM20%C NLC formulation incorporated into XG hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.102 shows the DSC curves of DM20%C incorporated into HEC hydrogel, obtained 
after 1 and 90 days of storage at room temperature. 
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Figure 5.102: DSC curves of DM20%C NLC formulation incorporated into HEC 
hydrogel after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.103 shows the DSC curves of DM20%C incorporated into PA hydrogel, obtained 
after 1 and 90 days of storage at room temperature. 
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Figure 5.103: DSC curves of DM20%C NLC formulation incorporated into PA hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
Figure 5.104 shows the DSC curves of DM20%C incorporated into CH hydrogel, obtained 
after 1 and 90 days of storage at room temperature. 
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Figure 5.104: DSC curves of DM20%C NLC formulation incorporated into CH hydrogel 
after 1 and 90 days of storage at room temperature (20°C). 
For all clotrimazole-loaded SLN and NLC formulations incorporated into different hydrogels 
it could be observed that during storage time the crystallinity of lipid matrix was practically 
constant. The melting enthalpy remained almost the same during 90 days of storage at room 
temperature, showing a melting event at 60°C. 
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To summarise, for all clotrimazole-loaded SLN and NLC containing hydrogels could be 
observed that crystallinity of the solid matrix remained practically constant during 90 days of 
storage at room temperature. Table XXTX shows the DSC results of clotrimazole-loaded SLN 
and NLC aqueous dispersions after their incorporation into different hydrogel formulations, 
obtained on day 1 and 90 after preparation. 
Table XXTX: DSC results of clotrimazole-loaded SLN and NLC aqueous dispersions after their 
incorporation into different hydrogel formulations, obtained on day 1 and 90 after production. 
Formulation Days of 
storage 
Melting 
point (°C) 
Onset 
(°C) 
Integral 
(mJ) 
Enthalpy 
(J/g) 
RI 
(%) 
D10%C-XG 1 59.08 56.22 737.88 8.77 45.3 
90 59.57 55.25 746.39 8.67 44.8 
D10%C-HEC 1 59.21 55.43 744.68 8.69 44.9 
90 61.38 60.60 745.53 8.68 44.9 
D10%C-PA 1 59.17 55.72 748.99 8.64 44.7 
90 59.27 55.11 749.85 8.63 44.6 
D10%C-CH 1 59.27 55.31 737.04 8.78 45.4 
90 59.32 55.19 738.73 8.76 45.3 
D20%C-XG 1 59.14 55.07 424.07 15.26 78.9 
90 59.59 57.15 424.62 15.24 78.8 
D20%C-HEC 1 59.01 56.11 425.46 15.21 78.6 
90 59.28 55.03 426.02 15.19 78.5 
D20%C-PA 1 59.21 55.46 423.23 15.29 79.0 
90 59.37 55.19 423.79 15.27 78.9 
D20%C-CH 1 59.25 55.14 424.62 15.24 78.8 
90 59.58 55.00 424.90 15.23 78.7 
DM20%C-XG 1 58.81 55.42 563.21 11.49 59.4 
90 57.75 52.51 564.19 11.47 59.3 
DM20%C-HEC 1 58.87 55.17 566.16 11.43 59.1 
90 53.18 51.36 567.15 11.41 59.0 
DM20%C-PA 1 58.80 55.59 564.68 11.46 59.2 
90 58.77 56.13 565.67 11.44 59.1 
DM20%C-CH 1 58.76 55.18 568.15 11.39 58.9 
90 58.97 54.89 569.15 11.37 58.8 
5.8. Rheological properties of SLN and NLC aqueous dispersions and hydrogels 
Conventional SLN and NLC aqueous dispersions contain about 10-20% (m/m) of lipid matrix 
and 80-90% (m/m) of water [48,81,113]. Therefore, their loading into a topical dosage form is 
limited. Hence drug loading is also limited. In addition, solid lipid particle liquid dispersions 
possess a low viscosity (approximately 100 mPa.s) and a yield value (Chapter IV, section 4.9) of 
practically zero [311]. Therefore, SLN and NLC aqueous dispersions usually have to be 
incorporated in convenient topical dosage forms, like hydrogels or creams, in order to obtain a 
topical application form having the desired semi-solid consistency [113,119]. 
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Incompatibilities with hydrogel or cream ingredients may occur due to interactions between 
the gel forming polymer, emulsifying agents, lipid and drug. Aggregation of the solid 
nanoparticles is also possible, especially when using polar gel forming polymers, like charged 
polysaccharides [107]. The use of neutralizing agents, like NaOH, for preparation of polyacrylic 
acid gels can also affect particle size, as reported above. Electrolytes, like sodium ions, can 
reduce the Ç of the particles, leading to aggregation, which is well known also for lipid 
nanoemulsions [97]. All these phenomena are able to affect the semi-solid consistency of the 
topical formulation and, therefore, its rheological status. 
The rheological status of a semi-solid drug carrier system is a very important physical 
parameter to study in the development process of a potential new drug delivery system for 
topical use [302], Rheological measurements provide essential information on different aspects 
concerning semi-solid preparations, such as application and performance on skin. Furthermore, 
drug release from semi-solid vehicles is influenced by their rheological behaviour. 
Rheometry might be particularly useful for the characterization of the viscoelastic properties 
of SLN and NLC aqueous dispersions and of SLN and NLC-containing hydrogels. Therefore, in 
the present work, an oscillation frequency sweep test was carried out for all developed SLN and 
NLC aqueous dispersions. In addition, continuous shear investigations were performed in all 
developed hydrogel formulations, in order to evaluate the shear rate as a function of shear stress. 
5.8.1. Oscillation frequency sweep test 
When performing oscillation measurements first the linear viscoelastic region has to be 
determined by a stress sweep at a constant frequency. As reported in Chapter IV, stress sweep is 
a dynamic test where the complex modulus G* is measured as a function of stress at a constant 
frequency. The range of stress over which G* is independent of the applied stress is called the 
linear viscoelastic region. Over the linear region the structure of the dispersion remains intact. 
Being in the viscoelastic region for all tested formulations 5 Pa was chosen as stress amplitude in 
the following studies. 
In order to get information about the viscous and elastic behaviour of the investigated 
systems and the network structure formed by particle-particle interactions an oscillation 
frequency sweep test has to be performed. This test provides a fingerprint of a viscoelastic 
system under non-destructive conditions [320]. The shape of the material function curves reveals 
structural characteristics of the system. Therefore, in the present work this test was performed 
over a frequency range from 0 to 10 Hz at constant stress amplitude of 5 Pa. 
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Figures 5.105 and 5.106 show the results of the oscillation frequency sweep test of 
clotrimazole-free and clotrimazole-loaded SLN formulations containing 10% of lipid matrix, 
respectively, after 1 day of storage at room temperature. 
As it can be observed in both figures, the storage modulus G' (elastic component) is grater 
than the loss modulus G" (viscous component) over the measured frequency range, which 
indicates the presence of a gel-like structure. Both parameters show a strong dependence on the 
applied frequency, i.e. they increase with the increase of the frequency. The presence of 
clotrimazole increased the magnitude of viscosity (n.*). 
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Figure 5.105: Storage modulus (G'), loss modulus (G") and complex viscosity (r)*) of 
clotrimazole-free SLN formulation D10%, as a function of the frequency at a constant 
stress amplitude of 5 Pa. 
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Figure 5.106: Storage modulus (G'), loss modulus (G") and complex viscosity (n,*) of 
clotrimazole-loaded SLN formulation D10%C, as a function of the frequency at a 
constant stress amplitude of 5 Pa. 
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Figures 5.107 and 5.108 show the results of the oscillation frequency sweep test of 
clotrimazole-free and clotrimazole-loaded SLN formulations containing 20% of lipid matrix, 
respectively, after 1 day of storage at room temperature. 
Both figures also evidence the storage modulus G' (elastic component) far grater than the 
loss modulus G" (viscous component) over the measured frequency range, indicating the 
presence of a gel-like structure. The loss modulus G" shows weak dependence on the applied 
frequency, i.e. it remains practically the same over the frequency range, while the storage 
modulus G' is more dependent on the applied frequency, especially when clotrimazole is present. 
The viscosity (r|*) decreases with increasing frequency. 
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Figure 5.107: Storage modulus (C), loss modulus (G") and complex viscosity (n*) of 
clotrimazole-free SLN formulation D20%, as a function of the frequency at a constant 
stress amplitude of 5 Pa. 
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Figure 5.108: Storage modulus (G'), loss modulus (G") and complex viscosity Of*) of 
clotrimazole-loaded SLN formulation D20%C, as a function of the frequency at a 
constant stress amplitude of 5 Pa. 
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Figures 5.109 and 5.110 show the results of the oscillation frequency sweep test of 
clotrimazole-free and clotrimazole-loaded NLC formulations containing 20% of lipid matrix, 
respectively, after 1 day of storage at room temperature. 
With regard to NLC formulations, the presence of clotrimazole in the lipid matrix was more 
emphasized than clotrimazole-loaded SLN formulations prepared with the same lipid content. 
Regarding drug-free NLC, the storage modulus G' appeared not so far from the loss modulus G" 
over the measured frequency range, while clotrimazole-loaded NLC seemed to have a gel-like 
structure because G' and G" are far grater from each other during the same frequency range. The 
increase of the applied frequency was followed by an increase in viscosity (n,*) for drug-free 
NLC formulations and a decrease in viscosity for drug-loaded NLC formulations. 
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Figure 5.109: Storage modulus (G'), loss modulus (G") and complex viscosity (n*) of 
clotrimazole-free NLC formulation DM20%, as a function of the frequency at a constant 
stress amplitude of 5 Pa. 
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Figure 5.110: Storage modulus (G'), loss modulus (G") and complex viscosity (n*) of 
clotrimazole-loaded NLC formulation DM20%C, as a function of the frequency at a 
constant stress amplitude of 5 Pa. 
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Lippacher showed that SLN dispersions possess higher elastic properties than emulsions of 
comparable lipid content [320]. In fact, if the storage modulus G' is higher by about one order of 
magnitude than the loss modulus G", and if both parameters show weak dependence on the 
applied frequency, the system is more elastic than viscous in the investigated frequency range 
[320]. The decrease in viscosity observed by increasing the applied frequency is also typical for 
viscoelastic solids and can be found for standard topical dosage forms, like Unguentum 
emulsifwans aquosum [113]. These results could be observed for SLN aqueous dispersions 
containing 20% of lipid matrix. 
A completely different rheological behaviour, as a function of the frequency, could be 
detected with 10% and 20% SLN dispersions. SLN aqueous dispersions having less lipid content 
reveal a complex viscosity and both moduli much lower, which exhibit the much weaker 
structure of the system having a more liquid-like character. In addition G' and G" are more 
dependent on the applied frequency than SLN aqueous dispersions having higher lipid content. 
Concerning to NLC aqueous dispersions, a typical viscoelastic behaviour could be observed for 
drug-loaded systems. 
To summarize, it was found that increasing the lipid concentration leads to a dramatic change 
in the rheological properties. In the present study, the viscoelastic properties were found to be 
comparable to standard dermal preparations, as reported earlier [113]. Therefore, semi-solid SLN 
aqueous dispersions appear a promising topical dosage form, especially when they are 
formulated with high lipid content. 
5.8.2. Continuous shear rheometry 
The rheological behaviour of hydrogels containing either SLN or NLC was evaluated after 
one week of storage at room temperature. 
Figures 5.111 and 5.112 show the flow curves of developed XG hydrogels containing 
clotrimazole-free and clotrimazole-loaded SLN and NLC formulations, respectively. 
The incorporation of lipid particles into XG hydrogels resulted in flow curves with plastic 
characteristics, where the shear rate increases by increasing shear stress. Ascending and 
descending flow curve overlap, showing no time effects like e.g. thixotropy. Lipid particles in 
the semi-solid system tend to align with increasing shear stress, which is alleviating the flow. 
This phenomenon was more emphasized for DM20% and D10%C, while SLN with higher lipid 
content (D20% and D20%C) revealed less dependency upon the applied shear stress. 
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The presence of clotrimazole increased the magnitude of the recorded shear rate during the 
experiment. 
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Figure 5.111: Shear rate of XG hydrogels containing clotrimazole-free lipid nanoparticles 
D10%, D20% and DM20%, as a function of shear stress. 
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Figure 5.112: Shear rate of XG hydrogels containing clotrimazole-loaded lipid 
nanoparticles D 10%C, D20%C and DM20%C, as a function of shear stress. 
Figures 5.113 and 5.114 show the flow curves of the developed HEC hydrogels containing 
clotrimazole-free and clotrimazole-loaded SLN and NLC formulations, respectively. 
The flow curves of HEC hydrogels containing D20%, D20%C, DM20% and DM20%C also 
revealed plastic characteristics. Nevertheless, the incorporation of D10% and D10%C into HEC 
hydrogels appeared to be responsible for a more pseudoplastic behaviour with a yield value 
almost zero, due to their lower lipid content. The increase of lipid content showed less 
dependency upon the applied shear stress. 
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Figure 5.113: Shear rate of HEC hydrogels containing clotrimazole-free lipid 
nanoparticles D10%, D20% and DM20%, as a function of shear stress. 
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Figure 5.114: Shear rate of HEC hydrogels containing clotrimazole-loaded lipid 
nanoparticles D10%C, D20%C and DM20%C, as a function of shear stress. 
Figures 5.115 and 5.116 show the flow curves of developed PA hydrogels containing 
clotrimazole-free and clotrimazole-loaded SLN and NLC formulations, respectively. 
The incorporation of SLN and NLC aqueous dispersions into PA hydrogels was responsible 
for a significant increase in yield value especially for SLN formulations. Unlike SLN containing 
10% of lipid content (D10% and D10%C) and NLC formulations (DM20% and DM20%C) the 
ascending and descending curve of SLN containing 20% of lipid content did not overlap, 
showing thixotropy. NLC formulations (DM20% and DM20%C) revealed more dependency 
upon the applied shear stress. 
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Figure 5.115: Shear rate of PA hydrogels containing clotrimazole-free lipid nanoparticles 
D10%, D20% and DM20%, as a function of shear stress. 
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Figure 5.116: Shear rate of PA hydrogels containing clotrimazole-loaded lipid 
nanoparticles D10%C, D20%C and DM20%C, as a function of shear stress. 
Figures 5.117 and 5.118 show the flow curves of developed CH hydrogels containing 
clotrimazole-free and clotrimazole-loaded SLN and NLC formulations, respectively. 
Concerning to CH hydrogels, a more pseudoplastic behaviour with a yield value of 
approximately zero was observed for formulations containing NLC or SLN with lower lipid 
content. The presence of drug into SLN containing 20% of lipid matrix revealed a more plastic 
behaviour, probably due to the higher mean particle size observed after PCS analysis of these 
systems. 
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Figure 5.117: Shear rate of CH hydrogels containing clotrimazole-free lipid nanoparticles 
D10%, D20% and DM20%, as a function of shear stress. 
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Figure 5.118: Shear rate of CH hydrogels containing clotrimazole-loaded lipid 
nanoparticles D10%C, D20%C and DM20%C, as a function of shear stress. 
In conclusion, the increase of the hydrogel lipid content leads to different flow 
characteristics. For hydrogels with higher lipid content, thixotropy could be observed. 
HEC and CH hydrogels are more liquid and they might not have a good consistency for 
topical administration. On the contrary, XG and PA hydrogels containing SLN and NLC 
revealed better rheological properties. Therefore, it can be envisaged that the combination of 
these later gel forming agents with SLN and NLC aqueous dispersions might comprise a novel 
drug delivery system for topical administration. 
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5.9. Occlusive properties of SLN and NLC aqueous dispersions and hydrogels 
It is well known that occlusion effect enhances the penetration of drugs through the stratum 
corneum, due to an increase in hydration of this layer [27]. For dermatológica! preparations 
occlusion is mainly achieved by using liquid and semi-solid paraffin [174]. However, these 
formulations feel greasy and have a glossy appearance. To overcome these drawbacks SLN-
containing topical formulations were suggested for this purpose [290]. 
Generally, nanoparticles are adhesive (i.e. they tend to adhere to cells and surfaces) and due 
to the film of nanoparticles formed on the surface of the skin, SLN possess occlusive properties 
[47,174,187,309]. This phenomenon offer the possibility to enhance the efficacy of drugs [174]. 
The occlusivity can be quantitatively evaluated in vitro by a filter test and in vivo by 
measurement of the transepidermal water loss (TEWL). For SLN the first systematic occlusion 
study was performed by Wissing et al., which have investigated the influence of the chemical 
nature of the lipid, the crystallinity of the lipid matrix and the particle size on occlusion effect 
[47]. 
In the present work, the occlusive effect of SLN and NLC aqueous dispersions and hydrogels 
containing SLN and NLC was analysed by the de Vringler in vitro test [290]. The dependency of 
occlusion factor F was determined as a function of the following factors: (i) number of 
homogenization cycles applied for sample preparation; (ii) used sample mass in the experiment; 
(iii) lipid formulation type (SLN or NLC); (iv) presence of clotrimazole and (v) type of hydrogel 
(XG, HEC, PA and CH). The occlusion factor F has been determined as a function of time, i.e. 
after 6, 24 and 48 hours of storage, at 32°C and 50% of relative humidity. Every experiment was 
carried out in triplicate. 
5.9.1. Dependency upon the number of homogenization cycles 
In order to study the dependency of the occlusion factor F upon the number of 
homogenization cycles, 200 mg of D10%, D20% andDM20% aqueous dispersions were applied 
at the surface of a filter, as described in Chapter IV, section 4.10. A visible film formation on top 
of the filter paper could be observed during the experiment. SLN and NLC aqueous dispersions 
applying 1 to 5 homogenization cycles were prepared, physicochemically characterized and their 
occlusion factor was determined after 6,24 and 48 hours of incubation time. 
Figures 5.119, 5.120 and 5.121 show the relationship between the occlusion factor F, the 
number of homogenization cycles and the particle size for D10%, D20% and DM20% aqueous 
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dispersions, respectively. According to the obtained results, the dependency of the occlusion 
factor F upon the particle size is perfectly clear. For all tested formulations it could be observed 
the increase of F with the decrease of the size of the lipid particles measured by PCS. 
-PCS diameter 
Figure 5.119: Effect of the number of homogenization cycles on occlusion factor F for 
D10% clotrimazole-free SLN aqueous dispersion. 
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Figure 5.120: Effect of the number of homogenization cycles on occlusion factor F for 
D20% clotrimazole-free SLN aqueous dispersion. 
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Figure 5.121: Effect of the number of homogenization cycles on occlusion factor F for 
DM20% clotrimazole-free NLC aqueous dispersion. 
The obtained results reveal that smaller particles show higher occlusion properties, which is 
in agreement to the results obtained by Wissing et al. [47]. Increasing homogenization cycles 
from 1 to 3, particle size decreased and occlusion factor increased significantly. From cycle 3 
onwards the decrease in particle size was almost neglected. In addition, the occlusion factor from 
cycle 3 to 5 remained fairly constant. 
It has been shown by electron microscopy that after evaporation of the water from an 
aqueous dispersion of SLN, a continuous film is formed at the surface [114]. 
The first model for the film formation by SLN on the skin was developed by Millier and 
Dingier, assuming a hexagonal packing of the particles in a monolayer [187]. Figure 5.122 
shows a comparison between 2 urn and 200 nm lipid particles, in correct size relationship. In 
hexagonal packing, about 76% of the surface is covered while 24% is uncovered, meaning that 
the uncovered surface is identical for both microparticles and nanoparticles. However, the holes 
in between the microparticles are relatively large and favour the hydrodynamic evaporation of 
water. In contrast, only tiny nanosized pores exist in the monolayer of lipid nanoparticles. From 
the pore dimensions, evaporation of water is hydrodynamically unfavourable. The pores are 
reminiscent of the occurrence of capillary condensation in silica gel. Water condensates in these 
pores due to their small size and reduced vapour pressure. Thus, the pores in the lipid 
nanoparticles film would rather attract than lose water. 
It has been earlier reported by Wissing et al. that particles in the micrometer range do not 
show pronounced occlusive effect [47]. For these particles, the occlusion factor F remained 
under 15 throughout the duration of the de Vringler in vitro test. This was due to the fact that 
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these particles formed a film on the filter paper with larger pores. Particles in the nanometer 
range revealed an occlusion factor which was 2 to 3 times as high as the factor obtained by 
particles in the micrometer range. For particles with a size ranging from 200 to 400 nm, there 
was only a slight decrease in occlusive effect. However, for particles of 600 nm and more, the 
occlusion factor strongly decreased. From these observations it could stated that for having high 
occlusivity, mean particle sizes of 400 nm are appropriate [181]. In the present study, particles 
having a mean size lower than 300 nm were obtained and used for determining the occlusion 
factor. Tt could be observed that these small nanoparticles showed a pronounced occlusive effect. 
Regarding the time dependency of the occlusive effect, it was reported that for particles 
having a mean diameter between 200 and 400 nm, the occlusion factor remains fairly constant 
throughout the experiment [47]. This was supported by findings that film formation takes place 
within the first hour. After film formation is completed, water evaporation should remain at a 
constant rate. 
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Figure 5.122: Model of film formation on the skin for 2 urn and 200 nm lipid particles. The 
film is shown as section (1), from the top (2) and as a new model of fusion of the 
nanoparticles to a pore-less film (3). (Adapted from Millier el al. [271). 
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5.9.2, Dependency upon applied sample mass 
Figure 5.123 shows the dependency of the occlusion factor upon sample mass. For this study, 
samples of 100, 150 and 200 mg, i.e. 5.3 mg/cm2, 8 mg/cm2 and 10.6 mg/cm2, respectively, of 
the DM20% NLC formulation were applied to the membrane. 
As reported by Wissing el al. for SLN formulations, F was more pronounced for higher 
sample quantities applied to the membrane [47]. 
The difference of the occlusion factor F between sample sizes of 5.3 mg/cm2 and 8 mg/cm2 
was greater than the difference between sample sizes of 8 mg/cm2 and 10.6 mg/cm2. After 48 h 
of incubation time F was approximately 11% higher using a sample size of 8 mg/cm in 
comparison to 5.3 mg/cm2, while the difference between 10.6 mg/cm2 and 8 mg/cm2 was only 
approximately 4%. This is due to the fact that the denseness of the particles on the filter is 
already relatively high at higher sample volume [47]. 
According to Muller et al. a critical value has to be reached, in order to enable film formation 
due to particle fusion [27]. Thus, probably, a sample size of 100 mg is not enough to cover the 
filter paper with NLC in order to obtain a sufficient occlusive effect. 
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Figure 5.123: Effect of the applied sample mass of NLC aqueous dispersions containing 
20% of lipid matrix on occlusion factor F. 
5.9.3. Dependency upon lipid formulation type and presence of clotrimazole 
Figure 5.124 shows the effect of the lipid formulation type (SLN and NLC) and the presence 
of clotrimazole on occlusion factor F. 
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This study was carried out in order to compare the occlusivity of SLN with different lipid 
content (10 and 20% mm), as well as SLN and NLC with the same lipid content (20% m'm). For 
these in vitro tests, 200 mg of D10%, D10%C, D20%, D20%C, DM20% and DM20%C aqueous 
dispersions were applied at the surface of the filter. 
As it could be expected, SLN with higher lipid content (20% m/rri) were responsible for the 
highest occlusion factor, either for both drug-free or for drug-loaded formulations 
(approximately 53.8% for D20% and 50.3% for D20%C) after 48 h of incubation time. NLC 
formulations revealed an occlusion factor lower than SLN formulations with the same lipid 
content (approximately 45.5% for DM20% and 43.7% for DM20%C) after the same period of 
incubation. SLN containing 10% of lipid matrix showed a F of 35.9% for D10% sample and of 
33.7% for D10%C, after 48h of incubation time. 
These results can be explained by the solid content of the tested formulations. In fact, the 
higher lipid content makes difficult the hydrodynamic conditions for evaporation of water. 
Therefore, SLN containing 20% of lipid F exhibited the highest value. For the same lipid 
content, NLC formulations showed a lower F value, due to the presence of a liquid core inside 
their lipidic structure, which can enhance or facilitate water evaporation. 
It has been found that the occlusion factor strongly depends on the degree of crystallinity of 
the lipid matrix, i.e. this effect is directly proportional [47,49]. In general, crystalline lipid 
particles are required to obtain a high occlusion factor and non-crystalline lipid nanoparticles, i.e. 
supercooled melts have no occlusive properties. 
According to these observations, NLC seems to be less crystalline in comparison to SLN 
with the same lipid content, because the former have an oil liquid core. Therefore, NLC must be 
responsible for a lower occlusion factor F. 
I Dl 0% ■ D20% D DM20% 
Figure 5.124: Effect of the lipid formulation (D10%, D20% and DM20%) and presence 
of clotrimazole on occlusion factor F. 
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5.9.4. Dependency upon hydrogel type 
Incorporation of SLN and NLC into topical formulations (creams, ointments, emulsions or 
hydrogels) can be performed to create supersaturated systems as reported earlier [27]. The 
increase in saturation solubility will lead to an increased diffusion pressure of drug into the skin. 
It might also be advantageous to combine solid lipid aqueous dispersions with topical 
formulations [8-10,229]. It has been recently observed by an in vivo study that addition of 4% of 
SLN to a conventional O/W cream leaded to an increase of skin hydration of 31% after 4 weeks 
[181]. 
Figure 5.125 shows the effect of the type of hydrogel on occlusion factor F, observed in the 
present study. As described before, four different hydrogels (XG, HEC, PA and CH) were 
prepared, 200 mg of each was applied at the surface of the filter and the respective occlusion 
factor was determined after 6, 24 and 48 h of incubation time. 
Figure 5.125: Effect of the type of hydrogel on occlusion factor F. 
After 48 h it was observed that HEC hydrogels were responsible for the highest occlusion 
factor F (approximately 31.6%). PA revealed an occlusion factor F of approximately 25% and 
CH of approximately 22%. XG was responsible for the lowest obtained value (approximately 
19.1%). 
In order to compare the occlusion factor F of the same hydrogels containing solid lipid 
aqueous dispersions, NLC containing 20% of lipid matrix were incorporated into the different 
hydrogels. 200 mg of each sample was applied at the surface of the filter and the respective 
occlusion factor was determined after 6, 24 and 48 h of incubation time. 
Chapter V 189 
Figure 5.126 shows the effect of the type of hydrogel on occlusion factor F for NLC 
formulation containing 20% of lipid matrix. Obtained results are in agreement with the occlusion 
effect observed for the different hydrogels (Figure 5.125). HEC was responsible for the highest 
occlusivity, while XG was responsible for the lowest value. However, when lipid particles were 
present the differences between the values obtained for occlusion factor F decreased, as 
expected. These results confirm the importance of solid lipid particles to enhance the occlusivity 
of topical formulations. 
Figure 5.126: Effect of the type of hydrogel on occlusion factor F of NLC formulation 
containing 20% of lipid matrix. 
When incorporated into topical formulations either SLN or NLC enhance the occlusive 
effect, due to their adhesive properties and the formation of a thin layer of densely packed 
nanoparticles. The dimensions of the spaces between the particles are very small, obstructing air 
circulation in these spaces and minimizing evaporation of water from the skin. Increased 
diffusion pressure and occlusive effect should distinctly enhance drug concentration in the skin 
or even drug penetration and systemic absorption. 
Decisive for the fate of clotrimazole is whether it is located in the SLN matrix or outside, i.e. 
distributed in the hydrogel. In the first case it is possible to localize the drug in the upper regions 
of skin. In the second one, even if using drug-free or drug-loaded SLN or NLC, occlusive effect 
of these particles govern the penetration of incorporating agents and enhanced penetration 
predominates [174]. 
It has been found that either SLN or NLC form films after application to the skin as a 
consequence of water evaporation, which leads to particle fusion and film formation (Figure 
5.116) [116]. Clotrimazole is localized in this film, thus penetration can be controlled. The small 
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particle size ensures close contact with stratum corneum and should increase the amount of drug 
penetrating into the viable skin. 
The principle of supersaturation can be used to explain the increase of drug penetration from 
topical microemulsions and, therefore, from solid lipid aqueous dispersions when applied to the 
skin. When topical formulations saturated with drug are applied to the skin, water from the skin 
diffuses into the semi-solid system resulting in a decrease of saturation solubility of the drug. 
The uptake of water by the topical formulation leads to supersaturation of the drug, obligating 
this later not to leave the system [27]. In an in vitro situation drugs crystals would be formed, 
while in vivo the only way to leave the topical formulation is to penetrate the skin. 
Figure 2.9 (Chapter II) explains the triggered drug release and supersaturation effect from 
NLC aqueous dispersions. Similar supersaturation systems can be created by incorporating drug-
loaded SLN and NLC in traditional hydrogels or creams saturated with drug [27,160]. During 
storage on the shelf, the drug remains inside the lipid nanoparticles, preserving their lipidic 
structure and, therefore, preserving drug accommodation. Application to the skin leads to an 
increase in temperature and water loss. This phenomenon initiates the transition to more stable 
lipid modifications in the lipid nanoparticles leading to drug expulsion. The drug is being 
expelled into the dispersion being already saturated with drug and thus leading to 
supersaturation. 
The obtained results in the present study confirmed that the degree of occlusivity of solid 
lipid aqueous dispersions correlates with particle size, lipid concentration, degree of crystallinity 
of lipid matrix and type of topical formulation. Therefore, when developing a new topical 
formulation based on SLN and NLC, it should be adjusted exactly to the desired degree of 
occlusion, on a controlled way. 
CHAPTER VI 
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Drug delivery to the skin presents unique opportunities but also obstacles due to the 
particular skin structure, physiology and barrier properties. Aiming to improve dermatological 
formulations, attempts are being made to design new topical drug delivery systems, i.e. 
particulate carriers that will enable a drug to reach the desired pharmaceutical site of action. One 
of the main possibilities is the use of based lipid carriers, such as SLN and NLC [6,7]. 
The materials used for preparation of SLN and NLC are excipients already present in 
cosmetic and pharmaceutical products accepted by the regulatory authorities. In fact, the full 
range of GRAS substances and substances of recognized GRAS status is available [259]. These 
substances also include compounds with surface activity or surfactants suitable for SLN and 
NLC stabilization. Therefore, based on the in vitro cytotoxicity and the in vivo toxicity data, 
either SLN or NLC appear to be very well tolerated drug carrier systems [12,13,84,102]. 
SLN and NLC possess a number of features advantageous for topical route [6,7]. The small 
particle size ensures a close contact to the stratum corneum and may increase the amount of 
incorporated agent penetrating into the viable skin. Due to their solid matrix, sustained drug 
release is possible and they can also be incorporated into semi-solid dosage forms. Furthermore, 
occlusive properties, as a result of a film formation on the skin surface, and chemical 
stabilization of incorporated drugs have also been reported [7,174,187]. 
With regard to the present work, pre-formulation studies were conducted in order to select 
the best lipid (or lipids) for incorporating clotrimazole in stable SLN and NLC formulations, as 
well as in order to select the emulsifying agent and the production conditions. 
To ensure the success of the incorporation process, the drug needs to be solubilized in the 
melted lipid, both at high and low temperatures. Therefore, the solubility of clotrimazole was 
screened by mixing the drug in different concentrations (1%, 5%, 10% and 20%, m/m) with 15 
different lipids and melting the mixtures at 90°C. Solubility was determined visually and 
microscopically either at 90°C or at room temperature (20°C), in order to evaluate the 
presence/absence of crystals of drug in the mixtures. Dynasan®\\6, Softisan®154, WitepsorHS, 
WitepsofSSS, WitepsofElS and Imwitor®\9l were selected for SLN preparation containing 
20% (m/m) of lipid matrix with different emulsifying agents (7teew®80, Span®S5, Lipoidosis, 
Lutrof®F6S, Tego Care®450, Tyloxapof and Lanette®N), at 90°C using a homogenization 
pressure of 500 bar and 3 homogenization cycles. 
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After particle size analysis by LD (d99%) on day 1 and day 7 of storage at room temperature, 
Dynasan®\\6 seemed to be the best lipid for the preparation of SLN using Tyloxapot as 
emulsifying agent, since the lowest d99% was obtained and maintained during one week of 
storage at room temperature (20°C). Therefore, Dynasan®\\(> and Tyloxapot® were selected, 
respectively, as the lipid and the emulsifying agent for preparation of SLN and NLC containing 
5% (m/m) of clotrimazole (with regard to the lipid matrix), at 90°C using a homogenization 
pressure of 500 bar and 3 homogenization cycles. 
Three different clotrimazole-free and clotrimazole-loaded SLN and NLC formulations, 
having distinct lipid concentrations (SLN 10%, SLN 20% and NLC 20%) were developed and 
characterized by LD, PCS, Ç, DSC and x-ray diffraction. The E.E., drug loading capacity and 
drug release profile were also determined after preparation. 
All developed clotrimazole-containing SLN and NLC formulations revealed E.E. higher than 
64% and loading capacities higher than 2.5%. Both clotrimazole-free and clotrimazole-loaded 
SLN and NLC aqueous dispersions showed a narrow particle size distribution measured by LD 
(d99%) and the presence of clotrimazole did not increase the mean particle size measured by 
PCS. NLC formulations revealed a lower PI (< 0.182), i.e. a narrow size distribution, in 
comparison to SLN formulations with the same lipid content (< 0.241). The former also showed 
a smaller mean particle size (approximately 180 nm). Concerning to the determination of Ç, drug-
free samples showed values between -17 mV and -37 mV, while drug-loaded samples showed 
values between -8 mV and -11 mV. Drug-free NLC formulations also showed lower Ç values in 
comparison to SLN samples. With regard to the evaluation of crystallinity of SLN and NLC, 
DSC and x-ray diffraction data indicated the presence of a crystalline matrix. In comparison to 
SLN with the same lipid content, NLC formulations evidenced lower lipid crystallinity, due to 
the existence of a liquid core. By x-ray diffraction studies, SLN formulations showed the 
characteristic peaks for P'/p modifications, while none of NLC formulations displayed any 
characteristic peaks in their x-ray patterns, revealing their lower lipid crystallinity, in agreement 
with the obtained DSC data. Although NLC formulations displayed a thermal event in DSC 
heating runs, they were more amorphous in comparison to SLN formulations. Therefore x-ray 
patterns did not show the characteristic P'/p modifications. 
Long term stability of SLN and NLC developed formulations was also assessed. Samples 
were stored at 4°C, 20°C and 40°C and physicochemically characterized during a period of three 
months. The E.E. and the drug loading capacity were evaluated for a period of 21 days in 
samples stored at room temperature (20°C). 
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Physicochemical stability of the developed SLN and NLC formulations was carried out 
regarding the following factors: lipid concentration, presence of clotrimazole and storage 
temperature during three months of the study. All samples were physicochemically stable at the 
different temperatures. SLN formulation with 10% (m/m) of lipid matrix stored at 40°C showed 
lower particle sizes. All formulations revealed a slightly decreased of Ç values during storage 
time. However, aqueous dispersions remained in the nanometer range during 3 months of storage 
at room temperature. Moreover, the presence of clotrimazole did not interfere neither with the 
particle size nor with the chemical stability of the investigated systems. 
For all investigated formulations E.E. higher than 50% were observed after 21 days of 
storage at room temperature (20°C). For SLN formulations, the sample with lower lipid content 
(10%, m/m) revealed a lower E.E. (approximately 57%) in comparison to the sample with 20% 
(m/m) of lipid content (approximately 59%). On the contrary, NLC formulation revealed the 
highest value (approximately 67%), due to the existence of the liquid core, which is responsible 
for more imperfections in the lattice, offering more space to accommodate clotrimazole 
molecules. Moreover, the oil compartment solubilizes clotrimazole increasing the drug content in 
the solid lipid system. 
Obtained results confirmed the higher loading capacity of NLC formulations (approximately 
3.5%, m/m), in comparison to SLN with the same lipid content (approximately 2.3%, m/m). For 
SLN formulations, the sample with lower lipid content (10%, m/m) revealed a higher loading 
capacity (approximately 3%, m/m) in comparison to the sample with 20% (m/m) of lipid content 
(approximately 2.3%, m/m). Thus, the presence of a liquid lipid in the carrier enhances both E.E. 
and drug loading capacity. 
Concerning to drug loss during storage time, it was observed that NLC formulation lost only 
6% of incorporated clotrimazole after 21 days of storage at room temperature, while SLN 
formulations slowed higher drug loss. SLN formulations containing 10% (m/m) of lipid matrix 
lost 10% and SLN formulations containing 20% (m/m) of lipid matrix lost 12% of incorporated 
drug. 
With regard to the release profile investigations, results revealed that clotrimazole was more 
quickly released from samples containing lower lipid concentration. NLC formulation was also 
responsible for the highest percentage of drug released (almost double in comparison to SLN 
formulations with the same lipid content). After 1 hour, the percentage of drug released from the 
NLC formulation was almost 10% (m/m). SLN formulations containing 10% (m/m) of lipid 
matrix revealed 7% (m/m) of drug released, while SLN formulations containing 20% (m/m) of 
lipid matrix revealed 4% (m/m) after the same period. The obtained release profiles are related to 
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the different drug incorporation and release mechanism models. NLC formulation is responsible 
for a more easily release due to their liquid core, where clotrimazole is less tightly incorporated, 
while in SLN formulations the drug is seizure in the solid core. SLN formulation containing 10% 
(m/m) of lipid matrix corresponds to the drug-enriched shell model, while SLN formulation 
containing 20% (m/m) of lipid matrix corresponds to the drug-enriched core model. A more 
quickly release was observed for SLN formulation corresponding to the drug-enriched shell 
model. 
SLN and NLC aqueous dispersions were incorporated into four different hydrogels: XG, 
HEC, PA and CH. Twelve different clotrimazole-free and clotrimazole-loaded formulations were 
developed and physicochemically characterized, concerning to particle size (by PCS and LD), Ç 
(by PCS) and crystalinity and interactions between components (by DSC). Long term stability of 
SLN and NLC containing hydrogels was also assessed by PCS, LD and DSC, during a period of 
three months at room temperature (20°C). 
Particle size characterization of SLN and NLC after their incorporation into different 
hydrogels revealed no peak in the micrometer range, except for both clotrimazole-free and 
clotrimazole-loaded SLN formulations containing 20% (m/m) of lipid matrix incorporated into 
XG hydrogels. This was probably caused by insoluble residues of this polysaccharide. The 
lowest particle size was observed for SLN containing 10% (m/m) of lipid matrix incorporated 
into PA hydrogels. These hydrogels were also responsible for the lowest PI value obtained for all 
SLN and NLC formulations after incorporation into the different hydrogels. The highest PI was 
obtained using CH hydrogels, especially for SLN samples containing 10% of lipid matrix. CH 
was also responsible for the highest mean particle size for all tested SLN and NLC formulations. 
This result is probably due to the polar character of this polymer and to the use of acetic acid for 
starting the gel formation process of CH. The use of acetic acid might affect the Ç at the surface 
of SLN and NLC and might be responsible for particle aggregation. 
With regard to physicochemical stability investigations, it could be observed that XG, HEC 
and PA hydrogels were not responsible for aggregation of SLN or NLC after their incorporation 
into the semi-solid systems. On the contrary, CH hydrogels showed particle aggregation. 
However, using this polymer particle size remained below 1 um. During storage at room 
temperature a decrease of Ç could be observed. For both clotrimazole-free and clotrimazole-
loaded SLN and NLC aqueous dispersions, the lipid content in the hydrogel was preserved. 
Concerning to thermal analysis, DSC curves of SLN and NLC aqueous dispersions incorporated 
into hydrogels revealed identical peaks compared to the correspondent aqueous dispersions. This 
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result indicates that SLN and NLC particles did not interfere with the gel forming agent when 
stored at room temperature (20°C). 
In order to evaluate the performance of semi-solid preparations on the skin, rheological 
measurements were carried out. An oscillation frequency sweep test was performed for all 
developed SLN and NLC aqueous dispersions. In addition, continuous shear investigations were 
performed in all hydrogel formulations, evaluating the shear rate as a function of shear stress. 
Viscoelastic properties of SLN and NLC aqueous dispersions were found to be comparable 
to conventional topical formulations. It was found that increasing the lipid concentration leads to 
a dramatic change in the rheological properties. SLN formulations revealed a presence of a gel-
like structure because the storage modulus "G"' was greater than the loss modulus "G"". This 
difference was more emphasized for SLN formulations containing 20% (m/m) of lipid matrix. 
Concerning to the presence of clotrimazole, the influence of drug in viscoelastic properties of 
SLN and NLC aqueous dispersions was more emphasized for NLC formulation than for SLN 
formulation with the same lipid content. Regarding to clotrimazole-free NLC formulations, the 
storage modulus "G"' appeared not so far from the loss modulus "G"" over the measured 
frequency range, while clotrimazole-loaded NLC formulations appeared to have a gel-like 
structure because "G"' and "G"" were grater from each other during the same frequency range. 
With regard to continuous shear rheometry, the incorporation of SLN and NLC aqueous 
dispersions into XG hydrogels resulted in flow curves with plastic characteristics. HEC 
hydrogels with 20% (m/m) of lipid containing SLN and NLC aqueous dispersions seemed to be 
responsible for a more plastic behaviour, while samples having less lipid content revealed a more 
pseudoplastic-like behaviour. PA hydrogels containing SLN with 20% (m/m) of lipid matrix 
showed thixotropy and NLC formulations prepared with the same lipid content revealed more 
dependency upon the applied shear stress. Concerning to CH hydrogels, these later revealed a 
more pseudoplastic-like behaviour when containing NLC formulations and SLN formulations 
with less lipid content. The presence of drug into SLN containing 20% (m/m) of lipid matrix 
revealed a more plastic behaviour. 
To summarize, thixotropy was observed for systems having higher lipid content. Increasing 
the lipid content leaded to different flow characteristics. HEC and CH hydrogels are more fluid 
and they might not have a good consistency for topical administration. In comparison to XG 
hydrogels, SLN and NLC aqueous dispersions containing PA hydrogels revealed less 
dependency upon the applied shear stress. 
It could be shown that physical properties, like physical state of the dispersed lipid phase, 
have a great impact on the formation of a semi-solid gel structure within lipid particle 
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dispersions. By employing viscoelastic measurements, it could be demonstrated that the 
existence of a solid particle matrix with a particle size in nanometer range is a prerequisite to 
form a semisolid dispersion having the appropriate consistency for topical administration. 
Occlusive properties of SLN and NLC aqueous dispersions and hydrogels containing SLN 
and NLC were analysed by the de Vringler in vitro test. The dependency of the occlusion factor 
(F) was determined with regard to the number of homogenization cycles used for preparation of 
nanoparticles, sample mass applied, nanoparticle formulations (SLN or NLC), presence of 
clotrimazole and hydrogel type (XG, HEC, PA or CH). The occlusion factor was determined as a 
function of time. 
The dependency of occlusion factor upon the particle size was clearly visible. For all tested 
formulations it could be observed the increase of occlusion factor with the decrease of particle 
size measured by PCS. The increase of the number of homogenization cycles from 1 to 3 leaded 
to a significant decrease of particle size. From cycle 3 onwards the decrease of particle size was 
almost neglected. Furthermore, the occlusion factor from cycle 3 to 5 remained practically 
constant. 
The dependency of the occlusion factor upon the applied sample mass was determined for 
NLC formulations. It was found that occlusion factor was more pronounced for a higher mass of 
sample, as reported by Wissing et al. for SLN formuliJtions [47]. 
In order to compare the occlusive properties between SLN and NLC aqueous dispersions, the 
occlusion factor was determined for all formulations. SLN with higher lipid content (20% m/m) 
were responsible for the highest occlusion factor for both clotrimazole-free and clotrimazole-
loaded formulations. NLC formulations revealed an occlusion factor lower than SLN 
formulations with the same lipid content, while SLN containing 10% (m/m) of lipid matrix 
showed the lowest occlusion factor. The higher lipid content turn difficult the hydrodynamic 
conditions for evaporation of water. Therefore, the highest value of occlusion factor was 
observed for SLN containing 20% (m/m) of lipid. For the same lipid content, NLC formulations 
showed an occlusion factor value lower than SLN due to the existence of a liquid core inside 
their lipidic structure, which can enhance or facilitate water evaporation. 
In order to compare the occlusion factor of nanoparticle aqueous dispersions containing 
hydrogels, NLC containing 20% (m/m) of lipid matrix were incorporated into four different 
hydrogels. HEC hydrogel was responsible for the highest occlusivity, while XG was responsible 
for the lowest value. Moreover, the occlusion factor obtained for NLC containing PA hydrogels 
was slightly higher than for NLC containing CH hydrogels. However, as expected, when lipid 
particles were incorporated into hydrogels the differences between the values of occlusion factor 
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decreased. These results confirm the importance of solid lipid particles to enhance the occlusivity 
and skin hydration of topical formulations. 
In conclusion, the results obtained in the present work clearly reveal that SLN and NLC are 
able to carry clotrimazole for topical drug delivery. It could be demonstrated that these systems 
have appropriate particle size and Ç, high E.E. and loading capacity for clotrimazole, which are 
dependent on the percentage of lipid matrix, and present a controlled release profile of the drug. 
Moreover, it is possible to prepare and characterize semi-solid systems based on hydrogels 
containing SLN and NLC having the desire physicochemical properties for the improvement of 
clotrimazole delivery in topical formulations. The gel forming agent is an important factor for 
optimizing the rheological and occlusive properties of semi-solid systems. 
According to the present investigation, some of the developed formulations might be selected 
as promising drug delivery systems for topical administration of clotrimazole. Thus, NLC 
formulation containing 20% (m/rri) of lipid matrix might be more advantageous for clotrimazole 
delivery, in comparison to the developed SLN formulations. With regard to semi-solid 
formulations, PA hydrogel might be the best vehicle for incorporation of NLC formulation 
containing 20% (m/m) of lipid matrix. 
The purpose of using lipid nanoparticles for topical drug delivery has further fields to be 
exploited. With regard to physicochemical characterization of lipid nanoparticles, other 
techniques should be employed in future investigations. These techniques include the electron 
microscopy that, in contrast to PCS and LD, provides direct information about the shape of the 
lipid particles [7] and the atomic force microscopy (AFM), which allows the observation of in 
situ processes occurring at the interfaces. Therefore, AFM can be used to image the 
morphological structure of lipid particles [93]. Transmission electron microscopy (TEM) can be 
employed for visualizing the colloidal particle size [323] and the Infrared and Raman 
spectroscopies are useful tools for investigating the structural properties of the lipids [324]. Both 
nuclear magnetic resonance (NMR) and electron spin resonance (ESR) are sensitive methods 
which can be employed for the detection of the presence of different colloidal species, such as 
liposomes or micelles that can be formed during the production process of SLN and NLC 
aqueous dispersions [7]. 
SLN have been found to modulate drug release into the skin [56] and to improve drug 
delivery to particular skin layers in vitro [57]. Further studies will be developed in order to assess 
the in vivo pharmacokinetic of clotrimazole-loaded SLN and NLC aqueous dispersions and the 
passage of the drug across the different strata of the skin. For this purpose, the performance of 
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SLN and NLC might be evaluated by the in vitro Transpore test proposed by Diffey et al. 
[325], which has relevance regarding to in vitrolin vivo correlations [179], 
These systems can be incorporated into topical dosage forms for dermal and mucosal drug 
delivery, maintaining their colloidal particle size. Further investigations should also be 
conducted in order to evaluate the large scale production of semi-solid SLN and NLC dispersions 
and the influence of scaling up on the colloidal structure of the carriers and gel structure. 
Concerning laboratory and industrial production of SLN and NLC aqueous dispersions, these 
systems can be prepared by HPH using piston-gap homogenizers [5,6]. For very expensive 
compounds, the use of an Avestin B3 apparatus is recommended having a batch volume as small 
as 3 ml dispersion [48]. The Micron Lab 40 can be considered as the standard machine for 
laboratory scale, where the batch size is 40 ml in the discontinuous version and approximately 
200-500 ml in the continuous version [326]. 
For topical products, a large batch is usually in the range of 100 kg up to 1000 kg. Such 
quantities can be easily realized using a Gaulin 5.5 (150 kg dispersion per hour) or a Ronnie 118 
going up to 2000 kg/h (APV Systems, Unna, Germany [17]). These homogenizers are accepted in 
production lines even for parenteral production. In addition, they are low cost equipments and, 
therefore are used in pharmaceutical industry [327]. 
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